

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
New York State

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	116044.4	484.8	483.6-486.1	57760.0	529.4	527.4-531.4	58284.4	456.6	454.9-458.3	34098.6	138.4	137.8-139.1	17042.2	161.8	160.7-162.9	17056.4	122.6	121.7-123.4
Oral cavity and pharynx	2771.2	11.4	11.2-11.6	1891.6	17.0	16.6-17.3	879.6	6.8	6.6-7.0	536.2	2.2	2.1-2.2	373.2	3.4	3.2-3.6	163.0	1.2	1.1-1.2
Lip	94.4	0.4	0.4-0.4	61.4	0.6	0.5-0.6	33.0	0.2	0.2-0.3	4.6	0.0	0.0-0.0	2.2	0.0	0.0-0.0	2.4	0.0	0.0-0.0
Tongue	860.8	3.5	3.4-3.6	594.8	5.2	5.0-5.4	266.0	2.0	1.9-2.2	132.0	0.5	0.5-0.6	87.2	0.8	0.7-0.9	44.8	0.3	0.3-0.4
Salivary gland	322.8	1.4	1.3-1.5	176.8	1.7	1.6-1.8	146.0	1.2	1.1-1.3	50.0	0.2	0.2-0.2	31.4	0.3	0.3-0.4	18.6	0.1	0.1-0.2
Floor of mouth	116.8	0.5	0.4-0.5	77.4	0.7	0.6-0.7	39.4	0.3	0.3-0.3	4.2	0.0	0.0-0.0	2.4	0.0	0.0-0.0	1.8	0.0	0.0-0.0
Gum & other mouth	396.0	1.6	1.6-1.7	215.2	2.0	1.9-2.1	180.8	1.4	1.3-1.5	77.2	0.3	0.3-0.3	47.0	0.4	0.4-0.5	30.2	0.2	0.2-0.2
Nasopharynx	176.2	0.8	0.7-0.8	123.4	1.2	1.1-1.3	52.8	0.4	0.4-0.5	53.8	0.2	0.2-0.3	39.6	0.4	0.3-0.4	14.2	0.1	0.1-0.1
Tonsil	475.0	1.9	1.8-2.0	389.0	3.4	3.2-3.5	86.0	0.6	0.6-0.7	44.6	0.2	0.2-0.2	38.4	0.3	0.3-0.4	6.2	0.0	0.0-0.1
Oropharynx	143.8	0.6	0.5-0.6	111.8	1.0	0.9-1.1	32.0	0.2	0.2-0.3	70.6	0.3	0.3-0.3	51.4	0.5	0.4-0.5	19.2	0.1	0.1-0.2
Hypopharynx	149.0	0.6	0.6-0.6	115.4	1.0	1.0-1.1	33.6	0.3	0.2-0.3	28.4	0.1	0.1-0.1	22.2	0.2	0.2-0.2	6.2	0.0	0.0-0.1
Other buccal cavity and pharynx	36.4	0.1	0.1-0.2	26.4	0.2	0.2-0.3	10.0	0.1	0.1-0.1	70.8	0.3	0.3-0.3	51.4	0.5	0.4-0.5	19.4	0.1	0.1-0.2
Digestive system	20287.4	83.9	83.3-84.4	11064.0	102.1	101.3-103.0	9223.4	69.1	68.5-69.8	9307.2	37.6	37.3-38.0	5156.6	48.0	47.4-48.6	4150.6	29.4	29.0-29.8
Esophagus	1099.6	4.4	4.3-4.5	827.6	7.5	7.2-7.7	272.0	2.0	1.9-2.1	833.0	3.3	3.2-3.4	643.4	5.8	5.6-6.1	189.6	1.3	1.3-1.4
Stomach	2041.2	8.5	8.4-8.7	1205.4	11.2	10.9-11.5	835.8	6.4	6.2-6.6	801.0	3.3	3.2-3.4	476.8	4.5	4.4-4.7	324.2	2.4	2.3-2.5
Small intestine	665.0	2.8	2.7-2.9	349.8	3.2	3.1-3.4	315.2	2.4	2.3-2.6	97.4	0.4	0.4-0.4	53.0	0.5	0.4-0.6	44.4	0.3	0.3-0.4
Colorectal	8974.0	37.7	37.4-38.1	4613.8	43.3	42.7-43.9	4360.2	33.2	32.7-33.6	2939.6	12.0	11.8-12.2	1475.8	14.1	13.8-14.4	1463.8	10.3	10.1-10.6
Colon excluding rectum	6336.2	26.5	26.2-26.8	3101.4	29.3	28.8-29.8	3234.8	24.3	23.9-24.7	2354.2	9.6	9.4-9.7	1145.0	11.0	10.7-11.2	1209.2	8.5	8.3-8.7
Cecum	1238.4	5.1	4.9-5.2	538.4	5.1	4.9-5.3	700.0	5.0	4.9-5.2									
Appendix	396.2	1.8	1.8-1.9	166.8	1.6	1.5-1.7	229.4	2.0	1.9-2.2									
Ascending colon	1218.2	5.0	4.9-5.2	555.4	5.3	5.1-5.5	662.8	4.8	4.6-5.0									
Hepatic flexure	282.0	1.2	1.1-1.2	146.8	1.4	1.3-1.5	135.2	1.0	0.9-1.1									
Transverse colon	581.4	2.4	2.3-2.5	287.4	2.7	2.6-2.9	294.0	2.1	2.0-2.3									
Splenic flexure	172.8	0.7	0.7-0.8	92.8	0.9	0.8-1.0	80.0	0.6	0.5-0.7									
Descending colon	399.8	1.7	1.6-1.8	224.8	2.1	2.0-2.3	175.0	1.4	1.3-1.5									
Sigmoid colon	1623.6	6.9	6.7-7.0	890.6	8.2	8.0-8.5	733.0	5.8	5.6-6.0									
Large intestine, NOS	423.8	1.7	1.6-1.8	198.4	1.9	1.8-2.0	225.4	1.6	1.5-1.7									
Rectum & rectosigmoid	2637.8	11.2	11.0-11.4	1512.4	14.0	13.7-14.3	1125.4	8.9	8.6-9.1	585.4	2.4	2.3-2.5	330.8	3.1	3.0-3.3	254.6	1.8	1.7-1.9
Rectosigmoid junction	620.0	2.6	2.5-2.7	339.0	3.1	3.0-3.3	281.0	2.2	2.1-2.3									
Rectum	2017.8	8.6	8.4-8.7	1173.4	10.9	10.6-11.2	844.4	6.6	6.4-6.9									
Anus, anal canal & anorectum	531.4	2.2	2.1-2.3	208.0	1.9	1.8-2.0	323.4	2.4	2.3-2.6	75.4	0.3	0.3-0.3	35.2	0.3	0.3-0.4	40.2	0.3	0.3-0.3
Liver and intrahepatic bile duct	2236.2	8.9	8.7-9.1	1582.6	13.8	13.5-14.1	653.6	4.8	4.6-5.0	1437.6	5.7	5.6-5.9	961.2	8.6	8.4-8.9	476.4	3.4	3.3-3.6

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
New York State

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	1807.8	7.1	7.0-7.3	1360.2	11.8	11.5-12.1	447.6	3.3	3.1-3.4	1006.6	4.0	3.9-4.1	744.4	6.6	6.4-6.8	262.2	1.8	1.7-1.9
Intrahepatic bile duct	428.4	1.8	1.7-1.8	222.4	2.0	1.9-2.2	206.0	1.5	1.4-1.6	431.0	1.8	1.7-1.8	216.8	2.0	1.9-2.2	214.2	1.6	1.5-1.7
Gallbladder	349.0	1.4	1.4-1.5	113.6	1.1	1.0-1.2	235.4	1.7	1.6-1.8	173.0	0.7	0.6-0.7	56.4	0.5	0.5-0.6	116.6	0.8	0.8-0.9
Other biliary	448.4	1.8	1.8-1.9	238.4	2.3	2.1-2.4	210.0	1.5	1.4-1.6	122.4	0.5	0.5-0.5	62.0	0.6	0.5-0.7	60.4	0.4	0.4-0.5
Pancreas	3551.2	14.4	14.2-14.7	1770.6	16.4	16.0-16.7	1780.6	12.9	12.6-13.1	2676.6	10.8	10.6-11.0	1327.0	12.3	12.0-12.6	1349.6	9.5	9.3-9.7
Retroperitoneum	107.8	0.5	0.4-0.5	57.0	0.5	0.5-0.6	50.8	0.4	0.4-0.5	17.0	0.1	0.1-0.1	10.6	0.1	0.1-0.1	6.4	0.0	0.0-0.1
Peritoneum, omentum & mesentery	98.4	0.4	0.4-0.4	7.8	0.1	0.1-0.1	90.6	0.7	0.6-0.7	51.0	0.2	0.2-0.2	9.4	0.1	0.1-0.1	41.6	0.3	0.3-0.3
Other digestive organs	185.2	0.8	0.7-0.8	89.4	0.8	0.8-0.9	95.8	0.7	0.6-0.8	83.2	0.3	0.3-0.4	45.8	0.4	0.4-0.5	37.4	0.3	0.2-0.3
Respiratory system	15204.2	61.6	61.1-62.0	7624.0	70.2	69.5-70.9	7580.2	55.3	54.7-55.8	8043.6	32.4	32.1-32.7	4184.4	39.2	38.6-39.7	3859.2	27.5	27.1-27.9
Nasal cavity, middle ear & sinuses	175.2	0.7	0.7-0.8	100.8	0.9	0.9-1.0	74.4	0.6	0.5-0.6	26.4	0.1	0.1-0.1	14.2	0.1	0.1-0.2	12.2	0.1	0.1-0.1
Larynx	743.8	3.0	2.9-3.1	587.4	5.2	5.0-5.4	156.4	1.2	1.1-1.3	209.2	0.8	0.8-0.9	164.8	1.5	1.4-1.6	44.4	0.3	0.3-0.4
Lung and bronchus	14234.8	57.6	57.2-58.0	6901.0	63.7	63.0-64.4	7333.8	53.4	52.8-53.9	7781.2	31.4	31.1-31.7	3989.4	37.4	36.8-37.9	3791.8	27.0	26.6-27.4
Pleura	6.6	0.0	0.0-0.0	4.0	0.0	0.0-0.1	2.6	0.0	0.0-0.0	11.2	0.0	0.0-0.1	7.8	0.1	0.1-0.1	3.4	0.0	0.0-0.0
Trachea, mediastinum, other respiratory	43.8	0.2	0.2-0.2	30.8	0.3	0.3-0.4	13.0	0.1	0.1-0.1	15.6	0.1	0.1-0.1	8.2	0.1	0.1-0.1	7.4	0.1	0.0-0.1
Bones & joints	236.0	1.2	1.1-1.2	135.6	1.4	1.3-1.5	100.4	1.0	0.9-1.1	85.8	0.4	0.4-0.4	49.6	0.5	0.4-0.6	36.2	0.3	0.3-0.4
Soft tissue (including heart)	807.2	3.6	3.5-3.8	447.8	4.4	4.2-4.6	359.4	3.1	2.9-3.2	285.0	1.2	1.2-1.3	147.0	1.4	1.3-1.5	138.0	1.1	1.0-1.2
Skin*	4715.0	20.1	19.8-20.3	2737.2	26.0	25.5-26.4	1977.8	15.9	15.6-16.3	583.8	2.4	2.3-2.5	376.0	3.6	3.5-3.8	207.8	1.5	1.4-1.5
Melanoma of the skin	4260.8	18.1	17.9-18.4	2471.0	23.4	22.9-23.8	1789.8	14.4	14.1-14.8	387.2	1.6	1.5-1.7	242.8	2.3	2.2-2.5	144.4	1.0	1.0-1.1
Breast	16985.4	73.5	73.0-74.0	166.4	1.5	1.4-1.7	16819.0	135.7	134.7-136.6	2531.0	10.4	10.3-10.6	25.8	0.2	0.2-0.3	2505.2	18.6	18.2-18.9
Breast (in situ)#	5093.4	22.7	22.4-23.0	20.8	0.2	0.2-0.2	5072.6	42.8	42.3-43.4									
Female genital system							7198.4	56.3	55.7-56.9							2097.0	15.4	15.1-15.7
Cervix uteri							840.6	7.7	7.4-7.9							239.4	2.0	1.8-2.1
Corpus uterus and NOS							4198.0	31.7	31.3-32.1							824.0	5.9	5.7-6.1
Ovary							1446.8	11.6	11.3-11.9							879.2	6.4	6.2-6.6
Vagina							82.4	0.6	0.6-0.7							21.2	0.1	0.1-0.2
Vulva							350.4	2.6	2.5-2.8							79.8	0.5	0.5-0.6
Other female genital organs							280.2	2.1	2.0-2.2							53.4	0.4	0.3-0.4
Male genital system				15941.8	138.0	137.0-139.0							1752.6	17.4	17.1-17.8			
Prostate				15242.4	130.7	129.8-131.7							1706.8	17.0	16.6-17.3			
Testis				580.2	6.1	5.9-6.4							20.8	0.2	0.2-0.2			
Penis				92.8	0.9	0.8-1.0							21.2	0.2	0.2-0.3			
Other male genital organs				26.4	0.3	0.2-0.3							3.8	0.0	0.0-0.1			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
New York State

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	9754.2	40.2	39.9-40.6	6834.4	63.9	63.3-64.6	2919.8	21.9	21.5-22.2	1704.0	6.8	6.7-7.0	1143.4	11.1	10.8-11.4	560.6	3.8	3.7-4.0
Urinary bladder (including in situ)	5446.2	22.2	21.9-22.4	4061.8	38.5	37.9-39.0	1384.4	10.0	9.7-10.2	979.8	3.9	3.8-4.0	683.0	6.8	6.5-7.0	296.8	2.0	1.9-2.1
Kidney and renal pelvis	4073.4	17.1	16.9-17.3	2624.0	24.0	23.6-24.5	1449.4	11.3	11.0-11.5	680.4	2.7	2.7-2.8	436.4	4.1	3.9-4.3	244.0	1.7	1.6-1.8
Ureter	139.8	0.6	0.5-0.6	85.2	0.8	0.7-0.9	54.6	0.4	0.3-0.4	20.0	0.1	0.1-0.1	8.4	0.1	0.1-0.1	11.6	0.1	0.1-0.1
Other urinary organs	94.8	0.4	0.4-0.4	63.4	0.6	0.5-0.7	31.4	0.2	0.2-0.3	23.8	0.1	0.1-0.1	15.6	0.2	0.1-0.2	8.2	0.1	0.0-0.1
Eye & orbit	205.8	0.9	0.8-1.0	103.0	1.0	0.9-1.1	102.8	0.9	0.8-0.9	16.2	0.1	0.1-0.1	7.6	0.1	0.0-0.1	8.6	0.1	0.0-0.1
Brain / other central nervous system (all behaviors)	4983.8	22.0	21.8-22.3	1944.4	18.9	18.5-19.3	3039.4	24.7	24.3-25.1	1069.0	4.5	4.4-4.7	575.2	5.4	5.2-5.6	493.8	3.8	3.6-4.0
Malignant brain / other central nervous system	1429.2	6.5	6.4-6.7	792.4	7.7	7.5-8.0	636.8	5.5	5.3-5.7	888.4	3.8	3.7-3.9	493.2	4.6	4.4-4.8	395.2	3.1	3.0-3.2
Malignant brain	1335.6	6.1	5.9-6.2	744.6	7.2	7.0-7.5	591.0	5.0	4.8-5.2									
Malignant other central nervous system	93.6	0.5	0.4-0.5	47.8	0.5	0.4-0.6	45.8	0.4	0.4-0.5									
Benign brain / other central nervous system#	3554.6	15.5	15.3-15.8	1152.0	11.1	10.9-11.4	2402.6	19.3	18.9-19.6	180.6	0.7	0.7-0.8	82.0	0.8	0.7-0.9	98.6	0.7	0.6-0.8
Benign brain	322.4	1.6	1.5-1.7	160.8	1.7	1.5-1.8	161.6	1.5	1.4-1.6									
Benign other central nervous system	3232.2	13.9	13.7-14.2	991.2	9.5	9.2-9.8	2241.0	17.7	17.4-18.1									
Endocrine system	4267.2	20.4	20.1-20.7	1177.8	11.5	11.2-11.8	3089.4	28.9	28.4-29.4	185.6	0.8	0.7-0.8	81.6	0.8	0.7-0.9	104.0	0.8	0.7-0.8
Thyroid	4026.4	19.3	19.0-19.6	1054.4	10.3	10.0-10.6	2972.0	27.9	27.4-28.4	126.8	0.5	0.5-0.6	55.0	0.5	0.5-0.6	71.8	0.5	0.4-0.6
Other endocrine (including thymus)	240.8	1.1	1.0-1.2	123.4	1.2	1.1-1.3	117.4	1.0	0.9-1.1	58.8	0.3	0.2-0.3	26.6	0.3	0.2-0.3	32.2	0.3	0.2-0.3
Lymphomas	5699.2	24.6	24.3-24.9	3063.8	29.3	28.8-29.8	2635.4	20.9	20.5-21.3	1259.6	5.2	5.0-5.3	704.2	6.9	6.6-7.1	555.4	3.9	3.8-4.1
Hodgkin lymphoma	632.6	3.1	3.0-3.2	342.6	3.5	3.3-3.7	290.0	2.8	2.6-2.9	64.4	0.3	0.2-0.3	37.6	0.4	0.3-0.4	26.8	0.2	0.2-0.3
Non-Hodgkin lymphomas	5066.6	21.5	21.2-21.8	2721.2	25.8	25.4-26.3	2345.4	18.1	17.8-18.4	1195.2	4.9	4.8-5.0	666.6	6.5	6.3-6.7	528.6	3.7	3.6-3.9
Myeloma	2006.4	8.2	8.1-8.4	1087.4	10.1	9.8-10.3	919.0	6.8	6.6-7.0	701.6	2.8	2.7-2.9	369.2	3.5	3.3-3.7	332.4	2.3	2.2-2.4
Leukemias	3750.8	16.0	15.8-16.3	2174.6	20.9	20.5-21.3	1576.2	12.3	12.0-12.6	1374.4	5.7	5.6-5.8	771.8	7.6	7.4-7.9	602.6	4.3	4.2-4.5
Lymphocytic leukemias	1935.4	8.2	8.1-8.4	1172.8	11.1	10.8-11.4	762.6	5.9	5.7-6.1	351.2	1.4	1.4-1.5	207.0	2.1	1.9-2.2	144.2	1.0	0.9-1.1
Acute lymphocytic leukemia	311.6	1.7	1.6-1.7	175.4	1.9	1.8-2.0	136.2	1.4	1.3-1.5	85.4	0.4	0.4-0.4	47.8	0.5	0.4-0.5	37.6	0.3	0.3-0.4
Chronic lymphocytic leukemia	1512.2	6.1	6.0-6.2	913.8	8.4	8.2-8.7	598.4	4.3	4.1-4.4	240.6	0.9	0.9-1.0	145.0	1.5	1.3-1.6	95.6	0.6	0.5-0.7
Other lymphocytic leukemias	111.6	0.5	0.4-0.5	83.6	0.8	0.7-0.9	28.0	0.2	0.2-0.3	25.2	0.1	0.1-0.1	14.2	0.1	0.1-0.2	11.0	0.1	0.1-0.1
Myeloid and monocytic leukemias	1618.6	7.0	6.8-7.1	900.6	8.8	8.5-9.1	718.0	5.6	5.4-5.8	770.0	3.2	3.1-3.3	426.2	4.2	4.0-4.4	343.8	2.5	2.4-2.7
Acute myeloid leukemia	1061.6	4.6	4.4-4.7	587.0	5.7	5.5-5.9	474.6	3.7	3.6-3.9	661.0	2.8	2.7-2.9	367.0	3.6	3.4-3.7	294.0	2.2	2.1-2.3
Acute monocytic leukemia	44.0	0.2	0.2-0.2	24.8	0.2	0.2-0.3	19.2	0.2	0.1-0.2	3.6	0.0	0.0-0.0	1.6	0.0	0.0-0.0	2.0	0.0	0.0-0.0
Chronic myeloid leukemia	480.2	2.1	2.0-2.2	271.0	2.6	2.5-2.8	209.2	1.7	1.6-1.8	58.2	0.2	0.2-0.3	29.6	0.3	0.2-0.3	28.6	0.2	0.2-0.2
Other myeloid/monocytic leukemias	32.8	0.1	0.1-0.2	17.8	0.2	0.1-0.2	15.0	0.1	0.1-0.1	47.2	0.2	0.2-0.2	28.0	0.3	0.2-0.3	19.2	0.1	0.1-0.2
Other leukemias	196.8	0.8	0.8-0.9	101.2	1.0	0.9-1.1	95.6	0.7	0.7-0.8	253.2	1.0	1.0-1.1	138.6	1.4	1.3-1.5	114.6	0.8	0.7-0.9
Other acute leukemias	48.6	0.2	0.2-0.2	25.8	0.2	0.2-0.3	22.8	0.2	0.1-0.2	83.6	0.3	0.3-0.4	45.6	0.5	0.4-0.5	38.0	0.3	0.2-0.3

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
New York State

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	148.2	0.6	0.6-0.7	75.4	0.7	0.7-0.8	72.8	0.6	0.5-0.6	169.6	0.7	0.7-0.7	93.0	0.9	0.8-1.0	76.6	0.5	0.5-0.6
Mesothelioma	183.2	0.8	0.7-0.8	130.0	1.3	1.2-1.4	53.2	0.4	0.4-0.5									
Kaposi sarcoma	136.8	0.6	0.6-0.7	120.0	1.2	1.1-1.3	16.8	0.1	0.1-0.2									
Myelodysplastic syndromes	1131.0	4.7	4.5-4.8	645.0	6.5	6.3-6.7	486.0	3.4	3.3-3.6									
Chronic myeloproliferative disorders [^]	1182.0	5.0	4.9-5.2	571.6	5.4	5.2-5.6	610.4	4.7	4.5-4.9									
Ill defined and unspecified sites	2152.0	8.8	8.6-8.9	1051.6	10.0	9.8-10.3	1100.4	7.8	7.6-8.0	2746.6	11.1	10.9-11.3	1406.0	13.4	13.1-13.8	1340.6	9.4	9.1-9.6

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

[^] Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
New York City**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	42153.8	443.9	441.9-445.8	20257.6	484.6	481.6-487.7	21896.2	420.3	417.8-422.9	12082.2	125.4	124.4-126.4	5884.2	147.4	145.7-149.2	6198.0	111.2	109.9-112.4
Oral cavity and pharynx	946.4	9.9	9.6-10.2	619.6	14.6	14.1-15.2	326.8	6.2	5.9-6.5	197.4	2.0	1.9-2.2	138.4	3.3	3.1-3.6	59.0	1.0	0.9-1.2
Lip	21.2	0.2	0.2-0.3	13.4	0.3	0.2-0.4	7.8	0.1	0.1-0.2	1.8	0.0	0.0-0.0	0.6	0.0	0.0-0.0	1.2	0.0	0.0-0.0
Tongue	258.6	2.7	2.5-2.8	171.2	4.0	3.7-4.3	87.4	1.6	1.5-1.8	42.4	0.4	0.4-0.5	27.8	0.7	0.6-0.8	14.6	0.2	0.2-0.3
Salivary gland	118.4	1.3	1.2-1.4	61.0	1.5	1.3-1.7	57.4	1.1	1.0-1.3	17.6	0.2	0.1-0.2	10.6	0.3	0.2-0.4	7.0	0.1	0.1-0.2
Floor of mouth	31.6	0.3	0.3-0.4	19.8	0.5	0.4-0.6	11.8	0.2	0.2-0.3	1.4	0.0	0.0-0.0	0.8	0.0	0.0-0.0	0.6	0.0	0.0-0.0
Gum & other mouth	153.6	1.6	1.5-1.7	80.2	1.9	1.7-2.1	73.4	1.3	1.2-1.5	24.2	0.2	0.2-0.3	14.6	0.4	0.3-0.4	9.6	0.2	0.1-0.2
Nasopharynx	108.6	1.2	1.1-1.3	75.8	1.8	1.6-2.0	32.8	0.7	0.6-0.8	32.8	0.4	0.3-0.4	25.2	0.6	0.5-0.7	7.6	0.1	0.1-0.2
Tonsil	133.2	1.4	1.3-1.5	106.2	2.4	2.2-2.7	27.0	0.5	0.4-0.6	11.6	0.1	0.1-0.2	10.6	0.2	0.2-0.3	1.0	0.0	0.0-0.0
Oropharynx	51.2	0.5	0.5-0.6	38.4	0.9	0.8-1.0	12.8	0.2	0.2-0.3	28.4	0.3	0.2-0.3	19.8	0.5	0.4-0.6	8.6	0.2	0.1-0.2
Hypopharynx	58.6	0.6	0.5-0.7	44.8	1.1	0.9-1.2	13.8	0.3	0.2-0.3	11.6	0.1	0.1-0.2	8.8	0.2	0.1-0.3	2.8	0.1	0.0-0.1
Other buccal cavity and pharynx	11.4	0.1	0.1-0.1	8.8	0.2	0.1-0.3	2.6	0.0	0.0-0.1	25.6	0.3	0.2-0.3	19.6	0.5	0.4-0.6	6.0	0.1	0.1-0.2
Digestive system	8163.0	85.3	84.5-86.2	4408.0	106.1	104.7-107.5	3755.0	69.4	68.4-70.4	3658.6	37.8	37.2-38.4	1976.4	48.6	47.6-49.5	1682.2	29.7	29.1-30.4
Esophagus	321.4	3.3	3.1-3.4	230.0	5.5	5.1-5.8	91.4	1.6	1.5-1.8	219.6	2.2	2.1-2.4	160.0	3.9	3.6-4.2	59.6	1.0	0.9-1.2
Stomach	990.0	10.4	10.1-10.7	563.8	13.7	13.2-14.3	426.2	8.0	7.6-8.3	425.6	4.5	4.3-4.7	251.6	6.3	6.0-6.7	174.0	3.1	2.9-3.4
Small intestine	236.6	2.5	2.4-2.7	117.2	2.8	2.6-3.1	119.4	2.3	2.1-2.5	30.6	0.3	0.3-0.4	15.4	0.4	0.3-0.5	15.2	0.3	0.2-0.4
Colorectal	3513.4	37.1	36.5-37.7	1810.8	44.0	43.1-45.0	1702.6	31.9	31.2-32.6	1144.0	11.9	11.6-12.2	565.6	14.2	13.7-14.7	578.4	10.2	9.8-10.6
Colon excluding rectum	2463.0	26.0	25.5-26.4	1222.2	29.9	29.1-30.7	1240.8	23.0	22.4-23.6	933.6	9.7	9.4-10.0	448.6	11.3	10.8-11.8	485.0	8.5	8.2-8.9
Cecum	448.4	4.7	4.5-4.9	193.8	4.8	4.5-5.1	254.6	4.6	4.3-4.8									
Appendix	127.0	1.4	1.3-1.5	54.2	1.3	1.2-1.5	72.8	1.5	1.3-1.7									
Ascending colon	467.8	4.9	4.7-5.1	221.0	5.5	5.2-5.8	246.8	4.5	4.2-4.7									
Hepatic flexure	110.4	1.1	1.1-1.2	57.6	1.4	1.3-1.6	52.8	1.0	0.8-1.1									
Transverse colon	221.0	2.3	2.2-2.5	110.2	2.7	2.5-3.0	110.8	2.0	1.9-2.2									
Splenic flexure	70.2	0.7	0.7-0.8	40.0	1.0	0.8-1.1	30.2	0.6	0.5-0.6									
Descending colon	184.0	1.9	1.8-2.1	101.2	2.4	2.2-2.7	82.8	1.6	1.4-1.7									
Sigmoid colon	659.6	7.0	6.7-7.2	359.8	8.6	8.2-9.0	299.8	5.8	5.5-6.1									
Large intestine, NOS	174.6	1.8	1.7-1.9	84.4	2.1	1.9-2.3	90.2	1.6	1.4-1.7									
Rectum & rectosigmoid	1050.4	11.2	10.8-11.5	588.6	14.1	13.6-14.6	461.8	8.9	8.5-9.2	210.4	2.2	2.1-2.4	117.0	2.9	2.7-3.2	93.4	1.7	1.5-1.8
Rectosigmoid junction	260.2	2.8	2.6-2.9	141.2	3.4	3.2-3.7	119.0	2.3	2.1-2.5									
Rectum	790.2	8.4	8.1-8.7	447.4	10.7	10.3-11.2	342.8	6.6	6.3-6.9									
Anus, anal canal & anorectum	218.0	2.3	2.1-2.4	100.0	2.4	2.2-2.6	118.0	2.2	2.0-2.4	30.2	0.3	0.3-0.4	16.0	0.4	0.3-0.5	14.2	0.3	0.2-0.3
Liver and intrahepatic bile duct	1077.6	10.9	10.6-11.2	754.8	17.4	16.8-17.9	322.8	5.8	5.5-6.1	648.0	6.6	6.4-6.8	429.2	10.1	9.7-10.6	218.8	3.9	3.6-4.1

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
New York City

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	897.0	9.1	8.8-9.3	661.2	15.1	14.6-15.7	235.8	4.2	4.0-4.5	473.8	4.8	4.6-5.0	345.8	8.1	7.7-8.5	128.0	2.2	2.1-2.4
Intrahepatic bile duct	180.6	1.9	1.8-2.0	93.6	2.2	2.0-2.4	87.0	1.6	1.4-1.7	174.2	1.8	1.7-1.9	83.4	2.0	1.8-2.2	90.8	1.6	1.5-1.8
Gallbladder	180.8	1.9	1.8-2.0	57.6	1.4	1.3-1.6	123.2	2.2	2.1-2.4	93.2	1.0	0.9-1.0	29.4	0.7	0.6-0.8	63.8	1.1	1.0-1.3
Other biliary	190.0	2.0	1.9-2.1	97.2	2.4	2.2-2.6	92.8	1.7	1.5-1.9	48.0	0.5	0.4-0.6	24.4	0.6	0.5-0.7	23.6	0.4	0.3-0.5
Pancreas	1302.4	13.5	13.2-13.8	626.0	15.2	14.7-15.8	676.4	12.1	11.7-12.5	968.4	10.0	9.7-10.3	461.2	11.4	10.9-11.8	507.2	8.9	8.6-9.3
Retroperitoneum	44.6	0.5	0.4-0.6	22.4	0.5	0.4-0.6	22.2	0.4	0.4-0.5	8.0	0.1	0.1-0.1	4.8	0.1	0.1-0.2	3.2	0.1	0.0-0.1
Peritoneum, omentum & mesentery	29.4	0.3	0.3-0.4	1.8	0.0	0.0-0.1	27.6	0.5	0.4-0.6	17.0	0.2	0.1-0.2	3.4	0.1	0.1-0.1	13.6	0.2	0.2-0.3
Other digestive organs	58.8	0.6	0.5-0.7	26.4	0.6	0.5-0.8	32.4	0.6	0.5-0.7	26.0	0.3	0.2-0.3	15.4	0.4	0.3-0.5	10.6	0.2	0.1-0.3
Respiratory system	4777.4	49.5	48.9-50.2	2471.2	60.3	59.2-61.4	2306.2	41.8	41.1-42.6	2417.0	24.9	24.5-25.4	1299.4	32.3	31.5-33.1	1117.6	19.7	19.2-20.3
Nasal cavity, middle ear & sinuses	65.8	0.7	0.6-0.8	37.6	0.9	0.8-1.1	28.2	0.5	0.5-0.7	9.2	0.1	0.1-0.1	4.8	0.1	0.1-0.2	4.4	0.1	0.1-0.1
Larynx	263.6	2.7	2.6-2.8	207.8	4.9	4.6-5.2	55.8	1.0	0.9-1.2	79.0	0.8	0.7-0.9	63.4	1.5	1.4-1.7	15.6	0.3	0.2-0.3
Lung and bronchus	4429.4	45.9	45.3-46.5	2212.6	54.1	53.1-55.2	2216.8	40.1	39.4-40.9	2317.6	23.9	23.5-24.4	1225.2	30.5	29.7-31.3	1092.4	19.3	18.8-19.8
Pleura	2.4	0.0	0.0-0.0	1.4	0.0	0.0-0.1	1.0	0.0	0.0-0.0	3.8	0.0	0.0-0.1	2.8	0.1	0.0-0.1	1.0	0.0	0.0-0.0
Trachea, mediastinum, other respiratory	16.2	0.2	0.1-0.2	11.8	0.3	0.2-0.4	4.4	0.1	0.1-0.1	7.4	0.1	0.1-0.1	3.2	0.1	0.0-0.1	4.2	0.1	0.0-0.1
Bones & joints	95.0	1.1	1.0-1.3	54.6	1.4	1.2-1.6	40.4	0.9	0.8-1.1	37.0	0.4	0.4-0.5	22.6	0.6	0.5-0.7	14.4	0.3	0.2-0.4
Soft tissue (including heart)	331.8	3.7	3.5-3.8	176.2	4.3	4.0-4.6	155.6	3.2	3.0-3.4	101.4	1.1	1.0-1.2	50.2	1.2	1.1-1.4	51.2	1.0	0.9-1.1
Skin*	1063.8	11.4	11.0-11.7	588.0	14.7	14.1-15.2	475.8	9.1	8.7-9.5	138.8	1.4	1.3-1.6	86.8	2.2	2.0-2.4	52.0	0.9	0.8-1.0
Melanoma of the skin	938.2	10.0	9.7-10.3	520.2	12.9	12.4-13.5	418.0	8.0	7.7-8.4	85.6	0.9	0.8-1.0	51.2	1.3	1.1-1.5	34.4	0.6	0.5-0.7
Breast	6531.4	70.5	69.7-71.3	66.6	1.6	1.5-1.8	6464.8	127.4	126.0-128.8	1014.6	10.6	10.3-10.9	8.8	0.2	0.2-0.3	1005.8	18.5	18.0-19.1
Breast (in situ)#	2189.6	24.2	23.7-24.7	10.4	0.3	0.2-0.3	2179.2	44.6	43.7-45.4									
Female genital system							2946.0	56.5	55.6-57.4							885.8	16.1	15.7-16.6
Cervix uteri							432.2	9.0	8.6-9.4							113.8	2.2	2.1-2.4
Corpus uteri and NOS							1689.8	31.5	30.8-32.2							385.6	6.9	6.6-7.2
Ovary							575.8	11.3	10.9-11.7							338.0	6.2	5.9-6.5
Vagina							32.4	0.6	0.5-0.7							9.6	0.2	0.1-0.2
Vulva							112.2	2.1	1.9-2.3							24.4	0.4	0.3-0.5
Other female genital organs							103.6	1.9	1.8-2.1							14.4	0.3	0.2-0.3
Male genital system				5819.4	133.1	131.5-134.7							702.6	18.5	17.9-19.2			
Prostate				5551.4	126.8	125.3-128.4							685.6	18.1	17.5-18.7			
Testis				220.4	5.1	4.8-5.4							6.6	0.2	0.1-0.2			
Penis				37.6	0.9	0.8-1.1							9.2	0.2	0.2-0.3			
Other male genital organs				10.0	0.3	0.2-0.3							1.2	0.0	0.0-0.1			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
New York City

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	3070.0	32.1	31.6-32.7	2111.2	51.8	50.8-52.8	958.8	17.8	17.2-18.3	548.0	5.7	5.4-5.9	366.6	9.4	9.0-9.9	181.4	3.1	2.9-3.3
Urinary bladder (including in situ)	1593.2	16.6	16.2-17.0	1176.2	29.6	28.8-30.4	417.0	7.5	7.2-7.8	310.6	3.2	3.0-3.4	210.8	5.6	5.2-5.9	99.8	1.7	1.5-1.8
Kidney and renal pelvis	1404.0	14.8	14.4-15.1	892.4	21.2	20.5-21.8	511.6	9.7	9.3-10.1	224.0	2.3	2.2-2.5	148.6	3.7	3.4-4.0	75.4	1.3	1.2-1.5
Ureter	39.2	0.4	0.3-0.5	22.8	0.6	0.5-0.7	16.4	0.3	0.2-0.4	6.0	0.1	0.0-0.1	3.0	0.1	0.0-0.1	3.0	0.0	0.0-0.1
Other urinary organs	33.6	0.4	0.3-0.4	19.8	0.5	0.4-0.6	13.8	0.3	0.2-0.3	7.4	0.1	0.1-0.1	4.2	0.1	0.1-0.2	3.2	0.1	0.0-0.1
Eye & orbit	75.4	0.8	0.7-0.9	38.0	0.9	0.8-1.1	37.4	0.7	0.6-0.9	5.6	0.1	0.0-0.1	2.6	0.1	0.0-0.1	3.0	0.1	0.0-0.1
Brain / other central nervous system (all behaviors)	1920.8	20.9	20.5-21.3	718.6	17.6	17.0-18.2	1202.2	23.5	22.9-24.1	334.4	3.6	3.4-3.8	176.6	4.3	4.1-4.6	157.8	3.0	2.8-3.2
Malignant brain / other central nervous system	530.4	5.9	5.7-6.1	291.6	7.1	6.7-7.5	238.8	4.9	4.6-5.2	283.8	3.1	2.9-3.2	153.4	3.8	3.5-4.0	130.4	2.5	2.3-2.7
Malignant brain	493.0	5.5	5.3-5.7	271.8	6.6	6.3-7.0	221.2	4.5	4.2-4.8									
Malignant other central nervous system	37.4	0.4	0.4-0.5	19.8	0.5	0.4-0.6	17.6	0.4	0.3-0.5									
Benign brain / other central nervous system#	1390.4	15.0	14.6-15.4	427.0	10.5	10.0-10.9	963.4	18.6	18.1-19.2	50.6	0.5	0.5-0.6	23.2	0.6	0.5-0.7	27.4	0.5	0.4-0.6
Benign brain	109.2	1.3	1.2-1.4	51.8	1.3	1.1-1.5	57.4	1.3	1.1-1.4									
Benign other central nervous system	1281.2	13.7	13.4-14.1	375.2	9.2	8.8-9.6	906.0	17.4	16.9-17.9									
Endocrine system	1930.2	21.6	21.2-22.1	491.8	11.7	11.3-12.2	1438.4	30.6	29.9-31.4	73.0	0.8	0.7-0.9	28.8	0.7	0.6-0.8	44.2	0.8	0.7-0.9
Thyroid	1817.8	20.4	20.0-20.8	437.6	10.4	10.0-10.9	1380.2	29.4	28.7-30.1	49.0	0.5	0.4-0.6	18.4	0.5	0.4-0.6	30.6	0.5	0.4-0.6
Other endocrine (including thymus)	112.4	1.2	1.1-1.4	54.2	1.3	1.1-1.5	58.2	1.2	1.1-1.4	24.0	0.3	0.2-0.3	10.4	0.3	0.2-0.3	13.6	0.3	0.2-0.4
Lymphomas	2131.4	23.0	22.5-23.4	1130.8	27.7	26.9-28.4	1000.6	19.3	18.8-19.9	435.4	4.6	4.4-4.8	242.2	6.1	5.8-6.5	193.2	3.4	3.2-3.7
Hodgkin lymphoma	260.6	3.0	2.8-3.1	141.8	3.4	3.2-3.7	118.8	2.6	2.4-2.8	23.6	0.3	0.2-0.3	13.4	0.3	0.3-0.4	10.2	0.2	0.1-0.3
Non-Hodgkin lymphomas	1870.8	20.0	19.6-20.4	989.0	24.2	23.5-24.9	881.8	16.8	16.3-17.3	411.8	4.3	4.1-4.5	228.8	5.8	5.5-6.2	183.0	3.2	3.0-3.5
Myeloma	859.6	8.9	8.7-9.2	440.0	10.6	10.2-11.1	419.6	7.7	7.4-8.0	274.0	2.8	2.7-3.0	140.2	3.5	3.2-3.8	133.8	2.3	2.2-2.5
Leukemias	1269.8	13.7	13.4-14.1	710.8	17.7	17.1-18.3	559.0	10.8	10.4-11.2	476.4	5.1	4.9-5.3	251.8	6.5	6.1-6.8	224.6	4.1	3.9-4.4
Lymphocytic leukemias	621.0	6.7	6.5-7.0	362.4	9.0	8.6-9.4	258.6	5.0	4.7-5.3	117.4	1.2	1.1-1.4	67.0	1.7	1.6-1.9	50.4	0.9	0.8-1.0
Acute lymphocytic leukemia	140.0	1.8	1.6-1.9	79.0	2.1	1.9-2.3	61.0	1.5	1.3-1.7	35.6	0.4	0.4-0.5	19.6	0.5	0.4-0.6	16.0	0.3	0.3-0.4
Chronic lymphocytic leukemia	445.6	4.6	4.4-4.8	257.0	6.3	6.0-6.7	188.6	3.4	3.1-3.6	74.6	0.8	0.7-0.8	43.8	1.2	1.0-1.3	30.8	0.5	0.4-0.6
Other lymphocytic leukemias	35.4	0.4	0.3-0.4	26.4	0.6	0.5-0.7	9.0	0.2	0.1-0.2	7.2	0.1	0.1-0.1	3.6	0.1	0.1-0.1	3.6	0.1	0.0-0.1
Myeloid and monocytic leukemias	568.2	6.1	5.9-6.4	307.4	7.7	7.3-8.1	260.8	5.0	4.7-5.3	267.2	2.9	2.7-3.0	136.6	3.5	3.2-3.8	130.6	2.4	2.2-2.6
Acute myeloid leukemia	371.2	4.0	3.8-4.2	195.4	4.9	4.6-5.2	175.8	3.4	3.2-3.6	232.2	2.5	2.3-2.6	119.0	3.1	2.8-3.3	113.2	2.1	1.9-2.3
Acute monocytic leukemia	13.0	0.1	0.1-0.2	7.2	0.2	0.1-0.3	5.8	0.1	0.1-0.2	0.2	0.0	0.0-0.0	0.2	0.0	0.0-0.0	0.0	0.0	0.0-0.0
Chronic myeloid leukemia	169.8	1.8	1.7-1.9	96.2	2.4	2.2-2.6	73.6	1.4	1.2-1.5	20.8	0.2	0.2-0.3	10.8	0.3	0.2-0.4	10.0	0.2	0.1-0.2
Other myeloid/monocytic leukemias	14.2	0.2	0.1-0.2	8.6	0.2	0.2-0.3	5.6	0.1	0.1-0.2	14.0	0.1	0.1-0.2	6.6	0.2	0.1-0.2	7.4	0.1	0.1-0.2
Other leukemias	80.6	0.9	0.8-0.9	41.0	1.0	0.9-1.2	39.6	0.8	0.7-0.9	91.8	1.0	0.9-1.1	48.2	1.2	1.1-1.4	43.6	0.8	0.7-0.9
Other acute leukemias	18.8	0.2	0.2-0.2	10.2	0.3	0.2-0.3	8.6	0.2	0.1-0.2	21.4	0.2	0.2-0.3	10.8	0.3	0.2-0.3	10.6	0.2	0.1-0.2

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
New York City**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	61.8	0.7	0.6-0.7	30.8	0.7	0.6-0.9	31.0	0.6	0.5-0.7	70.4	0.7	0.7-0.8	37.4	1.0	0.8-1.1	33.0	0.6	0.5-0.7
Mesothelioma	53.8	0.6	0.5-0.6	34.4	0.9	0.8-1.0	19.4	0.4	0.3-0.5									
Kaposi sarcoma	107.6	1.2	1.1-1.3	95.8	2.3	2.1-2.5	11.8	0.2	0.2-0.3									
Myelodysplastic syndromes	327.8	3.5	3.3-3.6	179.2	4.8	4.5-5.1	148.6	2.6	2.4-2.8									
Chronic myeloproliferative disorders [^]	390.2	4.1	4.0-4.3	182.4	4.4	4.1-4.7	207.8	3.9	3.7-4.2									
Ill defined and unspecified sites	733.4	7.6	7.4-7.9	348.0	8.7	8.2-9.1	385.4	6.8	6.5-7.2	832.8	8.6	8.4-8.9	413.4	10.4	9.9-10.9	419.4	7.4	7.1-7.7

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

[^] Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
New York State Excl New York City

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	73868.6	511.4	509.7-513.1	37491.4	556.3	553.7-558.9	36377.2	481.7	479.4-484.0	22016.4	146.7	145.9-147.6	11158.0	170.3	168.9-171.8	10858.4	130.3	129.1-131.4
Oral cavity and pharynx	1823.8	12.4	12.1-12.7	1271.0	18.4	17.9-18.9	552.8	7.2	6.9-7.5	338.8	2.2	2.1-2.3	234.8	3.4	3.2-3.6	104.0	1.2	1.1-1.3
Lip	73.0	0.5	0.4-0.6	47.8	0.7	0.6-0.8	25.2	0.3	0.3-0.4	2.8	0.0	0.0-0.0	1.6	0.0	0.0-0.1	1.2	0.0	0.0-0.0
Tongue	601.6	4.1	3.9-4.2	423.0	6.0	5.7-6.3	178.6	2.3	2.2-2.5	89.6	0.6	0.5-0.6	59.4	0.9	0.8-1.0	30.2	0.4	0.3-0.4
Salivary gland	204.4	1.5	1.4-1.6	115.8	1.8	1.7-2.0	88.6	1.2	1.1-1.3	32.4	0.2	0.2-0.3	20.8	0.3	0.3-0.4	11.6	0.1	0.1-0.2
Floor of mouth	85.2	0.6	0.5-0.6	57.6	0.8	0.7-0.9	27.6	0.3	0.3-0.4	2.8	0.0	0.0-0.0	1.6	0.0	0.0-0.0	1.2	0.0	0.0-0.0
Gum & other mouth	242.2	1.7	1.6-1.8	134.8	2.0	1.9-2.2	107.4	1.4	1.2-1.5	53.0	0.3	0.3-0.4	32.4	0.5	0.4-0.6	20.6	0.2	0.2-0.3
Nasopharynx	67.6	0.5	0.5-0.6	47.6	0.7	0.7-0.9	20.0	0.3	0.2-0.3	21.0	0.1	0.1-0.2	14.4	0.2	0.2-0.3	6.6	0.1	0.1-0.1
Tonsil	341.8	2.3	2.2-2.4	282.8	4.0	3.8-4.2	59.0	0.7	0.7-0.8	33.0	0.2	0.2-0.3	27.8	0.4	0.3-0.5	5.2	0.1	0.0-0.1
Oropharynx	92.6	0.6	0.5-0.7	73.4	1.0	0.9-1.1	19.2	0.2	0.2-0.3	42.2	0.3	0.2-0.3	31.6	0.4	0.4-0.5	10.6	0.1	0.1-0.2
Hypopharynx	90.4	0.6	0.5-0.7	70.6	1.0	0.9-1.1	19.8	0.2	0.2-0.3	16.8	0.1	0.1-0.1	13.4	0.2	0.2-0.3	3.4	0.0	0.0-0.1
Other buccal cavity and pharynx	25.0	0.2	0.1-0.2	17.6	0.3	0.2-0.3	7.4	0.1	0.1-0.1	45.2	0.3	0.3-0.3	31.8	0.5	0.4-0.6	13.4	0.2	0.1-0.2
Digestive system	12122.2	82.9	82.2-83.6	6654.2	99.6	98.5-100.7	5468.0	69.0	68.2-69.9	5648.6	37.5	37.1-38.0	3180.2	47.6	46.8-48.3	2468.4	29.2	28.7-29.8
Esophagus	778.0	5.2	5.0-5.3	597.4	8.7	8.4-9.0	180.6	2.2	2.1-2.4	613.4	4.0	3.9-4.2	483.4	7.0	6.8-7.3	130.0	1.5	1.4-1.7
Stomach	1050.6	7.2	7.0-7.5	641.2	9.7	9.3-10.0	409.4	5.3	5.1-5.5	375.4	2.6	2.4-2.7	225.2	3.4	3.2-3.7	150.2	1.8	1.7-2.0
Small intestine	428.4	3.0	2.8-3.1	232.6	3.5	3.3-3.7	195.8	2.6	2.4-2.7	66.8	0.5	0.4-0.5	37.6	0.6	0.5-0.7	29.2	0.4	0.3-0.4
Colorectal	5460.0	38.2	37.7-38.6	2802.4	42.9	42.2-43.7	2657.6	34.1	33.5-34.7	1795.6	12.0	11.8-12.3	910.2	14.0	13.6-14.4	885.4	10.4	10.1-10.7
Colon excluding rectum	3873.0	27.0	26.6-27.4	1879.0	29.0	28.4-29.6	1994.0	25.3	24.7-25.8	1420.6	9.5	9.3-9.7	696.4	10.8	10.4-11.1	724.2	8.4	8.2-8.7
Cecum	790.0	5.3	5.2-5.5	344.6	5.3	5.0-5.6	445.4	5.3	5.1-5.6									
Appendix	269.2	2.2	2.0-2.3	112.6	1.8	1.7-2.0	156.6	2.5	2.3-2.7									
Ascending colon	750.4	5.1	4.9-5.3	334.4	5.1	4.9-5.4	416.0	5.0	4.8-5.3									
Hepatic flexure	171.6	1.2	1.1-1.3	89.2	1.4	1.3-1.6	82.4	1.0	0.9-1.1									
Transverse colon	360.4	2.5	2.4-2.6	177.2	2.8	2.6-2.9	183.2	2.2	2.1-2.4									
Splenic flexure	102.6	0.7	0.6-0.8	52.8	0.8	0.7-0.9	49.8	0.6	0.5-0.7									
Descending colon	215.6	1.5	1.4-1.6	123.4	1.9	1.8-2.1	92.2	1.2	1.1-1.3									
Sigmoid colon	964.0	6.8	6.6-7.0	530.8	8.0	7.7-8.4	433.2	5.8	5.6-6.1									
Large intestine, NOS	249.2	1.7	1.6-1.8	114.0	1.8	1.6-1.9	135.2	1.6	1.5-1.7									
Rectum & rectosigmoid	1587.0	11.2	11.0-11.5	923.4	14.0	13.5-14.4	663.6	8.9	8.5-9.2	375.0	2.5	2.4-2.7	213.8	3.3	3.1-3.5	161.2	2.0	1.8-2.1
Rectosigmoid junction	359.8	2.5	2.4-2.7	197.8	3.0	2.8-3.2	162.0	2.2	2.0-2.3									
Rectum	1227.2	8.7	8.4-8.9	725.6	11.0	10.6-11.4	501.6	6.7	6.4-7.0									
Anus, anal canal & anorectum	313.4	2.1	2.0-2.3	108.0	1.6	1.5-1.8	205.4	2.6	2.5-2.8	45.2	0.3	0.3-0.4	19.2	0.3	0.2-0.4	26.0	0.3	0.3-0.4
Liver and intrahepatic bile duct	1158.2	7.5	7.3-7.7	827.6	11.6	11.2-12.0	330.6	4.1	3.9-4.3	789.6	5.2	5.0-5.3	532.0	7.7	7.4-8.0	257.6	3.1	2.9-3.3

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
New York State Excl New York City

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	910.4	5.9	5.7-6.0	698.8	9.7	9.3-10.0	211.6	2.6	2.4-2.8	532.8	3.4	3.3-3.6	398.6	5.6	5.4-5.9	134.2	1.6	1.5-1.7
Intrahepatic bile duct	247.8	1.7	1.6-1.8	128.8	1.9	1.8-2.1	119.0	1.5	1.4-1.6	256.8	1.7	1.6-1.8	133.4	2.0	1.9-2.2	123.4	1.5	1.4-1.7
Gallbladder	168.2	1.1	1.1-1.2	56.0	0.9	0.8-1.0	112.2	1.4	1.3-1.5	79.8	0.5	0.5-0.6	27.0	0.4	0.3-0.5	52.8	0.6	0.5-0.7
Other biliary	258.4	1.7	1.6-1.8	141.2	2.1	2.0-2.3	117.2	1.4	1.3-1.6	74.4	0.5	0.4-0.5	37.6	0.6	0.5-0.7	36.8	0.4	0.4-0.5
Pancreas	2248.4	15.0	14.8-15.3	1144.2	17.0	16.6-17.5	1104.2	13.4	13.0-13.8	1708.2	11.3	11.1-11.5	865.8	12.9	12.5-13.3	842.4	9.9	9.6-10.2
Retroperitoneum	63.2	0.5	0.4-0.5	34.6	0.5	0.4-0.6	28.6	0.4	0.3-0.5	9.0	0.1	0.0-0.1	5.8	0.1	0.1-0.1	3.2	0.0	0.0-0.1
Peritoneum, omentum & mesentery	69.0	0.5	0.4-0.5	6.0	0.1	0.1-0.1	63.0	0.8	0.7-0.9	34.0	0.2	0.2-0.3	6.0	0.1	0.1-0.1	28.0	0.3	0.3-0.4
Other digestive organs	126.4	0.8	0.8-0.9	63.0	1.0	0.8-1.1	63.4	0.8	0.7-0.9	57.2	0.4	0.3-0.4	30.4	0.5	0.4-0.5	26.8	0.3	0.3-0.4
Respiratory system	10426.0	69.3	68.7-69.9	5152.4	76.2	75.2-77.1	5273.6	64.3	63.5-65.1	5626.6	37.2	36.8-37.7	2885.0	43.3	42.6-44.0	2741.6	32.7	32.1-33.3
Nasal cavity, middle ear & sinuses	109.4	0.8	0.7-0.8	63.2	1.0	0.9-1.1	46.2	0.6	0.5-0.7	17.2	0.1	0.1-0.1	9.4	0.1	0.1-0.2	7.8	0.1	0.1-0.1
Larynx	480.2	3.2	3.0-3.3	379.6	5.4	5.2-5.7	100.6	1.3	1.2-1.4	130.2	0.8	0.8-0.9	101.4	1.5	1.3-1.6	28.8	0.3	0.3-0.4
Lung and bronchus	9804.6	65.1	64.5-65.7	4688.0	69.4	68.5-70.3	5116.6	62.3	61.5-63.1	5463.6	36.2	35.7-36.6	2764.2	41.5	40.8-42.3	2699.4	32.2	31.6-32.8
Pleura	4.2	0.0	0.0-0.0	2.6	0.0	0.0-0.1	1.6	0.0	0.0-0.0	7.4	0.0	0.0-0.1	5.0	0.1	0.1-0.1	2.4	0.0	0.0-0.1
Trachea, mediastinum, other respiratory	27.6	0.2	0.2-0.3	19.0	0.3	0.3-0.4	8.6	0.1	0.1-0.2	8.2	0.1	0.0-0.1	5.0	0.1	0.0-0.1	3.2	0.0	0.0-0.1
Bones & joints	141.0	1.2	1.1-1.3	81.0	1.4	1.3-1.5	60.0	1.0	0.9-1.1	48.8	0.4	0.3-0.4	27.0	0.5	0.4-0.5	21.8	0.3	0.3-0.4
Soft tissue (including heart)	475.0	3.6	3.4-3.7	271.2	4.4	4.2-4.6	203.8	3.0	2.8-3.2	183.6	1.3	1.2-1.4	96.8	1.5	1.4-1.7	86.8	1.1	1.0-1.3
Skin*	3651.0	26.0	25.6-26.4	2149.0	33.0	32.4-33.7	1502.0	21.0	20.5-21.5	445.0	3.0	2.8-3.1	289.2	4.5	4.3-4.7	155.8	1.8	1.7-2.0
Melanoma of the skin	3322.4	23.7	23.3-24.0	1950.6	29.9	29.3-30.5	1371.8	19.3	18.8-19.7	301.6	2.0	1.9-2.1	191.6	3.0	2.8-3.2	110.0	1.3	1.2-1.5
Breast	10447.8	75.3	74.6-75.9	99.8	1.5	1.4-1.6	10348.0	141.2	140.0-142.5	1516.4	10.3	10.1-10.6	17.0	0.3	0.2-0.3	1499.4	18.6	18.1-19.0
Breast (in situ)#	2903.2	21.7	21.3-22.0	10.4	0.2	0.1-0.2	2892.8	41.6	40.8-42.3									
Female genital system							4251.4	56.2	55.4-57.0							1211.2	14.9	14.5-15.3
Cervix uteri							408.0	6.8	6.5-7.1							125.6	1.8	1.6-1.9
Corpus uterus and NOS							2507.6	31.8	31.2-32.4							438.4	5.3	5.1-5.5
Ovary							871.0	11.8	11.4-12.1							541.2	6.6	6.3-6.9
Vagina							50.0	0.7	0.6-0.8							11.6	0.1	0.1-0.2
Vulva							238.2	3.0	2.8-3.2							55.4	0.6	0.5-0.7
Other female genital organs							176.6	2.2	2.0-2.3							39.0	0.5	0.4-0.5
Male genital system				10118.2	141.1	139.8-142.4							1050.0	16.8	16.3-17.2			
Prostate				9686.8	133.0	131.8-134.2							1021.2	16.3	15.8-16.8			
Testis				359.8	7.0	6.7-7.3							14.2	0.2	0.2-0.3			
Penis				55.2	0.9	0.8-1.0							12.0	0.2	0.1-0.2			
Other male genital organs				16.4	0.3	0.2-0.3							2.6	0.0	0.0-0.1			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
New York State Excl New York City

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	6683.4	45.5	45.0-46.0	4722.4	71.3	70.4-72.3	1961.0	24.7	24.2-25.2	1156.0	7.6	7.4-7.8	776.8	12.1	11.7-12.5	379.2	4.3	4.1-4.6
Urinary bladder (including in situ)	3852.6	25.8	25.4-26.1	2885.2	43.9	43.1-44.6	967.4	11.7	11.3-12.0	669.2	4.4	4.2-4.5	472.2	7.5	7.2-7.8	197.0	2.2	2.1-2.4
Kidney and renal pelvis	2669.0	18.7	18.3-19.0	1731.2	25.9	25.3-26.4	937.8	12.4	12.0-12.8	456.4	3.0	2.9-3.1	287.8	4.3	4.1-4.6	168.6	2.0	1.9-2.1
Ureter	100.6	0.7	0.6-0.7	62.4	1.0	0.9-1.1	38.2	0.5	0.4-0.5	14.0	0.1	0.1-0.1	5.4	0.1	0.1-0.1	8.6	0.1	0.1-0.1
Other urinary organs	61.2	0.4	0.4-0.5	43.6	0.7	0.6-0.8	17.6	0.2	0.2-0.3	16.4	0.1	0.1-0.1	11.4	0.2	0.1-0.2	5.0	0.1	0.0-0.1
Eye & orbit	130.4	1.0	0.9-1.0	65.0	1.0	0.9-1.1	65.4	0.9	0.8-1.1	10.6	0.1	0.1-0.1	5.0	0.1	0.0-0.1	5.6	0.1	0.0-0.1
Brain / other central nervous system (all behaviors)	3062.4	22.9	22.5-23.3	1225.4	19.8	19.3-20.3	1837.0	25.7	25.2-26.3	734.6	5.2	5.0-5.4	398.6	6.1	5.8-6.4	336.0	4.4	4.2-4.6
Malignant brain / other central nervous system	898.4	7.0	6.8-7.2	500.6	8.2	7.8-8.5	397.8	5.9	5.6-6.2	604.6	4.3	4.1-4.4	339.8	5.2	4.9-5.4	264.8	3.5	3.3-3.7
Malignant brain	842.2	6.5	6.3-6.7	472.6	7.7	7.3-8.0	369.6	5.4	5.2-5.7									
Malignant other central nervous system	56.2	0.5	0.4-0.6	28.0	0.5	0.4-0.6	28.2	0.5	0.4-0.6									
Benign brain / other central nervous system#	2164.0	15.9	15.6-16.3	724.8	11.6	11.2-12.0	1439.2	19.8	19.3-20.3	130.0	0.9	0.8-1.0	58.8	0.9	0.8-1.0	71.2	0.9	0.8-1.0
Benign brain	213.0	1.8	1.7-1.9	108.8	1.9	1.8-2.1	104.2	1.7	1.6-1.9									
Benign other central nervous system	1951.0	14.1	13.8-14.4	616.0	9.7	9.4-10.1	1335.0	18.1	17.6-18.5									
Endocrine system	2335.8	19.6	19.2-20.0	685.8	11.3	10.9-11.7	1650.0	27.7	27.1-28.4	112.6	0.8	0.7-0.9	52.8	0.8	0.7-1.0	59.8	0.7	0.7-0.8
Thyroid	2207.4	18.6	18.2-18.9	616.6	10.2	9.8-10.6	1590.8	26.9	26.3-27.5	77.8	0.5	0.5-0.6	36.6	0.6	0.5-0.7	41.2	0.5	0.4-0.5
Other endocrine (including thymus)	128.4	1.0	0.9-1.1	69.2	1.1	1.0-1.3	59.2	0.9	0.8-1.0	34.8	0.3	0.2-0.3	16.2	0.3	0.2-0.3	18.6	0.3	0.2-0.3
Lymphomas	3566.6	25.6	25.2-26.0	1932.4	30.1	29.5-30.8	1634.2	21.9	21.4-22.4	824.2	5.5	5.4-5.7	462.0	7.3	7.0-7.6	362.2	4.3	4.1-4.5
Hodgkin lymphoma	371.6	3.2	3.0-3.3	200.6	3.5	3.3-3.7	171.0	2.9	2.7-3.2	40.8	0.3	0.3-0.3	24.2	0.4	0.3-0.5	16.6	0.2	0.2-0.3
Non-Hodgkin lymphomas	3195.0	22.4	22.0-22.7	1731.8	26.6	26.1-27.2	1463.2	19.0	18.5-19.4	783.4	5.3	5.1-5.4	437.8	6.9	6.6-7.2	345.6	4.1	3.9-4.3
Myeloma	1146.8	7.8	7.6-8.0	647.4	9.7	9.4-10.1	499.4	6.2	6.0-6.5	427.6	2.8	2.7-2.9	229.0	3.5	3.3-3.7	198.6	2.3	2.1-2.4
Leukemias	2480.6	17.5	17.2-17.9	1463.4	22.8	22.2-23.3	1017.2	13.3	12.9-13.7	898.0	6.1	5.9-6.3	520.0	8.3	8.0-8.6	378.0	4.5	4.3-4.7
Lymphocytic leukemias	1314.2	9.2	9.0-9.4	810.2	12.4	12.0-12.8	504.0	6.5	6.3-6.8	233.8	1.6	1.5-1.7	140.0	2.3	2.1-2.5	93.8	1.1	1.0-1.2
Acute lymphocytic leukemia	171.6	1.6	1.5-1.7	96.4	1.8	1.6-2.0	75.2	1.4	1.2-1.5	49.8	0.4	0.3-0.4	28.2	0.5	0.4-0.6	21.6	0.3	0.3-0.4
Chronic lymphocytic leukemia	1066.4	7.1	6.9-7.2	656.6	9.7	9.3-10.0	409.8	4.9	4.7-5.1	166.0	1.1	1.0-1.1	101.2	1.6	1.5-1.8	64.8	0.7	0.6-0.7
Other lymphocytic leukemias	76.2	0.5	0.5-0.6	57.2	0.9	0.8-1.0	19.0	0.3	0.2-0.3	18.0	0.1	0.1-0.1	10.6	0.2	0.1-0.2	7.4	0.1	0.1-0.1
Myeloid and monocytic leukemias	1050.2	7.5	7.3-7.7	593.0	9.4	9.1-9.8	457.2	6.1	5.8-6.3	502.8	3.4	3.3-3.6	289.6	4.6	4.3-4.8	213.2	2.6	2.4-2.8
Acute myeloid leukemia	690.4	4.9	4.8-5.1	391.6	6.2	5.9-6.5	298.8	3.9	3.7-4.2	428.8	2.9	2.8-3.1	248.0	3.9	3.7-4.1	180.8	2.2	2.1-2.4
Acute monocytic leukemia	31.0	0.2	0.2-0.3	17.6	0.3	0.2-0.4	13.4	0.2	0.1-0.2	3.4	0.0	0.0-0.0	1.4	0.0	0.0-0.0	2.0	0.0	0.0-0.0
Chronic myeloid leukemia	310.2	2.2	2.1-2.4	174.6	2.8	2.6-3.0	135.6	1.8	1.7-2.0	37.4	0.3	0.2-0.3	18.8	0.3	0.2-0.4	18.6	0.2	0.2-0.3
Other myeloid/monocytic leukemias	18.6	0.1	0.1-0.2	9.2	0.1	0.1-0.2	9.4	0.1	0.1-0.2	33.2	0.2	0.2-0.3	21.4	0.3	0.3-0.4	11.8	0.1	0.1-0.2
Other leukemias	116.2	0.8	0.7-0.9	60.2	1.0	0.8-1.1	56.0	0.7	0.6-0.8	161.4	1.1	1.0-1.2	90.4	1.5	1.3-1.6	71.0	0.8	0.7-0.9
Other acute leukemias	29.8	0.2	0.2-0.2	15.6	0.2	0.2-0.3	14.2	0.2	0.1-0.2	62.2	0.4	0.4-0.5	34.8	0.6	0.5-0.7	27.4	0.3	0.3-0.4

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
New York State Excl New York City**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	86.4	0.6	0.6-0.7	44.6	0.7	0.6-0.8	41.8	0.5	0.5-0.6	99.2	0.7	0.6-0.7	55.6	0.9	0.8-1.0	43.6	0.5	0.4-0.6
Mesothelioma	129.4	0.9	0.8-1.0	95.6	1.5	1.4-1.7	33.8	0.4	0.4-0.5									
Kaposi sarcoma	29.2	0.2	0.2-0.3	24.2	0.4	0.3-0.5	5.0	0.1	0.0-0.1									
Myelodysplastic syndromes	803.0	5.4	5.2-5.6	465.6	7.5	7.2-7.8	337.4	3.9	3.7-4.1									
Chronic myeloproliferative disorders [^]	791.4	5.6	5.5-5.8	389.0	6.1	5.8-6.4	402.4	5.2	5.0-5.4									
Ill defined and unspecified sites	1417.2	9.5	9.3-9.7	703.2	10.9	10.5-11.2	714.0	8.4	8.1-8.7	1913.8	12.6	12.4-12.9	992.6	15.3	14.8-15.7	921.2	10.7	10.4-11.0

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

[^] Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019**

Bronx

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	6481.4	439.4	434.6-444.3	3149.0	503.3	495.3-511.5	3332.4	399.0	392.8-405.2	2040.6	139.6	136.9-142.4	1002.2	171.7	166.8-176.6	1038.4	119.7	116.4-123.0
Oral cavity and pharynx	149.4	10.0	9.3-10.8	100.4	15.7	14.4-17.2	49.0	5.8	5.1-6.6	39.2	2.7	2.3-3.1	27.0	4.4	3.7-5.3	12.2	1.4	1.1-1.8
Lip	3.2	0.2	0.1-0.3	2.2	0.3	0.2-0.6	1.0	0.1	0.0-0.3	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1
Tongue	34.4	2.3	2.0-2.7	24.2	3.7	3.1-4.5	10.2	1.2	0.9-1.6	8.0	0.5	0.4-0.7	5.6	0.9	0.6-1.3	2.4	0.3	0.1-0.5
Salivary gland	14.0	1.0	0.8-1.2	6.8	1.1	0.7-1.5	7.2	0.9	0.6-1.2	3.2	0.2	0.1-0.4	1.0	0.2	0.1-0.4	2.2	0.2	0.1-0.5
Floor of mouth	6.2	0.4	0.3-0.6	3.8	0.5	0.3-0.8	2.4	0.3	0.1-0.5	0.2	0.0	0.0-0.1	0.2	0.0	0.0-0.2	0.0	0.0	0.0-0.1
Gum & other mouth	24.2	1.7	1.4-2.0	12.2	2.0	1.5-2.5	12.0	1.4	1.1-1.8	5.0	0.3	0.2-0.5	3.4	0.5	0.3-0.9	1.6	0.2	0.1-0.3
Nasopharynx	12.2	0.8	0.6-1.1	9.2	1.5	1.1-2.0	3.0	0.3	0.2-0.6	4.8	0.4	0.2-0.5	3.0	0.5	0.3-0.9	1.8	0.3	0.1-0.5
Tonsil	29.4	2.0	1.6-2.3	22.4	3.5	2.9-4.2	7.0	0.8	0.6-1.1	3.6	0.2	0.1-0.4	3.4	0.5	0.3-0.8	0.2	0.0	0.0-0.1
Oropharynx	10.0	0.7	0.5-0.9	8.0	1.2	0.9-1.7	2.0	0.2	0.1-0.4	6.0	0.4	0.3-0.6	4.2	0.7	0.4-1.1	1.8	0.2	0.1-0.4
Hypopharynx	14.8	1.0	0.8-1.3	10.8	1.8	1.3-2.3	4.0	0.5	0.3-0.7	3.4	0.2	0.1-0.4	2.6	0.4	0.2-0.8	0.8	0.1	0.0-0.2
Other buccal cavity and pharynx	1.0	0.1	0.0-0.2	0.8	0.1	0.0-0.4	0.2	0.0	0.0-0.1	5.0	0.3	0.2-0.5	3.6	0.6	0.3-0.9	1.4	0.2	0.1-0.4
Digestive system	1345.2	91.3	89.1-93.5	731.2	118.0	114.1-122.0	614.0	72.0	69.4-74.6	609.4	41.5	40.1-43.1	334.6	56.0	53.3-58.8	274.8	31.4	29.7-33.1
Esophagus	50.2	3.4	3.0-3.8	36.8	6.0	5.1-6.9	13.4	1.6	1.2-2.0	36.0	2.4	2.1-2.8	24.6	4.0	3.3-4.8	11.4	1.3	1.0-1.7
Stomach	144.0	10.0	9.3-10.8	75.8	12.7	11.4-14.1	68.2	8.2	7.3-9.1	58.6	4.1	3.7-4.6	34.6	6.1	5.2-7.1	24.0	2.9	2.4-3.4
Small intestine	43.6	3.0	2.6-3.4	21.6	3.7	3.0-4.5	22.0	2.6	2.1-3.2	4.4	0.3	0.2-0.5	2.2	0.4	0.2-0.7	2.2	0.3	0.1-0.5
Colorectal	533.6	36.6	35.2-38.1	273.2	44.5	42.1-47.0	260.4	30.9	29.2-32.7	188.8	13.0	12.2-13.9	93.0	16.0	14.5-17.5	95.8	10.9	9.9-12.0
Colon excluding rectum	373.4	25.7	24.6-26.9	186.0	30.6	28.6-32.7	187.4	22.2	20.8-23.7	155.0	10.7	9.9-11.4	71.8	12.3	11.1-13.7	83.2	9.5	8.6-10.4
Cecum	74.4	5.1	4.6-5.7	30.4	5.1	4.3-5.9	44.0	5.2	4.5-5.9									
Appendix	20.4	1.5	1.2-1.8	7.2	1.2	0.8-1.7	13.2	1.7	1.3-2.2									
Ascending colon	68.0	4.7	4.2-5.3	34.2	5.7	4.9-6.7	33.8	4.0	3.4-4.6									
Hepatic flexure	18.2	1.2	1.0-1.5	9.2	1.6	1.1-2.1	9.0	1.0	0.7-1.4									
Transverse colon	33.2	2.3	1.9-2.6	19.4	3.1	2.5-3.8	13.8	1.6	1.3-2.1									
Splenic flexure	11.4	0.8	0.6-1.0	6.4	1.0	0.7-1.4	5.0	0.6	0.4-0.9									
Descending colon	26.2	1.8	1.5-2.1	14.8	2.4	1.9-3.0	11.4	1.3	1.0-1.7									
Sigmoid colon	99.4	6.8	6.2-7.5	53.4	8.7	7.7-9.8	46.0	5.6	4.9-6.4									
Large intestine, NOS	22.2	1.5	1.2-1.8	11.0	1.9	1.4-2.4	11.2	1.2	0.9-1.6									
Rectum & rectosigmoid	160.2	10.9	10.1-11.7	87.2	13.9	12.6-15.3	73.0	8.7	7.8-9.7	33.8	2.4	2.0-2.7	21.2	3.6	3.0-4.4	12.6	1.4	1.1-1.9
Rectosigmoid junction	34.8	2.4	2.0-2.8	18.6	3.0	2.4-3.7	16.2	1.9	1.5-2.4									
Rectum	125.4	8.5	7.9-9.2	68.6	10.9	9.7-12.1	56.8	6.8	6.0-7.7									
Anus, anal canal & anorectum	45.0	3.0	2.6-3.4	21.8	3.3	2.7-4.0	23.2	2.8	2.3-3.3	6.0	0.4	0.3-0.6	3.4	0.5	0.3-0.8	2.6	0.3	0.2-0.5
Liver and intrahepatic bile duct	232.2	15.1	14.2-16.0	163.8	25.0	23.3-26.8	68.4	7.7	6.9-8.6	133.8	8.9	8.2-9.6	91.0	14.5	13.1-15.9	42.8	4.8	4.2-5.5

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019**

Bronx

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	206.8	13.4	12.6-14.3	150.6	22.9	21.2-24.6	56.2	6.3	5.6-7.1	104.4	6.9	6.3-7.5	77.8	12.3	11.1-13.6	26.6	3.0	2.5-3.5
Intrahepatic bile duct	25.4	1.7	1.4-2.0	13.2	2.1	1.6-2.7	12.2	1.4	1.1-1.8	29.4	2.0	1.7-2.3	13.2	2.2	1.7-2.8	16.2	1.8	1.4-2.3
Gallbladder	38.8	2.6	2.3-3.1	13.8	2.3	1.8-3.0	25.0	2.9	2.4-3.4	18.8	1.3	1.0-1.5	6.2	1.0	0.7-1.4	12.6	1.4	1.1-1.8
Other biliary	31.0	2.1	1.8-2.5	13.6	2.2	1.7-2.8	17.4	2.0	1.6-2.5	7.4	0.5	0.4-0.7	3.4	0.6	0.4-1.0	4.0	0.5	0.3-0.7
Pancreas	202.0	13.7	12.9-14.6	101.6	16.7	15.3-18.3	100.4	11.5	10.5-12.6	146.4	10.0	9.3-10.8	72.8	12.4	11.1-13.7	73.6	8.4	7.6-9.3
Retroperitoneum	6.4	0.4	0.3-0.6	3.4	0.5	0.3-0.8	3.0	0.4	0.2-0.6	1.0	0.1	0.0-0.2	0.4	0.1	0.0-0.2	0.6	0.1	0.0-0.2
Peritoneum, omentum & mesentery	6.2	0.4	0.3-0.6	0.6	0.1	0.0-0.3	5.6	0.7	0.4-1.0	2.6	0.2	0.1-0.3	0.4	0.1	0.0-0.2	2.2	0.3	0.1-0.5
Other digestive organs	12.2	0.9	0.6-1.1	5.2	1.0	0.6-1.4	7.0	0.8	0.6-1.1	5.6	0.4	0.3-0.6	2.6	0.4	0.2-0.7	3.0	0.4	0.2-0.6
Respiratory system	742.0	50.3	48.7-51.9	389.2	64.2	61.3-67.2	352.8	40.7	38.8-42.7	413.0	28.1	26.9-29.4	226.2	38.2	36.0-40.6	186.8	21.3	19.9-22.7
Nasal cavity, middle ear & sinuses	12.0	0.8	0.6-1.0	7.2	1.1	0.8-1.5	4.8	0.6	0.4-0.9	2.6	0.2	0.1-0.3	0.8	0.1	0.0-0.4	1.8	0.2	0.1-0.4
Larynx	59.4	4.0	3.5-4.5	42.6	6.8	5.9-7.8	16.8	2.0	1.6-2.5	18.2	1.2	1.0-1.5	14.2	2.4	1.9-3.0	4.0	0.5	0.3-0.7
Lung and bronchus	666.6	45.2	43.7-46.8	336.2	55.8	53.1-58.6	330.4	38.0	36.2-40.0	390.0	26.5	25.4-27.8	210.0	35.5	33.3-37.7	180.0	20.5	19.2-21.9
Pleura	0.6	0.0	0.0-0.1	0.4	0.1	0.0-0.2	0.2	0.0	0.0-0.1	0.6	0.0	0.0-0.1	0.4	0.1	0.0-0.2	0.2	0.0	0.0-0.1
Trachea, mediastinum, other respiratory	3.4	0.3	0.1-0.4	2.8	0.5	0.2-0.8	0.6	0.1	0.0-0.2	1.6	0.1	0.1-0.2	0.8	0.1	0.0-0.4	0.8	0.1	0.0-0.3
Bones & joints	16.2	1.1	0.9-1.4	9.0	1.3	1.0-1.8	7.2	1.0	0.7-1.3	8.6	0.6	0.4-0.8	5.4	0.8	0.5-1.2	3.2	0.4	0.2-0.6
Soft tissue (including heart)	45.2	3.2	2.8-3.6	21.8	3.5	2.8-4.2	23.4	3.0	2.4-3.6	13.4	0.9	0.7-1.2	5.6	0.9	0.6-1.2	7.8	0.9	0.7-1.3
Skin*	79.4	5.6	5.1-6.2	41.8	7.3	6.3-8.4	37.6	4.5	3.9-5.2	15.0	1.0	0.8-1.3	10.2	1.7	1.3-2.3	4.8	0.5	0.3-0.8
Melanoma of the skin	58.6	4.1	3.7-4.6	30.8	5.4	4.6-6.4	27.8	3.3	2.8-4.0	7.6	0.5	0.4-0.7	5.0	0.8	0.5-1.3	2.6	0.3	0.2-0.5
Breast	955.2	65.8	63.9-67.7	8.6	1.4	1.0-1.9	946.6	115.0	111.7-118.4	171.8	11.9	11.1-12.7	1.6	0.3	0.1-0.5	170.2	20.0	18.7-21.4
Breast (in situ)#	296.6	20.3	19.3-21.4	1.8	0.3	0.2-0.6	294.8	35.9	34.1-37.9									
Female genital system							464.4	55.7	53.4-58.0							148.2	17.3	16.1-18.6
Cervix uteri							76.2	9.9	8.9-11.0							21.2	2.6	2.2-3.2
Corpus uteri and NOS							266.0	31.1	29.4-32.8							72.8	8.4	7.5-9.3
Ovary							87.0	10.5	9.5-11.5							44.6	5.2	4.6-6.0
Vagina							6.0	0.7	0.5-1.0							1.8	0.2	0.1-0.4
Vulva							15.6	1.9	1.5-2.4							4.4	0.5	0.3-0.8
Other female genital organs							13.6	1.6	1.2-2.0							3.4	0.4	0.2-0.6
Male genital system				989.6	151.8	147.5-156.2							130.0	24.4	22.5-26.4			
Prostate				956.4	146.8	142.5-151.1							126.2	23.7	21.8-25.6			
Testis				22.8	3.3	2.7-4.0							2.4	0.4	0.2-0.7			
Penis				8.8	1.4	1.0-1.9							1.4	0.3	0.1-0.6			
Other male genital organs				1.6	0.3	0.1-0.5							0.0	0.0	0.0-0.1			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019**

Bronx

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	444.8	30.3	29.0-31.6	286.8	47.5	45.1-50.1	158.0	18.5	17.2-19.9	89.6	6.2	5.7-6.8	56.0	10.0	8.8-11.3	33.6	3.8	3.2-4.4
Urinary bladder (including in situ)	199.8	13.8	12.9-14.7	139.0	24.1	22.3-26.0	60.8	7.0	6.3-7.9	46.0	3.2	2.8-3.7	28.4	5.3	4.4-6.2	17.6	1.9	1.6-2.4
Kidney and renal pelvis	236.8	15.9	15.0-16.9	143.2	22.7	21.0-24.4	93.6	11.0	10.0-12.1	42.4	2.9	2.5-3.4	27.2	4.6	3.9-5.5	15.2	1.7	1.3-2.2
Ureter	3.8	0.2	0.1-0.4	2.0	0.4	0.2-0.7	1.8	0.2	0.1-0.4	0.2	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.2	0.0	0.0-0.1
Other urinary organs	4.4	0.3	0.2-0.5	2.6	0.4	0.2-0.7	1.8	0.2	0.1-0.4	1.0	0.1	0.0-0.2	0.4	0.1	0.0-0.3	0.6	0.1	0.0-0.2
Eye & orbit	11.4	0.8	0.6-1.0	6.6	1.0	0.7-1.5	4.8	0.6	0.4-0.9	0.8	0.1	0.0-0.1	0.4	0.1	0.0-0.2	0.4	0.0	0.0-0.1
Brain / other central nervous system (all behaviors)	314.6	21.7	20.7-22.9	106.8	17.1	15.7-18.7	207.8	25.2	23.7-26.8	51.8	3.5	3.1-4.0	26.8	4.4	3.7-5.2	25.0	3.0	2.5-3.5
Malignant brain / other central nervous system	77.0	5.4	4.8-5.9	40.2	6.4	5.5-7.3	36.8	4.6	3.9-5.3	43.4	3.0	2.6-3.4	23.2	3.8	3.1-4.6	20.2	2.4	2.0-2.9
Malignant brain	71.2	4.9	4.4-5.5	37.2	5.9	5.1-6.8	34.0	4.2	3.6-4.9									
Malignant other central nervous system	5.8	0.4	0.3-0.6	3.0	0.5	0.3-0.8	2.8	0.4	0.2-0.6									
Benign brain / other central nervous system#	237.6	16.4	15.5-17.4	66.6	10.8	9.6-12.0	171.0	20.6	19.3-22.1	8.4	0.6	0.4-0.8	3.6	0.6	0.3-0.9	4.8	0.5	0.3-0.8
Benign brain	19.0	1.3	1.0-1.6	9.6	1.4	1.0-1.9	9.4	1.2	0.9-1.6									
Benign other central nervous system	218.6	15.1	14.2-16.0	57.0	9.4	8.3-10.5	161.6	19.5	18.1-20.9									
Endocrine system	234.0	16.5	15.6-17.5	48.6	7.7	6.7-8.7	185.4	24.0	22.4-25.6	11.6	0.8	0.6-1.1	4.6	0.8	0.5-1.2	7.0	0.8	0.6-1.2
Thyroid	216.6	15.3	14.4-16.2	41.0	6.5	5.6-7.4	175.6	22.7	21.2-24.3	7.6	0.5	0.4-0.7	3.4	0.6	0.3-0.9	4.2	0.5	0.3-0.8
Other endocrine (including thymus)	17.4	1.2	1.0-1.5	7.6	1.2	0.8-1.7	9.8	1.2	0.9-1.7	4.0	0.3	0.2-0.4	1.2	0.2	0.1-0.4	2.8	0.3	0.2-0.6
Lymphomas	326.2	22.6	21.5-23.7	167.2	27.0	25.1-28.9	159.0	19.4	18.0-20.8	75.6	5.3	4.7-5.8	42.2	7.2	6.3-8.3	33.4	3.9	3.3-4.6
Hodgkin lymphoma	45.2	3.2	2.8-3.6	24.6	3.7	3.1-4.5	20.6	2.7	2.2-3.2	4.6	0.3	0.2-0.5	2.8	0.5	0.2-0.8	1.8	0.2	0.1-0.4
Non-Hodgkin lymphomas	281.0	19.4	18.4-20.5	142.6	23.2	21.5-25.0	138.4	16.7	15.5-18.0	71.0	4.9	4.4-5.5	39.4	6.8	5.8-7.8	31.6	3.7	3.1-4.3
Myeloma	171.0	11.5	10.8-12.4	86.4	13.9	12.6-15.4	84.6	10.0	9.0-11.0	51.8	3.5	3.1-4.0	27.8	4.6	3.9-5.5	24.0	2.7	2.2-3.2
Leukemias	186.2	12.8	11.9-13.6	96.4	15.7	14.3-17.2	89.8	10.7	9.8-11.8	75.6	5.2	4.7-5.7	38.2	6.5	5.6-7.5	37.4	4.3	3.7-5.0
Lymphocytic leukemias	86.6	5.9	5.3-6.5	48.8	7.7	6.8-8.8	37.8	4.5	3.8-5.2	16.6	1.2	0.9-1.4	10.8	1.9	1.4-2.4	5.8	0.6	0.4-0.9
Acute lymphocytic leukemia	27.8	1.9	1.6-2.3	17.0	2.4	1.9-3.0	10.8	1.4	1.1-1.9	7.4	0.5	0.4-0.7	5.2	0.8	0.5-1.2	2.2	0.3	0.1-0.5
Chronic lymphocytic leukemia	53.6	3.6	3.2-4.1	28.6	4.8	4.0-5.7	25.0	2.8	2.3-3.3	8.8	0.6	0.4-0.8	5.6	1.1	0.7-1.5	3.2	0.3	0.2-0.5
Other lymphocytic leukemias	5.2	0.4	0.2-0.5	3.2	0.5	0.3-0.8	2.0	0.2	0.1-0.4	0.4	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.4	0.0	0.0-0.2
Myeloid and monocytic leukemias	86.8	6.0	5.4-6.6	42.4	7.0	6.1-8.1	44.4	5.3	4.6-6.1	42.0	2.9	2.5-3.3	20.0	3.4	2.7-4.1	22.0	2.6	2.1-3.1
Acute myeloid leukemia	55.6	3.9	3.4-4.4	27.4	4.6	3.9-5.5	28.2	3.4	2.9-4.1	37.6	2.6	2.2-3.0	17.8	3.0	2.4-3.7	19.8	2.3	1.9-2.9
Acute monocytic leukemia	1.0	0.1	0.0-0.2	0.4	0.1	0.0-0.2	0.6	0.1	0.0-0.2	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1
Chronic myeloid leukemia	27.0	1.8	1.5-2.2	13.2	2.1	1.6-2.7	13.8	1.6	1.2-2.0	2.8	0.2	0.1-0.3	1.4	0.2	0.1-0.5	1.4	0.1	0.1-0.3
Other myeloid/monocytic leukemias	3.2	0.2	0.1-0.3	1.4	0.2	0.1-0.4	1.8	0.2	0.1-0.4	1.6	0.1	0.1-0.2	0.8	0.1	0.0-0.4	0.8	0.1	0.0-0.3
Other leukemias	12.8	0.9	0.7-1.1	5.2	0.9	0.6-1.3	7.6	1.0	0.7-1.3	17.0	1.2	0.9-1.5	7.4	1.3	0.9-1.8	9.6	1.1	0.8-1.5
Other acute leukemias	3.4	0.2	0.1-0.4	1.2	0.2	0.1-0.5	2.2	0.3	0.1-0.5	3.2	0.2	0.1-0.4	1.4	0.2	0.1-0.4	1.8	0.2	0.1-0.4

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019**

Bronx

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	9.4	0.7	0.5-0.9	4.0	0.7	0.4-1.0	5.4	0.7	0.5-1.0	13.8	0.9	0.7-1.2	6.0	1.1	0.7-1.5	7.8	0.9	0.6-1.3
Mesothelioma	7.0	0.5	0.3-0.7	4.8	0.9	0.6-1.3	2.2	0.3	0.1-0.5									
Kaposi sarcoma	20.0	1.4	1.1-1.7	17.8	2.7	2.2-3.4	2.2	0.3	0.1-0.5									
Myelodysplastic syndromes	43.6	3.0	2.6-3.4	23.4	4.1	3.4-4.9	20.2	2.4	1.9-2.9									
Chronic myeloproliferative disorders [^]	65.8	4.5	4.0-5.0	27.6	4.5	3.8-5.3	38.2	4.5	3.9-5.2									
Ill defined and unspecified sites	107.8	7.3	6.7-7.9	51.6	8.7	7.7-9.9	56.2	6.2	5.5-7.0	143.6	9.8	9.1-10.5	69.2	12.0	10.7-13.4	74.4	8.4	7.5-9.3

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

[^] Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
Kings (Brooklyn)

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	12258.2	442.8	439.3-446.4	5847.8	487.1	481.4-492.8	6410.4	416.7	412.1-421.4	3555.4	128.0	126.1-130.0	1715.4	150.6	147.4-153.9	1840.0	113.6	111.2-116.0
Oral cavity and pharynx	258.0	9.4	8.8-9.9	167.2	13.9	12.9-14.9	90.8	5.8	5.3-6.4	52.0	1.9	1.7-2.2	37.4	3.2	2.8-3.7	14.6	0.9	0.7-1.1
Lip	6.6	0.2	0.2-0.3	4.0	0.4	0.2-0.5	2.6	0.2	0.1-0.3	0.4	0.0	0.0-0.0	0.0	0.0	0.0-0.1	0.4	0.0	0.0-0.1
Tongue	60.2	2.2	1.9-2.4	39.6	3.2	2.8-3.7	20.6	1.3	1.1-1.6	8.8	0.3	0.2-0.4	6.2	0.5	0.4-0.8	2.6	0.1	0.1-0.3
Salivary gland	30.6	1.1	0.9-1.3	14.0	1.2	0.9-1.5	16.6	1.0	0.8-1.3	4.2	0.2	0.1-0.2	2.2	0.2	0.1-0.3	2.0	0.1	0.1-0.2
Floor of mouth	8.6	0.3	0.2-0.4	5.8	0.5	0.3-0.7	2.8	0.2	0.1-0.3	0.6	0.0	0.0-0.1	0.2	0.0	0.0-0.1	0.4	0.0	0.0-0.1
Gum & other mouth	45.4	1.6	1.4-1.9	25.8	2.2	1.8-2.6	19.6	1.2	1.0-1.5	7.2	0.3	0.2-0.4	3.6	0.3	0.2-0.5	3.6	0.2	0.1-0.4
Nasopharynx	43.6	1.6	1.4-1.9	29.6	2.4	2.0-2.8	14.0	0.9	0.7-1.2	11.2	0.4	0.3-0.5	9.6	0.8	0.6-1.1	1.6	0.1	0.0-0.2
Tonsil	28.4	1.0	0.9-1.2	22.0	1.8	1.5-2.2	6.4	0.4	0.3-0.6	2.8	0.1	0.1-0.2	2.6	0.2	0.1-0.4	0.2	0.0	0.0-0.1
Oropharynx	15.8	0.5	0.4-0.7	11.8	0.9	0.7-1.2	4.0	0.2	0.1-0.4	8.2	0.3	0.2-0.4	6.0	0.5	0.3-0.7	2.2	0.1	0.1-0.3
Hypopharynx	15.2	0.6	0.4-0.7	11.8	1.0	0.8-1.3	3.4	0.2	0.1-0.4	1.6	0.1	0.0-0.1	1.4	0.1	0.0-0.2	0.2	0.0	0.0-0.1
Other buccal cavity and pharynx	3.6	0.1	0.1-0.2	2.8	0.2	0.1-0.4	0.8	0.0	0.0-0.1	7.0	0.3	0.2-0.4	5.6	0.5	0.3-0.7	1.4	0.1	0.0-0.2
Digestive system	2409.6	86.7	85.1-88.3	1290.6	108.5	105.8-111.2	1119.0	70.4	68.5-72.3	1083.4	38.9	37.8-39.9	582.0	50.1	48.3-52.0	501.4	30.5	29.3-31.8
Esophagus	87.6	3.1	2.8-3.4	61.6	5.1	4.6-5.7	26.0	1.6	1.3-1.9	56.2	2.0	1.8-2.2	43.8	3.7	3.2-4.2	12.4	0.7	0.6-1.0
Stomach	315.2	11.4	10.8-12.0	184.0	15.6	14.6-16.7	131.2	8.3	7.7-9.0	143.2	5.3	4.9-5.7	83.2	7.4	6.7-8.2	60.0	3.7	3.3-4.2
Small intestine	69.8	2.6	2.3-2.8	32.0	2.7	2.3-3.2	37.8	2.5	2.1-2.8	10.0	0.4	0.3-0.5	4.8	0.4	0.3-0.6	5.2	0.3	0.2-0.5
Colorectal	1079.6	39.1	38.1-40.2	553.4	47.0	45.2-48.8	526.2	33.4	32.1-34.7	350.2	12.6	12.0-13.2	171.2	15.0	14.0-16.1	179.0	10.8	10.1-11.6
Colon excluding rectum	755.6	27.3	26.4-28.2	372.2	31.7	30.3-33.2	383.4	24.2	23.1-25.3	289.0	10.3	9.8-10.9	139.0	12.2	11.3-13.2	150.0	9.0	8.4-9.7
Cecum	134.4	4.8	4.5-5.2	58.4	5.0	4.5-5.7	76.0	4.7	4.2-5.2									
Appendix	33.0	1.2	1.0-1.4	13.2	1.1	0.8-1.4	19.8	1.4	1.1-1.7									
Ascending colon	140.8	5.1	4.7-5.5	63.0	5.4	4.8-6.0	77.8	4.9	4.4-5.4									
Hepatic flexure	32.0	1.1	1.0-1.3	16.2	1.4	1.1-1.8	15.8	1.0	0.8-1.2									
Transverse colon	70.4	2.5	2.3-2.8	35.4	3.0	2.6-3.5	35.0	2.1	1.8-2.5									
Splenic flexure	20.6	0.7	0.6-0.9	11.6	1.0	0.8-1.3	9.0	0.6	0.4-0.7									
Descending colon	65.0	2.4	2.1-2.6	35.2	3.0	2.5-3.5	29.8	1.9	1.6-2.3									
Sigmoid colon	199.2	7.2	6.8-7.7	110.6	9.2	8.5-10.0	88.6	5.8	5.2-6.4									
Large intestine, NOS	60.2	2.2	1.9-2.4	28.6	2.6	2.2-3.1	31.6	1.9	1.6-2.3									
Rectum & rectosigmoid	324.0	11.8	11.2-12.4	181.2	15.2	14.2-16.3	142.8	9.2	8.5-9.9	61.2	2.2	2.0-2.5	32.2	2.8	2.4-3.3	29.0	1.8	1.5-2.1
Rectosigmoid junction	78.0	2.8	2.6-3.1	43.4	3.7	3.2-4.2	34.6	2.2	1.9-2.6									
Rectum	246.0	9.0	8.5-9.5	137.8	11.6	10.7-12.5	108.2	7.0	6.4-7.6									
Anus, anal canal & anorectum	50.4	1.8	1.6-2.1	21.2	1.7	1.4-2.1	29.2	1.8	1.6-2.2	6.2	0.2	0.2-0.3	3.4	0.3	0.2-0.5	2.8	0.2	0.1-0.3
Liver and intrahepatic bile duct	286.0	10.0	9.5-10.6	200.8	16.2	15.2-17.2	85.2	5.2	4.7-5.8	179.6	6.3	5.9-6.8	118.4	9.7	8.9-10.6	61.2	3.7	3.3-4.2

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
Kings (Brooklyn)

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	239.8	8.4	7.9-8.9	177.2	14.2	13.3-15.2	62.6	3.8	3.4-4.3	129.8	4.6	4.2-4.9	92.8	7.5	6.9-8.3	37.0	2.2	1.9-2.6
Intrahepatic bile duct	46.2	1.6	1.4-1.9	23.6	2.0	1.6-2.4	22.6	1.4	1.2-1.7	49.8	1.8	1.6-2.0	25.6	2.2	1.8-2.6	24.2	1.5	1.2-1.8
Gallbladder	50.2	1.8	1.6-2.0	15.4	1.3	1.1-1.7	34.8	2.1	1.8-2.5	22.6	0.8	0.7-1.0	5.6	0.5	0.3-0.7	17.0	1.1	0.8-1.3
Other biliary	49.6	1.8	1.6-2.0	26.6	2.3	1.9-2.7	23.0	1.4	1.2-1.7	16.4	0.6	0.5-0.7	8.8	0.8	0.6-1.0	7.6	0.5	0.3-0.7
Pancreas	386.4	13.8	13.2-14.5	182.0	15.3	14.3-16.4	204.4	12.6	11.8-13.4	281.6	10.1	9.6-10.6	133.2	11.4	10.6-12.4	148.4	9.0	8.4-9.7
Retroperitoneum	13.6	0.5	0.4-0.7	6.6	0.6	0.4-0.8	7.0	0.5	0.3-0.7	4.0	0.1	0.1-0.2	2.2	0.2	0.1-0.3	1.8	0.1	0.0-0.2
Peritoneum, omentum & mesentery	6.0	0.2	0.1-0.3	0.2	0.0	0.0-0.1	5.8	0.4	0.2-0.5	3.6	0.1	0.1-0.2	1.0	0.1	0.0-0.2	2.6	0.1	0.1-0.3
Other digestive organs	15.2	0.5	0.4-0.7	6.8	0.6	0.4-0.8	8.4	0.5	0.4-0.7	9.8	0.3	0.2-0.4	6.4	0.5	0.4-0.8	3.4	0.2	0.1-0.3
Respiratory system	1344.2	48.1	47.0-49.3	731.8	62.6	60.6-64.7	612.4	38.1	36.7-39.5	686.6	24.6	23.8-25.5	392.6	34.3	32.7-35.9	294.0	18.0	17.0-18.9
Nasal cavity, middle ear & sinuses	17.2	0.6	0.5-0.8	10.6	0.9	0.7-1.2	6.6	0.4	0.3-0.6	1.4	0.1	0.0-0.1	1.2	0.1	0.0-0.2	0.2	0.0	0.0-0.1
Larynx	74.8	2.6	2.4-2.9	59.0	4.9	4.4-5.5	15.8	1.0	0.8-1.2	22.4	0.8	0.7-1.0	19.4	1.7	1.4-2.1	3.0	0.2	0.1-0.3
Lung and bronchus	1247.4	44.7	43.6-45.8	659.0	56.5	54.5-58.5	588.4	36.6	35.2-37.9	660.0	23.7	22.9-24.5	370.2	32.3	30.8-33.8	289.8	17.7	16.8-18.7
Pleura	1.0	0.0	0.0-0.1	0.6	0.1	0.0-0.2	0.4	0.0	0.0-0.1	0.6	0.0	0.0-0.1	0.6	0.0	0.0-0.1	0.0	0.0	0.0-0.1
Trachea, mediastinum, other respiratory	3.8	0.1	0.1-0.2	2.6	0.2	0.1-0.4	1.2	0.1	0.0-0.2	2.2	0.1	0.0-0.1	1.2	0.1	0.0-0.2	1.0	0.1	0.0-0.2
Bones & joints	29.6	1.2	1.0-1.4	17.0	1.4	1.2-1.8	12.6	0.9	0.7-1.2	10.4	0.4	0.3-0.5	6.4	0.5	0.4-0.7	4.0	0.3	0.2-0.4
Soft tissue (including heart)	96.0	3.6	3.3-3.9	48.4	4.0	3.5-4.6	47.6	3.3	2.9-3.8	30.8	1.1	1.0-1.3	14.8	1.3	1.0-1.6	16.0	1.0	0.8-1.3
Skin*	268.4	9.9	9.3-10.4	140.4	12.2	11.3-13.1	128.0	8.3	7.7-9.0	34.2	1.2	1.0-1.4	20.2	1.8	1.4-2.2	14.0	0.8	0.6-1.1
Melanoma of the skin	234.8	8.6	8.1-9.1	123.6	10.7	9.9-11.6	111.2	7.2	6.6-7.9	21.4	0.8	0.6-1.0	11.8	1.1	0.8-1.4	9.6	0.6	0.4-0.8
Breast	1901.2	70.5	69.1-72.0	20.0	1.7	1.4-2.1	1881.2	125.7	123.1-128.3	326.6	11.8	11.3-12.4	2.6	0.2	0.1-0.4	324.0	20.5	19.5-21.5
Breast (in situ)#	592.4	22.5	21.7-23.3	3.0	0.3	0.1-0.4	589.4	40.8	39.3-42.3									
Female genital system							912.8	58.9	57.2-60.7							289.0	18.0	17.0-18.9
Cervix uteri							139.0	9.6	8.9-10.3							38.4	2.5	2.2-2.9
Corpus uteri and NOS							525.8	33.2	31.9-34.5							128.0	7.8	7.2-8.5
Ovary							171.2	11.2	10.5-12.0							109.8	6.9	6.3-7.5
Vagina							10.4	0.7	0.5-0.9							2.6	0.1	0.1-0.3
Vulva							35.4	2.2	1.9-2.6							6.2	0.4	0.2-0.5
Other female genital organs							31.0	2.0	1.7-2.3							4.0	0.2	0.1-0.4
Male genital system				1697.0	135.8	132.8-138.8							209.6	19.4	18.3-20.7			
Prostate				1614.8	129.4	126.5-132.3							205.2	19.0	17.9-20.3			
Testis				68.0	5.2	4.6-5.8							1.4	0.1	0.0-0.2			
Penis				11.0	0.9	0.7-1.2							3.0	0.3	0.1-0.4			
Other male genital organs				3.2	0.3	0.2-0.5							0.0	0.0	0.0-0.1			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
Kings (Brooklyn)

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	873.6	31.4	30.5-32.4	605.2	51.7	49.8-53.6	268.4	17.0	16.1-18.0	146.0	5.2	4.8-5.6	100.8	9.1	8.3-9.9	45.2	2.7	2.3-3.1
Urinary bladder (including in situ)	441.0	15.9	15.3-16.6	332.6	29.2	27.8-30.7	108.4	6.8	6.2-7.4	84.0	3.0	2.7-3.3	57.6	5.4	4.8-6.0	26.4	1.5	1.3-1.8
Kidney and renal pelvis	412.2	14.8	14.2-15.5	262.6	21.5	20.3-22.7	149.6	9.6	8.9-10.3	58.8	2.1	1.9-2.4	41.2	3.5	3.1-4.1	17.6	1.1	0.8-1.3
Ureter	10.0	0.4	0.3-0.5	5.2	0.5	0.3-0.7	4.8	0.3	0.2-0.5	1.2	0.0	0.0-0.1	0.6	0.1	0.0-0.2	0.6	0.0	0.0-0.1
Other urinary organs	10.4	0.4	0.3-0.5	4.8	0.5	0.3-0.7	5.6	0.3	0.2-0.5	2.0	0.1	0.0-0.1	1.4	0.1	0.0-0.2	0.6	0.0	0.0-0.1
Eye & orbit	22.6	0.8	0.7-1.0	9.6	0.8	0.6-1.1	13.0	0.9	0.7-1.1	1.4	0.1	0.0-0.1	1.0	0.1	0.0-0.2	0.4	0.0	0.0-0.1
Brain / other central nervous system (all behaviors)	597.0	22.1	21.3-22.9	218.2	18.2	17.1-19.3	378.8	25.0	23.9-26.2	102.0	3.7	3.4-4.1	54.8	4.6	4.1-5.2	47.2	3.1	2.7-3.5
Malignant brain / other central nervous system	162.6	6.0	5.6-6.5	90.6	7.4	6.7-8.1	72.0	4.9	4.4-5.5	82.6	3.0	2.8-3.4	45.4	3.8	3.3-4.4	37.2	2.5	2.1-2.9
Malignant brain	147.2	5.5	5.1-5.9	82.8	6.8	6.1-7.5	64.4	4.4	3.9-5.0									
Malignant other central nervous system	15.4	0.6	0.4-0.7	7.8	0.6	0.4-0.9	7.6	0.5	0.4-0.7									
Benign brain / other central nervous system#	434.4	16.1	15.4-16.8	127.6	10.8	10.0-11.7	306.8	20.1	19.1-21.2	19.4	0.7	0.6-0.9	9.4	0.8	0.6-1.1	10.0	0.6	0.4-0.8
Benign brain	35.6	1.4	1.2-1.6	16.0	1.3	1.0-1.6	19.6	1.4	1.2-1.8									
Benign other central nervous system	398.8	14.7	14.0-15.3	111.6	9.5	8.7-10.3	287.2	18.7	17.7-19.7									
Endocrine system	610.6	22.8	22.0-23.6	155.6	12.6	11.7-13.5	455.0	31.7	30.4-33.1	25.6	0.9	0.8-1.1	9.0	0.8	0.6-1.1	16.6	1.0	0.8-1.3
Thyroid	574.4	21.4	20.6-22.3	136.2	11.1	10.2-12.0	438.2	30.5	29.2-31.9	15.4	0.5	0.4-0.7	4.0	0.4	0.2-0.6	11.4	0.7	0.5-0.9
Other endocrine (including thymus)	36.2	1.3	1.1-1.6	19.4	1.5	1.2-1.9	16.8	1.2	0.9-1.5	10.2	0.4	0.3-0.5	5.0	0.4	0.3-0.6	5.2	0.3	0.2-0.5
Lymphomas	599.2	22.0	21.2-22.9	318.8	26.7	25.4-28.1	280.4	18.3	17.4-19.3	117.6	4.3	4.0-4.7	60.0	5.4	4.8-6.0	57.6	3.6	3.2-4.0
Hodgkin lymphoma	86.6	3.3	3.0-3.6	46.0	3.8	3.3-4.3	40.6	2.9	2.5-3.3	6.4	0.2	0.2-0.3	2.8	0.3	0.1-0.4	3.6	0.2	0.1-0.4
Non-Hodgkin lymphomas	512.6	18.8	18.0-19.5	272.8	23.0	21.7-24.2	239.8	15.5	14.6-16.4	111.2	4.1	3.7-4.4	57.2	5.1	4.5-5.7	54.0	3.3	2.9-3.8
Myeloma	253.4	9.1	8.6-9.6	127.4	10.9	10.0-11.7	126.0	7.9	7.3-8.6	83.4	3.0	2.7-3.3	41.6	3.7	3.2-4.2	41.8	2.5	2.2-2.9
Leukemias	356.0	13.1	12.5-13.7	192.2	16.4	15.4-17.5	163.8	10.6	9.9-11.4	133.0	4.9	4.5-5.3	68.8	6.1	5.4-6.8	64.2	4.1	3.6-4.6
Lymphocytic leukemias	169.2	6.2	5.8-6.7	93.6	8.0	7.3-8.8	75.6	4.9	4.4-5.4	35.0	1.3	1.1-1.5	18.0	1.6	1.3-2.0	17.0	1.0	0.8-1.3
Acute lymphocytic leukemia	39.2	1.6	1.3-1.8	21.2	1.8	1.5-2.2	18.0	1.4	1.1-1.7	10.8	0.4	0.3-0.5	5.4	0.5	0.3-0.7	5.4	0.4	0.2-0.5
Chronic lymphocytic leukemia	122.2	4.4	4.0-4.8	67.0	5.8	5.2-6.5	55.2	3.4	3.0-3.8	21.4	0.8	0.6-0.9	10.8	1.0	0.7-1.3	10.6	0.6	0.4-0.8
Other lymphocytic leukemias	7.8	0.3	0.2-0.4	5.4	0.4	0.3-0.6	2.4	0.1	0.1-0.3	2.8	0.1	0.1-0.2	1.8	0.2	0.1-0.3	1.0	0.1	0.0-0.1
Myeloid and monocytic leukemias	160.2	5.9	5.5-6.3	86.6	7.4	6.7-8.2	73.6	4.8	4.3-5.3	72.6	2.7	2.4-3.0	38.0	3.3	2.9-3.9	34.6	2.2	1.9-2.6
Acute myeloid leukemia	103.8	3.8	3.5-4.2	54.0	4.7	4.2-5.3	49.8	3.2	2.8-3.7	63.0	2.3	2.1-2.6	33.2	2.9	2.5-3.4	29.8	1.9	1.6-2.3
Acute monocytic leukemia	5.2	0.2	0.1-0.3	2.8	0.3	0.1-0.4	2.4	0.2	0.1-0.3	0.0	0.0	0.0-0.0	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1
Chronic myeloid leukemia	47.6	1.7	1.5-2.0	26.8	2.2	1.9-2.7	20.8	1.3	1.1-1.6	6.4	0.2	0.2-0.3	3.8	0.3	0.2-0.5	2.6	0.1	0.1-0.3
Other myeloid/monocytic leukemias	3.6	0.1	0.1-0.2	3.0	0.2	0.1-0.4	0.6	0.0	0.0-0.1	3.2	0.1	0.1-0.2	1.0	0.1	0.0-0.2	2.2	0.1	0.1-0.3
Other leukemias	26.6	1.0	0.8-1.2	12.0	1.0	0.8-1.3	14.6	0.9	0.7-1.2	25.4	0.9	0.8-1.1	12.8	1.1	0.9-1.4	12.6	0.8	0.6-1.1
Other acute leukemias	5.0	0.2	0.1-0.3	2.0	0.2	0.1-0.3	3.0	0.2	0.1-0.3	5.0	0.2	0.1-0.3	2.2	0.2	0.1-0.3	2.8	0.2	0.1-0.3

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
Kings (Brooklyn)**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	21.6	0.8	0.6-1.0	10.0	0.8	0.6-1.1	11.6	0.8	0.6-1.0	20.4	0.8	0.6-0.9	10.6	0.9	0.7-1.2	9.8	0.6	0.5-0.9
Mesothelioma	16.2	0.6	0.5-0.7	9.6	0.8	0.6-1.1	6.6	0.4	0.3-0.6									
Kaposi sarcoma	27.0	1.0	0.8-1.2	23.6	1.9	1.6-2.3	3.4	0.2	0.1-0.3									
Myelodysplastic syndromes	82.4	3.0	2.7-3.3	45.0	4.2	3.7-4.8	37.4	2.3	2.0-2.7									
Chronic myeloproliferative disorders [^]	108.6	4.0	3.6-4.3	53.0	4.4	3.9-4.9	55.6	3.5	3.1-4.0									
All defined and unspecified sites	229.2	8.2	7.7-8.7	104.8	9.1	8.4-10.0	124.4	7.5	6.9-8.2	243.2	8.8	8.3-9.3	123.2	10.9	10.0-11.8	120.0	7.3	6.7-7.9

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

[^] Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
New York (Manhattan)

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	8762.8	449.0	444.7-453.3	4201.8	486.3	479.6-493.0	4561.0	429.5	423.7-435.3	2386.6	117.1	115.0-119.3	1149.8	135.7	132.1-139.3	1236.8	105.0	102.4-107.8
Oral cavity and pharynx	226.0	11.5	10.8-12.2	151.8	17.4	16.2-18.7	74.2	6.8	6.1-7.6	41.8	2.0	1.8-2.3	28.8	3.3	2.8-3.9	13.0	1.1	0.8-1.4
Lip	6.0	0.3	0.2-0.4	3.4	0.4	0.2-0.6	2.6	0.2	0.1-0.4	0.8	0.0	0.0-0.1	0.4	0.0	0.0-0.2	0.4	0.0	0.0-0.1
Tongue	76.0	3.8	3.5-4.3	51.2	5.8	5.1-6.6	24.8	2.3	1.9-2.7	11.0	0.5	0.4-0.7	7.0	0.8	0.6-1.1	4.0	0.3	0.2-0.5
Salivary gland	29.2	1.5	1.2-1.7	16.4	1.9	1.5-2.4	12.8	1.2	0.9-1.5	4.2	0.2	0.1-0.3	2.8	0.3	0.2-0.6	1.4	0.1	0.0-0.2
Floor of mouth	8.0	0.4	0.3-0.6	4.8	0.6	0.4-0.8	3.2	0.3	0.2-0.5	0.4	0.0	0.0-0.1	0.2	0.0	0.0-0.1	0.2	0.0	0.0-0.1
Gum & other mouth	27.6	1.4	1.2-1.7	13.2	1.5	1.2-1.9	14.4	1.3	1.0-1.6	3.8	0.2	0.1-0.3	2.4	0.3	0.1-0.5	1.4	0.1	0.0-0.3
Nasopharynx	15.0	0.8	0.6-1.0	10.0	1.2	0.8-1.5	5.0	0.5	0.3-0.7	4.4	0.2	0.1-0.3	3.8	0.4	0.3-0.7	0.6	0.1	0.0-0.2
Tonsil	37.6	1.9	1.7-2.2	31.4	3.5	3.0-4.2	6.2	0.6	0.4-0.8	2.0	0.1	0.0-0.2	1.8	0.2	0.1-0.4	0.2	0.0	0.0-0.1
Oropharynx	11.2	0.6	0.4-0.8	8.6	1.0	0.7-1.4	2.6	0.3	0.1-0.5	6.4	0.3	0.2-0.5	4.0	0.5	0.3-0.7	2.4	0.2	0.1-0.4
Hypopharynx	13.0	0.7	0.5-0.9	10.8	1.3	0.9-1.7	2.2	0.2	0.1-0.5	3.4	0.2	0.1-0.3	2.2	0.3	0.1-0.5	1.2	0.1	0.0-0.3
Other buccal cavity and pharynx	2.4	0.1	0.1-0.2	2.0	0.2	0.1-0.4	0.4	0.0	0.0-0.2	5.4	0.3	0.2-0.4	4.2	0.5	0.3-0.8	1.2	0.1	0.0-0.2
Digestive system	1523.6	77.0	75.2-78.8	820.0	95.5	92.5-98.5	703.6	62.5	60.4-64.6	702.4	34.4	33.2-35.6	381.6	44.6	42.6-46.7	320.8	26.7	25.4-28.1
Esophagus	63.0	3.1	2.8-3.5	40.8	4.7	4.1-5.4	22.2	1.8	1.5-2.2	47.0	2.3	2.0-2.6	32.0	3.7	3.2-4.4	15.0	1.2	1.0-1.5
Stomach	149.4	7.6	7.0-8.2	84.0	9.9	8.9-10.9	65.4	5.9	5.3-6.6	68.4	3.3	3.0-3.7	42.8	5.0	4.3-5.7	25.6	2.2	1.8-2.6
Small intestine	43.2	2.2	1.9-2.5	21.2	2.4	2.0-2.9	22.0	2.0	1.7-2.5	6.2	0.3	0.2-0.4	3.6	0.4	0.2-0.7	2.6	0.2	0.1-0.4
Colorectal	643.6	33.0	31.8-34.2	334.0	39.2	37.4-41.2	309.6	28.2	26.8-29.7	204.2	10.1	9.5-10.7	103.2	12.3	11.2-13.4	101.0	8.4	7.7-9.2
Colon excluding rectum	443.0	22.5	21.6-23.5	220.2	26.0	24.5-27.7	222.8	19.9	18.7-21.2	157.0	7.7	7.2-8.3	77.8	9.2	8.3-10.2	79.2	6.6	6.0-7.3
Cecum	80.8	4.0	3.6-4.5	38.4	4.6	3.9-5.3	42.4	3.7	3.2-4.2									
Appendix	31.0	1.7	1.4-2.0	14.4	1.8	1.4-2.3	16.6	1.6	1.2-2.0									
Ascending colon	83.8	4.2	3.8-4.6	37.0	4.4	3.8-5.1	46.8	4.0	3.5-4.6									
Hepatic flexure	22.0	1.1	0.9-1.3	11.2	1.3	1.0-1.7	10.8	0.9	0.7-1.3									
Transverse colon	41.2	2.1	1.8-2.4	18.8	2.3	1.8-2.8	22.4	2.0	1.6-2.4									
Splenic flexure	12.4	0.6	0.5-0.8	7.6	0.9	0.6-1.2	4.8	0.4	0.3-0.6									
Descending colon	28.2	1.5	1.2-1.8	15.6	1.9	1.5-2.3	12.6	1.2	0.9-1.5									
Sigmoid colon	113.6	5.9	5.4-6.4	63.6	7.4	6.6-8.3	50.0	4.8	4.2-5.5									
Large intestine, NOS	30.0	1.5	1.3-1.8	13.6	1.6	1.3-2.1	16.4	1.4	1.1-1.7									
Rectum & rectosigmoid	200.6	10.5	9.8-11.1	113.8	13.2	12.1-14.3	86.8	8.3	7.5-9.1	47.2	2.4	2.1-2.7	25.4	3.1	2.5-3.7	21.8	1.8	1.5-2.2
Rectosigmoid junction	51.6	2.7	2.4-3.1	29.2	3.4	2.9-4.0	22.4	2.2	1.8-2.6									
Rectum	149.0	7.8	7.2-8.3	84.6	9.8	8.9-10.8	64.4	6.1	5.4-6.9									
Anus, anal canal & anorectum	67.2	3.5	3.1-3.9	33.8	4.0	3.4-4.7	33.4	3.0	2.5-3.5	11.2	0.6	0.4-0.8	6.2	0.7	0.5-1.1	5.0	0.4	0.3-0.7
Liver and intrahepatic bile duct	208.2	10.3	9.7-10.9	139.6	15.8	14.6-17.0	68.6	5.9	5.2-6.5	123.8	6.0	5.6-6.5	80.4	9.2	8.3-10.2	43.4	3.6	3.1-4.1

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
New York (Manhattan)

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	166.4	8.2	7.6-8.7	118.8	13.3	12.2-14.4	47.6	4.0	3.5-4.6	92.2	4.5	4.1-4.9	65.2	7.4	6.6-8.3	27.0	2.2	1.8-2.6
Intrahepatic bile duct	41.8	2.1	1.8-2.4	20.8	2.5	2.0-3.0	21.0	1.8	1.5-2.3	31.6	1.6	1.3-1.8	15.2	1.8	1.4-2.3	16.4	1.4	1.1-1.8
Gallbladder	26.2	1.3	1.1-1.5	9.4	1.1	0.8-1.4	16.8	1.4	1.1-1.8	17.4	0.9	0.7-1.1	6.2	0.7	0.5-1.1	11.2	0.9	0.7-1.2
Other biliary	30.0	1.5	1.3-1.8	16.6	2.0	1.5-2.4	13.4	1.2	0.9-1.5	9.2	0.4	0.3-0.6	4.6	0.5	0.3-0.8	4.6	0.4	0.2-0.6
Pancreas	263.8	13.1	12.4-13.8	130.6	15.3	14.1-16.5	133.2	11.4	10.5-12.3	206.4	10.0	9.4-10.7	99.2	11.7	10.6-12.7	107.2	8.9	8.1-9.7
Retroperitoneum	9.4	0.5	0.4-0.7	3.8	0.5	0.3-0.7	5.6	0.6	0.4-0.8	0.4	0.0	0.0-0.1	0.2	0.0	0.0-0.2	0.2	0.0	0.0-0.1
Peritoneum, omentum & mesentery	8.0	0.4	0.3-0.6	0.4	0.1	0.0-0.2	7.6	0.7	0.5-1.0	3.6	0.2	0.1-0.3	0.4	0.0	0.0-0.2	3.2	0.3	0.2-0.5
Other digestive organs	11.6	0.6	0.4-0.8	5.8	0.7	0.5-1.0	5.8	0.5	0.3-0.7	4.6	0.2	0.1-0.3	2.8	0.3	0.2-0.6	1.8	0.1	0.1-0.3
Respiratory system	974.0	48.1	46.7-49.5	453.0	52.6	50.4-54.8	521.0	44.9	43.1-46.7	475.8	23.1	22.2-24.1	227.8	26.6	25.1-28.3	248.0	20.6	19.4-21.8
Nasal cavity, middle ear & sinuses	15.6	0.8	0.6-1.0	8.6	1.0	0.7-1.4	7.0	0.7	0.4-0.9	3.0	0.2	0.1-0.3	1.8	0.2	0.1-0.4	1.2	0.1	0.0-0.3
Larynx	46.6	2.3	2.0-2.7	36.8	4.2	3.6-4.8	9.8	0.9	0.7-1.2	14.4	0.7	0.5-0.9	11.2	1.3	0.9-1.6	3.2	0.3	0.1-0.4
Lung and bronchus	907.0	44.7	43.4-46.1	404.6	47.1	45.0-49.2	502.4	43.2	41.5-44.9	456.6	22.2	21.3-23.1	214.0	25.1	23.6-26.6	242.6	20.1	19.0-21.3
Pleura	0.8	0.0	0.0-0.1	0.4	0.1	0.0-0.2	0.4	0.0	0.0-0.1	1.0	0.0	0.0-0.1	0.8	0.1	0.0-0.3	0.2	0.0	0.0-0.1
Trachea, mediastinum, other respiratory	4.0	0.2	0.1-0.3	2.6	0.3	0.2-0.5	1.4	0.1	0.1-0.3	0.8	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.8	0.1	0.0-0.2
Bones & joints	17.6	1.1	0.9-1.4	10.8	1.4	1.0-1.9	6.8	0.8	0.6-1.2	6.2	0.3	0.2-0.5	4.0	0.5	0.3-0.7	2.2	0.2	0.1-0.5
Soft tissue (including heart)	72.0	3.9	3.5-4.4	40.0	4.9	4.2-5.6	32.0	3.2	2.7-3.8	25.2	1.3	1.1-1.6	13.8	1.7	1.3-2.1	11.4	1.1	0.8-1.4
Skin*	379.2	19.3	18.5-20.3	219.0	25.7	24.2-27.3	160.2	14.8	13.8-15.9	36.8	1.8	1.5-2.1	23.6	2.8	2.3-3.3	13.2	1.1	0.8-1.4
Melanoma of the skin	352.2	17.9	17.1-18.8	203.8	23.8	22.4-25.4	148.4	13.7	12.7-14.8	23.8	1.1	0.9-1.4	15.6	1.8	1.4-2.3	8.2	0.7	0.5-0.9
Breast	1438.8	76.8	75.0-78.7	17.2	2.0	1.6-2.4	1421.6	140.6	137.3-144.1	191.6	9.6	9.0-10.3	1.2	0.1	0.0-0.3	190.4	16.9	15.9-18.1
Breast (in situ)#	532.8	30.0	28.9-31.2	2.8	0.3	0.2-0.5	530.0	56.6	54.4-58.8									
Female genital system							552.6	52.7	50.7-54.8							166.6	14.6	13.6-15.6
Cervix uteri							68.2	7.1	6.3-7.9							17.2	1.6	1.3-2.1
Corpus uterus and NOS							318.2	29.8	28.3-31.4							62.6	5.4	4.8-6.0
Ovary							112.2	10.8	9.9-11.8							74.2	6.6	5.9-7.3
Vagina							5.2	0.5	0.3-0.7							2.4	0.2	0.1-0.4
Vulva							23.2	2.2	1.8-2.7							6.0	0.5	0.3-0.7
Other female genital organs							25.6	2.3	1.9-2.7							4.2	0.4	0.2-0.6
Male genital system				1206.2	134.5	131.1-138.0							145.2	17.3	16.1-18.6			
Prostate				1133.0	126.6	123.2-129.9							142.8	17.0	15.8-18.3			
Testis				65.6	7.0	6.3-7.9							0.8	0.1	0.0-0.2			
Penis				5.6	0.7	0.4-1.0							1.4	0.2	0.1-0.4			
Other male genital organs				2.0	0.2	0.1-0.4							0.2	0.0	0.0-0.1			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
New York (Manhattan)

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	614.6	31.0	29.9-32.1	425.0	50.0	47.9-52.2	189.6	17.1	16.0-18.3	110.6	5.2	4.8-5.7	72.2	8.5	7.7-9.5	38.4	3.0	2.6-3.5
Urinary bladder (including in situ)	357.0	17.6	16.8-18.4	260.0	30.8	29.1-32.5	97.0	8.3	7.5-9.1	68.6	3.2	2.9-3.6	46.0	5.5	4.8-6.3	22.6	1.7	1.4-2.1
Kidney and renal pelvis	239.6	12.5	11.8-13.3	154.0	18.0	16.7-19.3	85.6	8.2	7.4-9.1	39.6	1.9	1.7-2.2	24.8	2.9	2.4-3.5	14.8	1.2	0.9-1.5
Ureter	7.8	0.4	0.3-0.5	4.6	0.5	0.3-0.8	3.2	0.3	0.2-0.5	1.2	0.1	0.0-0.1	0.4	0.0	0.0-0.2	0.8	0.1	0.0-0.2
Other urinary organs	10.2	0.5	0.4-0.7	6.4	0.8	0.5-1.1	3.8	0.3	0.2-0.5	1.2	0.1	0.0-0.1	1.0	0.1	0.0-0.3	0.2	0.0	0.0-0.1
Eye & orbit	17.6	1.0	0.8-1.2	9.4	1.2	0.8-1.5	8.2	0.9	0.6-1.2	1.8	0.1	0.0-0.2	0.8	0.1	0.0-0.3	1.0	0.1	0.0-0.3
Brain / other central nervous system (all behaviors)	393.0	21.3	20.3-22.3	157.8	19.3	17.9-20.7	235.2	23.0	21.6-24.4	70.6	3.7	3.3-4.1	38.6	4.6	4.0-5.4	32.0	3.0	2.5-3.5
Malignant brain / other central nervous system	120.8	6.9	6.3-7.5	68.6	8.6	7.7-9.6	52.2	5.4	4.7-6.2	62.0	3.3	2.9-3.7	35.0	4.2	3.6-4.9	27.0	2.5	2.1-3.0
Malignant brain	113.2	6.4	5.8-7.0	63.6	7.9	7.0-8.8	49.6	5.1	4.5-5.9									
Malignant other central nervous system	7.6	0.5	0.3-0.7	5.0	0.7	0.4-1.1	2.6	0.3	0.1-0.5									
Benign brain / other central nervous system#	272.2	14.4	13.6-15.2	89.2	10.7	9.7-11.8	183.0	17.5	16.4-18.8	8.6	0.4	0.3-0.6	3.6	0.4	0.3-0.7	5.0	0.4	0.3-0.6
Benign brain	18.8	1.2	0.9-1.4	10.2	1.3	1.0-1.8	8.6	1.0	0.7-1.4									
Benign other central nervous system	253.4	13.3	12.5-14.0	79.0	9.4	8.5-10.4	174.4	16.5	15.4-17.7									
Endocrine system	356.4	19.6	18.7-20.6	98.6	11.5	10.5-12.6	257.8	27.1	25.6-28.7	11.2	0.6	0.5-0.8	4.8	0.6	0.4-0.9	6.4	0.7	0.4-1.0
Thyroid	339.2	18.6	17.7-19.5	91.8	10.6	9.6-11.6	247.4	26.0	24.5-27.6	7.4	0.4	0.3-0.5	3.4	0.4	0.2-0.7	4.0	0.3	0.2-0.5
Other endocrine (including thymus)	17.2	1.0	0.8-1.3	6.8	0.9	0.6-1.3	10.4	1.2	0.8-1.5	3.8	0.3	0.2-0.4	1.4	0.2	0.1-0.4	2.4	0.3	0.2-0.6
Lymphomas	486.2	25.3	24.2-26.3	254.4	30.2	28.5-31.9	231.8	21.5	20.2-22.8	90.4	4.5	4.0-4.9	49.8	5.9	5.2-6.7	40.6	3.4	2.9-3.9
Hodgkin lymphoma	49.8	2.7	2.4-3.1	24.8	2.9	2.4-3.5	25.0	2.6	2.1-3.1	4.4	0.2	0.1-0.3	2.6	0.3	0.2-0.5	1.8	0.2	0.1-0.3
Non-Hodgkin lymphomas	436.4	22.5	21.6-23.5	229.6	27.2	25.6-28.9	206.8	18.9	17.7-20.1	86.0	4.2	3.8-4.7	47.2	5.6	4.9-6.4	38.8	3.2	2.8-3.7
Myeloma	158.8	7.9	7.4-8.5	84.6	9.8	8.9-10.8	74.2	6.5	5.8-7.2	49.8	2.4	2.1-2.8	26.2	3.1	2.6-3.7	23.6	2.0	1.6-2.4
Leukemias	273.4	14.3	13.6-15.1	159.2	19.3	17.9-20.7	114.2	10.6	9.7-11.5	101.4	5.1	4.7-5.6	52.2	6.5	5.7-7.3	49.2	4.2	3.6-4.7
Lymphocytic leukemias	149.8	7.9	7.3-8.5	94.0	11.5	10.4-12.6	55.8	5.2	4.5-5.9	25.6	1.3	1.0-1.5	16.0	1.9	1.5-2.4	9.6	0.8	0.6-1.1
Acute lymphocytic leukemia	21.0	1.5	1.2-1.8	12.0	1.8	1.3-2.3	9.0	1.3	0.9-1.7	6.2	0.3	0.2-0.5	3.2	0.4	0.2-0.7	3.0	0.3	0.2-0.5
Chronic lymphocytic leukemia	120.0	5.9	5.5-6.4	74.6	8.8	7.9-9.7	45.4	3.8	3.3-4.4	17.2	0.8	0.7-1.0	12.0	1.5	1.1-1.9	5.2	0.4	0.3-0.6
Other lymphocytic leukemias	8.8	0.5	0.3-0.6	7.4	0.9	0.6-1.2	1.4	0.1	0.0-0.3	2.2	0.1	0.0-0.2	0.8	0.1	0.0-0.2	1.4	0.1	0.0-0.3
Myeloid and monocytic leukemias	108.6	5.6	5.2-6.2	56.4	6.8	6.0-7.7	52.2	4.8	4.2-5.5	58.4	3.0	2.6-3.4	26.6	3.3	2.8-4.0	31.8	2.7	2.3-3.2
Acute myeloid leukemia	73.2	3.8	3.4-4.3	36.6	4.5	3.8-5.2	36.6	3.3	2.9-3.9	50.0	2.6	2.3-2.9	22.8	2.9	2.4-3.5	27.2	2.3	2.0-2.8
Acute monocytic leukemia	1.4	0.1	0.0-0.2	0.8	0.1	0.0-0.3	0.6	0.1	0.0-0.2	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1
Chronic myeloid leukemia	32.4	1.7	1.4-1.9	18.4	2.1	1.7-2.6	14.0	1.3	1.0-1.7	3.8	0.2	0.1-0.3	1.8	0.2	0.1-0.4	2.0	0.2	0.1-0.3
Other myeloid/monocytic leukemias	1.6	0.1	0.0-0.2	0.6	0.1	0.0-0.2	1.0	0.1	0.0-0.2	4.6	0.2	0.1-0.4	2.0	0.2	0.1-0.4	2.6	0.2	0.1-0.4
Other leukemias	15.0	0.8	0.6-1.0	8.8	1.0	0.7-1.4	6.2	0.6	0.4-0.9	17.4	0.9	0.7-1.1	9.6	1.2	0.9-1.6	7.8	0.6	0.4-0.9
Other acute leukemias	3.6	0.2	0.1-0.3	2.2	0.3	0.1-0.5	1.4	0.2	0.1-0.3	4.4	0.2	0.1-0.3	2.0	0.2	0.1-0.4	2.4	0.2	0.1-0.3

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
New York (Manhattan)**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	11.4	0.6	0.4-0.7	6.6	0.8	0.5-1.1	4.8	0.4	0.3-0.7	13.0	0.7	0.5-0.9	7.6	1.0	0.7-1.3	5.4	0.4	0.3-0.6
Mesothelioma	9.8	0.5	0.4-0.7	6.0	0.7	0.5-1.0	3.8	0.3	0.2-0.5									
Kaposi sarcoma	31.0	1.6	1.4-1.9	29.8	3.4	2.9-4.0	1.2	0.1	0.0-0.2									
Myelodysplastic syndromes	72.8	3.6	3.2-4.0	37.2	4.6	3.9-5.3	35.6	3.0	2.6-3.5									
Chronic myeloproliferative disorders [^]	91.8	4.7	4.3-5.2	44.6	5.3	4.6-6.0	47.2	4.2	3.7-4.8									
All defined and unspecified sites	139.6	7.0	6.5-7.6	66.4	7.9	7.1-8.8	73.2	6.3	5.7-7.1	167.8	8.2	7.6-8.7	82.8	9.8	8.9-10.8	85.0	7.0	6.3-7.7

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

[^] Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019**

Queens

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	11590.0	425.0	421.5-428.6	5567.4	453.5	448.1-459.0	6022.6	411.2	406.4-416.0	3245.0	116.6	114.8-118.4	1596.0	136.1	133.0-139.1	1649.0	104.0	101.7-106.3
Oral cavity and pharynx	253.2	9.2	8.7-9.7	159.0	12.6	11.7-13.5	94.2	6.4	5.8-7.0	52.0	1.8	1.6-2.1	36.0	2.9	2.5-3.4	16.0	1.0	0.8-1.3
Lip	4.2	0.1	0.1-0.2	3.0	0.2	0.1-0.4	1.2	0.1	0.0-0.2	0.4	0.0	0.0-0.0	0.2	0.0	0.0-0.1	0.2	0.0	0.0-0.1
Tongue	70.2	2.5	2.3-2.8	43.4	3.4	2.9-3.9	26.8	1.8	1.5-2.1	12.4	0.4	0.3-0.6	7.6	0.6	0.4-0.8	4.8	0.3	0.2-0.4
Salivary gland	36.8	1.4	1.2-1.6	19.6	1.6	1.3-2.0	17.2	1.3	1.0-1.6	4.4	0.2	0.1-0.3	3.2	0.3	0.2-0.5	1.2	0.1	0.0-0.2
Floor of mouth	7.6	0.3	0.2-0.4	4.4	0.3	0.2-0.5	3.2	0.2	0.1-0.3	0.2	0.0	0.0-0.0	0.2	0.0	0.0-0.1	0.0	0.0	0.0-0.1
Gum & other mouth	45.2	1.6	1.4-1.9	23.0	1.9	1.5-2.3	22.2	1.4	1.2-1.7	6.4	0.2	0.2-0.3	4.0	0.3	0.2-0.5	2.4	0.1	0.1-0.3
Nasopharynx	34.8	1.3	1.1-1.5	24.8	2.0	1.6-2.4	10.0	0.7	0.5-1.0	9.6	0.3	0.2-0.5	7.0	0.5	0.4-0.8	2.6	0.2	0.1-0.3
Tonsil	27.0	0.9	0.8-1.1	21.8	1.6	1.3-2.0	5.2	0.4	0.2-0.5	2.6	0.1	0.0-0.2	2.2	0.2	0.1-0.3	0.4	0.0	0.0-0.1
Oropharynx	10.6	0.4	0.3-0.5	7.4	0.6	0.4-0.8	3.2	0.2	0.1-0.4	7.0	0.3	0.2-0.4	5.2	0.4	0.3-0.6	1.8	0.1	0.0-0.2
Hypopharynx	13.4	0.5	0.4-0.6	9.4	0.7	0.5-1.0	4.0	0.3	0.2-0.4	2.8	0.1	0.1-0.2	2.2	0.2	0.1-0.3	0.6	0.0	0.0-0.1
Other buccal cavity and pharynx	3.4	0.1	0.1-0.2	2.2	0.2	0.1-0.3	1.2	0.1	0.0-0.2	6.2	0.2	0.1-0.3	4.2	0.3	0.2-0.5	2.0	0.1	0.1-0.2
Digestive system	2362.2	85.9	84.3-87.5	1276.0	104.4	101.8-107.1	1086.2	71.2	69.3-73.2	1017.4	36.4	35.3-37.4	545.4	45.5	43.7-47.3	472.0	29.3	28.1-30.5
Esophagus	92.4	3.2	3.0-3.6	68.8	5.5	4.9-6.1	23.6	1.5	1.2-1.8	61.8	2.2	1.9-2.4	45.8	3.8	3.3-4.3	16.0	1.0	0.8-1.2
Stomach	331.2	12.1	11.6-12.8	189.6	15.7	14.7-16.7	141.6	9.5	8.8-10.2	133.6	4.9	4.5-5.3	79.8	6.8	6.1-7.5	53.8	3.4	3.0-3.9
Small intestine	65.2	2.4	2.1-2.7	34.4	2.8	2.4-3.3	30.8	2.1	1.8-2.4	7.8	0.3	0.2-0.4	3.6	0.3	0.2-0.4	4.2	0.3	0.2-0.4
Colorectal	1025.2	37.7	36.6-38.7	530.0	43.6	42.0-45.4	495.2	33.0	31.7-34.3	319.8	11.5	10.9-12.1	157.6	13.4	12.5-14.4	162.2	10.1	9.4-10.8
Colon excluding rectum	720.6	26.4	25.6-27.3	358.2	29.7	28.3-31.2	362.4	23.9	22.8-25.0	265.6	9.6	9.0-10.1	127.6	11.0	10.1-11.9	138.0	8.5	7.9-9.2
Cecum	131.6	4.7	4.4-5.1	57.2	4.8	4.3-5.4	74.4	4.7	4.2-5.2									
Appendix	35.0	1.4	1.2-1.6	15.4	1.3	1.0-1.6	19.6	1.5	1.2-1.9									
Ascending colon	137.4	5.0	4.6-5.4	66.0	5.6	5.0-6.3	71.4	4.5	4.1-5.0									
Hepatic flexure	32.0	1.2	1.0-1.4	17.8	1.5	1.2-1.9	14.2	0.9	0.7-1.1									
Transverse colon	61.0	2.3	2.0-2.5	28.2	2.4	2.0-2.9	32.8	2.2	1.8-2.5									
Splenic flexure	20.8	0.8	0.6-0.9	12.0	1.0	0.7-1.3	8.8	0.6	0.4-0.8									
Descending colon	52.4	1.9	1.7-2.2	29.4	2.4	2.0-2.8	23.0	1.6	1.3-1.9									
Sigmoid colon	200.4	7.3	6.9-7.8	106.0	8.5	7.8-9.3	94.4	6.4	5.9-7.1									
Large intestine, NOS	50.0	1.8	1.6-2.0	26.2	2.2	1.8-2.6	23.8	1.5	1.2-1.8									
Rectum & rectosigmoid	304.6	11.2	10.7-11.8	171.8	13.9	13.0-14.9	132.8	9.1	8.4-9.8	54.2	1.9	1.7-2.2	30.0	2.5	2.1-2.9	24.2	1.5	1.3-1.8
Rectosigmoid junction	78.4	2.9	2.6-3.2	42.0	3.4	2.9-3.9	36.4	2.5	2.1-2.9									
Rectum	226.2	8.4	7.9-8.9	129.8	10.6	9.7-11.4	96.4	6.6	6.0-7.3									
Anus, anal canal & anorectum	43.4	1.5	1.3-1.8	17.6	1.4	1.1-1.7	25.8	1.6	1.4-1.9	5.0	0.2	0.1-0.3	2.4	0.2	0.1-0.4	2.6	0.2	0.1-0.3
Liver and intrahepatic bile duct	285.6	10.1	9.6-10.7	203.8	16.0	15.0-17.1	81.8	5.3	4.8-5.9	170.2	6.0	5.6-6.5	111.8	9.0	8.2-9.8	58.4	3.7	3.3-4.2

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019**
Queens

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	231.6	8.2	7.7-8.7	174.6	13.7	12.8-14.6	57.0	3.7	3.3-4.2	116.2	4.1	3.8-4.4	86.8	6.9	6.3-7.6	29.4	1.8	1.5-2.1
Intrahepatic bile duct	54.0	2.0	1.7-2.2	29.2	2.4	2.0-2.8	24.8	1.6	1.4-2.0	54.0	1.9	1.7-2.2	25.0	2.0	1.7-2.4	29.0	1.9	1.6-2.2
Gallbladder	56.4	2.1	1.8-2.3	16.4	1.4	1.1-1.7	40.0	2.6	2.2-3.0	29.6	1.0	0.9-1.2	9.0	0.7	0.5-1.0	20.6	1.3	1.0-1.6
Other biliary	69.8	2.6	2.3-2.9	35.6	3.1	2.6-3.6	34.2	2.3	1.9-2.7	12.4	0.4	0.3-0.5	6.4	0.5	0.4-0.8	6.0	0.3	0.2-0.5
Pancreas	357.8	12.8	12.2-13.5	166.4	13.9	12.9-14.9	191.4	11.9	11.2-12.7	263.6	9.4	8.9-9.9	122.4	10.2	9.4-11.0	141.2	8.6	8.0-9.3
Retroperitoneum	10.2	0.4	0.3-0.5	5.6	0.4	0.3-0.6	4.6	0.3	0.2-0.5	2.6	0.1	0.1-0.2	2.0	0.2	0.1-0.3	0.6	0.0	0.0-0.1
Peritoneum, omentum & mesentery	7.4	0.3	0.2-0.4	0.4	0.0	0.0-0.1	7.0	0.5	0.3-0.7	6.2	0.2	0.2-0.3	1.6	0.1	0.1-0.3	4.6	0.3	0.2-0.4
Other digestive organs	17.6	0.6	0.5-0.8	7.4	0.6	0.4-0.8	10.2	0.7	0.5-0.9	4.8	0.2	0.1-0.3	3.0	0.3	0.1-0.4	1.8	0.1	0.1-0.2
Respiratory system	1303.6	46.8	45.7-48.0	694.8	57.6	55.7-59.6	608.8	38.9	37.5-40.3	627.6	22.4	21.6-23.2	344.8	29.2	27.8-30.6	282.8	17.4	16.5-18.4
Nasal cavity, middle ear & sinuses	16.2	0.6	0.5-0.8	9.0	0.7	0.5-1.0	7.2	0.5	0.4-0.7	1.8	0.1	0.0-0.1	0.8	0.1	0.0-0.2	1.0	0.1	0.0-0.2
Larynx	62.8	2.2	2.0-2.5	53.2	4.3	3.8-4.9	9.6	0.6	0.5-0.8	19.2	0.7	0.5-0.8	15.6	1.3	1.0-1.6	3.6	0.2	0.1-0.3
Lung and bronchus	1220.2	43.8	42.7-44.9	629.2	52.3	50.4-54.2	591.0	37.7	36.3-39.1	603.2	21.5	20.7-22.3	326.6	27.7	26.3-29.1	276.6	17.1	16.2-18.0
Pleura	0.0	0.0	0.0-0.0	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1	1.2	0.0	0.0-0.1	0.6	0.1	0.0-0.2	0.6	0.0	0.0-0.1
Trachea, mediastinum, other respiratory	4.4	0.2	0.1-0.3	3.4	0.3	0.2-0.5	1.0	0.1	0.0-0.2	2.2	0.1	0.0-0.1	1.2	0.1	0.0-0.2	1.0	0.1	0.0-0.2
Bones & joints	24.2	1.1	0.9-1.3	14.0	1.3	1.0-1.7	10.2	0.8	0.6-1.1	9.2	0.4	0.3-0.5	5.2	0.5	0.3-0.7	4.0	0.3	0.2-0.5
Soft tissue (including heart)	100.6	3.9	3.5-4.2	56.6	4.7	4.2-5.3	44.0	3.2	2.8-3.7	24.4	0.9	0.7-1.1	12.8	1.1	0.8-1.4	11.6	0.8	0.6-1.0
Skin*	237.6	8.8	8.3-9.3	131.0	11.2	10.3-12.1	106.6	7.2	6.6-7.9	40.2	1.5	1.3-1.7	25.4	2.2	1.8-2.6	14.8	1.0	0.7-1.2
Melanoma of the skin	206.8	7.6	7.2-8.1	113.4	9.7	8.9-10.5	93.4	6.3	5.7-6.9	24.4	0.9	0.8-1.1	14.2	1.2	0.9-1.5	10.2	0.7	0.5-0.9
Breast	1809.0	67.6	66.2-69.1	17.0	1.4	1.2-1.8	1792.0	124.8	122.1-127.5	265.2	9.6	9.1-10.1	2.6	0.2	0.1-0.4	262.6	17.0	16.1-18.0
Breast (in situ)#	632.2	24.1	23.2-25.0	2.4	0.2	0.1-0.4	629.8	45.2	43.6-46.9									
Female genital system							814.2	55.8	54.0-57.6							228.2	14.7	13.8-15.6
Cervix uteri							127.0	9.5	8.8-10.3							31.4	2.2	1.8-2.5
Corpus uteri and NOS							458.6	30.3	29.0-31.6							100.4	6.3	5.8-6.9
Ovary							162.8	11.7	10.9-12.5							86.4	5.6	5.1-6.2
Vagina							7.6	0.5	0.4-0.7							2.6	0.2	0.1-0.3
Vulva							30.4	1.9	1.6-2.3							5.6	0.3	0.2-0.5
Other female genital organs							27.8	1.8	1.5-2.2							1.8	0.1	0.1-0.2
Male genital system				1566.2	121.1	118.4-123.9							179.0	16.2	15.1-17.3			
Prostate				1503.2	115.7	113.0-118.4							174.0	15.7	14.7-16.8			
Testis				50.4	4.3	3.8-4.9							1.6	0.1	0.1-0.3			
Penis				10.2	0.9	0.6-1.2							2.8	0.2	0.1-0.4			
Other male genital organs				2.4	0.2	0.1-0.4							0.6	0.0	0.0-0.1			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
Queens

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	849.8	31.0	30.0-31.9	587.2	49.1	47.3-51.0	262.6	17.1	16.2-18.1	150.2	5.4	5.0-5.8	100.0	8.8	8.0-9.6	50.2	3.1	2.7-3.5
Urinary bladder (including in situ)	443.0	16.0	15.3-16.7	329.4	28.2	26.8-29.6	113.6	7.1	6.5-7.7	83.2	3.0	2.7-3.3	58.0	5.2	4.6-5.8	25.2	1.5	1.3-1.9
Kidney and renal pelvis	388.2	14.3	13.7-15.0	246.0	19.9	18.8-21.1	142.2	9.6	8.9-10.4	62.0	2.2	2.0-2.5	39.6	3.4	2.9-3.9	22.4	1.4	1.1-1.7
Ureter	12.2	0.4	0.3-0.6	7.2	0.6	0.4-0.9	5.0	0.3	0.2-0.5	2.6	0.1	0.1-0.2	1.4	0.1	0.1-0.3	1.2	0.1	0.0-0.2
Other urinary organs	6.4	0.2	0.2-0.3	4.6	0.4	0.3-0.6	1.8	0.1	0.1-0.2	2.4	0.1	0.0-0.2	1.0	0.1	0.0-0.2	1.4	0.1	0.0-0.2
Eye & orbit	19.6	0.7	0.6-0.9	11.0	0.9	0.7-1.2	8.6	0.6	0.4-0.8	1.0	0.0	0.0-0.1	0.4	0.0	0.0-0.1	0.6	0.0	0.0-0.1
Brain / other central nervous system (all behaviors)	495.2	18.9	18.2-19.7	187.4	15.9	14.9-17.0	307.8	21.4	20.3-22.6	87.2	3.3	3.0-3.7	44.4	3.8	3.3-4.4	42.8	2.9	2.5-3.4
Malignant brain / other central nervous system	133.0	5.2	4.8-5.7	73.4	6.2	5.6-6.9	59.6	4.4	3.9-4.9	74.6	2.8	2.6-3.2	38.4	3.3	2.8-3.8	36.2	2.5	2.1-2.9
Malignant brain	126.4	5.0	4.6-5.4	70.4	5.9	5.3-6.6	56.0	4.1	3.6-4.6									
Malignant other central nervous system	6.6	0.3	0.2-0.4	3.0	0.3	0.2-0.5	3.6	0.3	0.2-0.4									
Benign brain / other central nervous system#	362.2	13.7	13.1-14.4	114.0	9.7	8.9-10.6	248.2	17.1	16.1-18.1	12.6	0.5	0.4-0.6	6.0	0.5	0.4-0.8	6.6	0.4	0.3-0.6
Benign brain	29.6	1.2	1.0-1.5	12.0	1.1	0.8-1.4	17.6	1.4	1.1-1.7									
Benign other central nervous system	332.6	12.5	11.9-13.1	102.0	8.6	7.9-9.4	230.6	15.7	14.8-16.7									
Endocrine system	550.6	22.2	21.4-23.1	135.8	11.2	10.4-12.1	414.8	32.7	31.2-34.2	20.0	0.7	0.6-0.9	8.2	0.7	0.5-0.9	11.8	0.8	0.6-1.0
Thyroid	513.8	20.8	20.0-21.6	118.6	9.8	9.0-10.7	395.2	31.3	29.9-32.7	14.8	0.5	0.4-0.7	5.8	0.5	0.3-0.7	9.0	0.6	0.4-0.8
Other endocrine (including thymus)	36.8	1.4	1.2-1.6	17.2	1.4	1.1-1.7	19.6	1.4	1.1-1.7	5.2	0.2	0.1-0.3	2.4	0.2	0.1-0.3	2.8	0.2	0.1-0.4
Lymphomas	560.6	21.1	20.3-21.9	305.4	25.7	24.4-27.0	255.2	17.6	16.6-18.6	125.4	4.5	4.2-4.9	74.2	6.4	5.8-7.1	51.2	3.1	2.8-3.6
Hodgkin lymphoma	62.0	2.6	2.3-3.0	35.6	3.1	2.7-3.6	26.4	2.2	1.8-2.6	5.6	0.2	0.1-0.3	3.4	0.3	0.2-0.4	2.2	0.2	0.1-0.3
Non-Hodgkin lymphomas	498.6	18.5	17.8-19.3	269.8	22.5	21.3-23.8	228.8	15.4	14.5-16.3	119.8	4.3	4.0-4.7	70.8	6.1	5.5-6.8	49.0	3.0	2.6-3.4
Myeloma	223.8	8.1	7.6-8.6	112.6	9.2	8.4-10.0	111.2	7.2	6.6-7.8	73.4	2.6	2.3-2.9	35.8	3.0	2.6-3.5	37.6	2.3	2.0-2.7
Leukemias	350.6	13.4	12.7-14.0	200.2	17.1	16.0-18.2	150.4	10.4	9.7-11.2	131.2	4.8	4.4-5.2	75.4	6.6	5.9-7.3	55.8	3.6	3.2-4.1
Lymphocytic leukemias	163.4	6.3	5.8-6.7	94.4	8.0	7.3-8.8	69.0	4.8	4.3-5.4	32.4	1.2	1.0-1.4	18.2	1.6	1.3-2.0	14.2	0.9	0.7-1.2
Acute lymphocytic leukemia	44.0	2.0	1.8-2.3	25.2	2.4	2.0-2.9	18.8	1.7	1.3-2.1	9.4	0.4	0.3-0.5	5.4	0.5	0.3-0.7	4.0	0.3	0.2-0.5
Chronic lymphocytic leukemia	110.0	3.9	3.6-4.3	62.4	5.1	4.5-5.7	47.6	3.0	2.6-3.4	21.2	0.7	0.6-0.9	11.8	1.0	0.8-1.3	9.4	0.6	0.4-0.8
Other lymphocytic leukemias	9.4	0.3	0.2-0.4	6.8	0.5	0.4-0.7	2.6	0.2	0.1-0.3	1.8	0.1	0.0-0.1	1.0	0.1	0.0-0.2	0.8	0.1	0.0-0.2
Myeloid and monocytic leukemias	166.2	6.3	5.9-6.7	93.8	8.1	7.3-8.8	72.4	5.0	4.4-5.5	74.4	2.7	2.5-3.0	41.8	3.7	3.2-4.2	32.6	2.1	1.8-2.5
Acute myeloid leukemia	108.4	4.1	3.7-4.5	60.6	5.2	4.6-5.8	47.8	3.3	2.8-3.7	64.4	2.4	2.1-2.6	36.6	3.2	2.8-3.7	27.8	1.8	1.5-2.1
Acute monocytic leukemia	4.2	0.2	0.1-0.2	2.2	0.2	0.1-0.3	2.0	0.1	0.1-0.3	0.2	0.0	0.0-0.0	0.2	0.0	0.0-0.1	0.0	0.0	0.0-0.1
Chronic myeloid leukemia	49.0	1.9	1.6-2.1	28.2	2.4	2.0-2.9	20.8	1.4	1.1-1.7	5.8	0.2	0.1-0.3	2.6	0.2	0.1-0.4	3.2	0.2	0.1-0.3
Other myeloid/monocytic leukemias	4.6	0.2	0.1-0.3	2.8	0.3	0.1-0.4	1.8	0.1	0.1-0.3	4.0	0.2	0.1-0.2	2.4	0.2	0.1-0.4	1.6	0.1	0.0-0.2
Other leukemias	21.0	0.8	0.6-1.0	12.0	1.0	0.8-1.3	9.0	0.6	0.5-0.9	24.4	0.9	0.7-1.0	15.4	1.3	1.0-1.6	9.0	0.6	0.4-0.8
Other acute leukemias	5.6	0.2	0.1-0.3	4.0	0.3	0.2-0.5	1.6	0.1	0.0-0.2	6.2	0.2	0.1-0.3	4.4	0.4	0.2-0.6	1.8	0.1	0.0-0.2

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019**

Queens

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	15.4	0.6	0.5-0.7	8.0	0.7	0.5-0.9	7.4	0.5	0.4-0.7	18.2	0.6	0.5-0.8	11.0	0.9	0.7-1.2	7.2	0.4	0.3-0.6
Mesothelioma	13.8	0.5	0.4-0.7	8.8	0.8	0.6-1.0	5.0	0.3	0.2-0.5									
Kaposi sarcoma	24.6	0.9	0.8-1.1	20.8	1.8	1.4-2.1	3.8	0.2	0.1-0.4									
Myelodysplastic syndromes	102.6	3.8	3.5-4.1	58.4	5.4	4.8-6.1	44.2	2.7	2.4-3.1									
Chronic myeloproliferative disorders [^]	85.4	3.2	2.9-3.5	39.2	3.2	2.8-3.7	46.2	3.1	2.7-3.6									
Ill defined and unspecified sites	204.8	7.3	6.9-7.8	100.0	8.4	7.7-9.2	104.8	6.5	6.0-7.1	226.0	8.1	7.7-8.6	112.4	9.6	8.8-10.4	113.6	7.1	6.5-7.7

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

[^] Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
Richmond (Staten Island)

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	3061.4	528.9	520.3-537.6	1491.6	566.3	553.1-579.7	1569.8	506.1	494.6-517.8	854.6	145.5	141.1-150.1	420.8	168.3	161.0-175.9	433.8	129.9	124.3-135.6
Oral cavity and pharynx	59.8	10.0	8.8-11.2	41.2	14.9	12.9-17.2	18.6	5.7	4.5-7.0	12.4	2.0	1.5-2.5	9.2	3.3	2.4-4.4	3.2	0.9	0.5-1.5
Lip	1.2	0.2	0.1-0.5	0.8	0.3	0.1-0.8	0.4	0.1	0.0-0.5	0.2	0.0	0.0-0.2	0.0	0.0	0.0-0.3	0.2	0.1	0.0-0.4
Tongue	17.8	2.9	2.3-3.6	12.8	4.5	3.5-5.9	5.0	1.4	0.9-2.2	2.2	0.3	0.2-0.6	1.4	0.5	0.2-1.1	0.8	0.2	0.1-0.6
Salivary gland	7.8	1.4	1.0-2.0	4.2	1.7	1.0-2.6	3.6	1.2	0.7-2.0	1.6	0.3	0.1-0.5	1.4	0.6	0.2-1.2	0.2	0.1	0.0-0.4
Floor of mouth	1.2	0.2	0.1-0.4	1.0	0.3	0.1-0.8	0.2	0.0	0.0-0.4	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.3	0.0	0.0	0.0-0.3
Gum & other mouth	11.2	1.9	1.4-2.5	6.0	2.3	1.5-3.3	5.2	1.5	1.0-2.3	1.8	0.3	0.1-0.6	1.2	0.5	0.2-1.0	0.6	0.2	0.0-0.5
Nasopharynx	3.0	0.5	0.3-0.8	2.2	0.8	0.4-1.5	0.8	0.2	0.1-0.6	2.8	0.5	0.2-0.8	1.8	0.7	0.3-1.3	1.0	0.3	0.1-0.7
Tonsil	10.8	1.8	1.3-2.4	8.6	3.1	2.2-4.2	2.2	0.7	0.3-1.3	0.6	0.1	0.0-0.3	0.6	0.2	0.0-0.6	0.0	0.0	0.0-0.3
Oropharynx	3.6	0.6	0.3-0.9	2.6	0.9	0.5-1.6	1.0	0.3	0.1-0.8	0.8	0.1	0.0-0.3	0.4	0.1	0.0-0.5	0.4	0.1	0.0-0.5
Hypopharynx	2.2	0.4	0.2-0.7	2.0	0.7	0.3-1.3	0.2	0.1	0.0-0.4	0.4	0.1	0.0-0.2	0.4	0.1	0.0-0.5	0.0	0.0	0.0-0.3
Other buccal cavity and pharynx	1.0	0.1	0.0-0.4	1.0	0.3	0.1-0.8	0.0	0.0	0.0-0.3	2.0	0.3	0.2-0.6	2.0	0.7	0.3-1.4	0.0	0.0	0.0-0.3
Digestive system	522.4	88.9	85.5-92.5	290.2	109.7	103.9-115.6	232.2	71.8	67.6-76.1	246.0	41.3	39.0-43.7	132.8	50.7	46.8-54.9	113.2	33.7	30.9-36.6
Esophagus	28.2	4.6	3.9-5.4	22.0	7.9	6.5-9.6	6.2	1.9	1.3-2.8	18.6	3.1	2.5-3.8	13.8	5.0	3.8-6.3	4.8	1.5	0.9-2.3
Stomach	50.2	8.6	7.6-9.8	30.4	11.9	10.0-14.0	19.8	6.1	4.9-7.5	21.8	3.7	3.1-4.5	11.2	4.5	3.3-5.8	10.6	3.2	2.4-4.3
Small intestine	14.8	2.5	2.0-3.2	8.0	2.9	2.1-4.1	6.8	2.2	1.5-3.2	2.2	0.4	0.2-0.7	1.2	0.5	0.2-1.0	1.0	0.3	0.1-0.7
Colorectal	231.4	40.1	37.8-42.6	120.2	46.7	43.0-50.7	111.2	34.6	31.7-37.7	81.0	13.8	12.5-15.3	40.6	16.3	14.1-18.8	40.4	11.8	10.2-13.6
Colon excluding rectum	170.4	29.5	27.5-31.6	85.6	33.4	30.3-36.9	84.8	26.2	23.7-28.9	67.0	11.5	10.3-12.8	32.4	13.1	11.1-15.4	34.6	10.2	8.7-11.9
Cecum	27.2	4.7	3.9-5.6	9.4	3.6	2.6-4.9	17.8	5.4	4.3-6.7									
Appendix	7.6	1.4	1.0-2.0	4.0	1.6	1.0-2.5	3.6	1.2	0.7-2.0									
Ascending colon	37.8	6.6	5.7-7.6	20.8	8.5	6.9-10.4	17.0	5.1	4.0-6.3									
Hepatic flexure	6.2	1.1	0.7-1.6	3.2	1.2	0.7-2.0	3.0	1.0	0.6-1.7									
Transverse colon	15.2	2.5	2.0-3.2	8.4	3.1	2.2-4.3	6.8	2.1	1.4-3.0									
Splenic flexure	5.0	0.9	0.6-1.4	2.4	1.0	0.5-1.8	2.6	0.9	0.5-1.5									
Descending colon	12.2	2.1	1.6-2.7	6.2	2.3	1.5-3.3	6.0	1.9	1.3-2.7									
Sigmoid colon	47.0	8.1	7.1-9.3	26.2	10.1	8.4-12.0	20.8	6.6	5.3-8.0									
Large intestine, NOS	12.2	2.1	1.6-2.7	5.0	1.9	1.2-2.9	7.2	2.1	1.5-3.0									
Rectum & rectosigmoid	61.0	10.6	9.4-11.9	34.6	13.3	11.3-15.5	26.4	8.3	6.9-10.0	14.0	2.3	1.8-3.0	8.2	3.2	2.3-4.4	5.8	1.6	1.1-2.3
Rectosigmoid junction	17.4	3.0	2.4-3.8	8.0	3.1	2.2-4.2	9.4	3.0	2.2-4.0									
Rectum	43.6	7.6	6.6-8.7	26.6	10.2	8.5-12.2	17.0	5.4	4.3-6.7									
Anus, anal canal & anorectum	12.0	2.0	1.5-2.5	5.6	2.0	1.3-3.0	6.4	1.8	1.2-2.7	1.8	0.3	0.1-0.6	0.6	0.2	0.0-0.7	1.2	0.3	0.1-0.8
Liver and intrahepatic bile duct	65.6	10.6	9.5-11.9	46.8	16.5	14.4-18.9	18.8	5.7	4.6-7.1	40.6	6.7	5.8-7.7	27.6	10.0	8.3-11.9	13.0	3.9	3.0-5.0

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
Richmond (Staten Island)

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	52.4	8.5	7.5-9.6	40.0	14.1	12.2-16.3	12.4	3.8	2.9-5.0	31.2	5.1	4.3-6.0	23.2	8.3	6.8-10.1	8.0	2.4	1.7-3.3
Intrahepatic bile duct	13.2	2.2	1.7-2.8	6.8	2.4	1.7-3.4	6.4	1.9	1.3-2.7	9.4	1.6	1.2-2.1	4.4	1.7	1.0-2.6	5.0	1.5	0.9-2.2
Gallbladder	9.2	1.7	1.2-2.2	2.6	1.0	0.5-1.8	6.6	2.1	1.5-3.1	4.8	0.8	0.5-1.2	2.4	0.9	0.5-1.6	2.4	0.7	0.4-1.3
Other biliary	9.6	1.6	1.2-2.2	4.8	1.8	1.2-2.8	4.8	1.5	1.0-2.3	2.6	0.4	0.2-0.7	1.2	0.4	0.1-0.9	1.4	0.4	0.2-0.9
Pancreas	92.4	15.5	14.1-17.0	45.4	17.0	14.8-19.5	47.0	14.2	12.4-16.2	70.4	11.7	10.5-13.1	33.6	12.7	10.8-14.9	36.8	11.0	9.4-12.7
Retroperitoneum	5.0	0.9	0.6-1.4	3.0	1.1	0.6-1.9	2.0	0.7	0.3-1.4	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.3	0.0	0.0	0.0-0.3
Peritoneum, omentum & mesentery	1.8	0.3	0.1-0.6	0.2	0.1	0.0-0.4	1.6	0.5	0.2-1.1	1.0	0.2	0.1-0.4	0.0	0.0	0.0-0.3	1.0	0.3	0.1-0.7
Other digestive organs	2.2	0.4	0.2-0.7	1.2	0.5	0.2-1.1	1.0	0.3	0.1-0.7	1.2	0.2	0.1-0.5	0.6	0.3	0.1-0.8	0.6	0.2	0.0-0.6
Respiratory system	413.6	69.9	66.9-73.1	202.4	78.3	73.4-83.5	211.2	64.4	60.5-68.5	214.0	36.4	34.2-38.7	108.0	43.3	39.6-47.2	106.0	31.6	28.9-34.5
Nasal cavity, middle ear & sinuses	4.8	0.8	0.5-1.2	2.2	0.9	0.4-1.6	2.6	0.8	0.4-1.4	0.4	0.1	0.0-0.3	0.2	0.1	0.0-0.4	0.2	0.0	0.0-0.4
Larynx	20.0	3.3	2.7-4.1	16.2	6.2	4.9-7.7	3.8	1.2	0.7-1.9	4.8	0.8	0.5-1.2	3.0	1.1	0.6-1.9	1.8	0.5	0.2-1.1
Lung and bronchus	388.2	65.7	62.7-68.7	183.6	71.1	66.5-76.0	204.6	62.3	58.5-66.4	207.8	35.3	33.2-37.6	104.4	41.9	38.3-45.8	103.4	30.8	28.1-33.6
Pleura	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.3	0.0	0.0	0.0-0.3	0.4	0.1	0.0-0.3	0.4	0.2	0.0-0.7	0.0	0.0	0.0-0.3
Trachea, mediastinum, other respiratory	0.6	0.1	0.0-0.3	0.4	0.2	0.0-0.6	0.2	0.1	0.0-0.4	0.6	0.1	0.0-0.4	0.0	0.0	0.0-0.3	0.6	0.2	0.0-0.7
Bones & joints	7.4	1.5	1.0-2.0	3.8	1.6	1.0-2.6	3.6	1.3	0.8-2.2	2.6	0.5	0.3-0.9	1.6	0.8	0.3-1.5	1.0	0.3	0.1-0.8
Soft tissue (including heart)	18.0	3.4	2.7-4.2	9.4	3.8	2.8-5.1	8.6	3.0	2.2-4.1	7.6	1.3	0.9-1.8	3.2	1.2	0.7-2.0	4.4	1.5	0.9-2.2
Skin*	99.2	17.5	16.0-19.2	55.8	22.0	19.4-24.9	43.4	14.2	12.3-16.3	12.6	2.2	1.7-2.8	7.4	3.2	2.3-4.5	5.2	1.5	1.0-2.3
Melanoma of the skin	85.8	15.0	13.6-16.6	48.6	19.0	16.6-21.6	37.2	12.2	10.4-14.1	8.4	1.5	1.1-2.0	4.6	2.1	1.3-3.2	3.8	1.1	0.7-1.8
Breast	427.2	75.2	71.9-78.5	3.8	1.5	0.9-2.3	423.4	138.1	132.1-144.4	59.4	10.0	8.9-11.2	0.8	0.3	0.1-0.9	58.6	17.2	15.3-19.4
Breast (in situ)#	135.6	24.7	22.8-26.7	0.4	0.2	0.0-0.7	135.2	46.3	42.8-50.1									
Female genital system							202.0	64.0	60.0-68.3							53.8	16.1	14.2-18.2
Cervix uteri							21.8	8.0	6.5-9.7							5.6	1.8	1.2-2.7
Corpus uteri and NOS							121.2	37.0	34.0-40.2							21.8	6.6	5.4-8.0
Ovary							42.6	13.8	12.0-15.9							23.0	6.7	5.5-8.1
Vagina							3.2	1.1	0.6-1.8							0.2	0.1	0.0-0.4
Vulva							7.6	2.3	1.6-3.2							2.2	0.6	0.3-1.2
Other female genital organs							5.6	1.9	1.2-2.7							1.0	0.3	0.1-0.8
Male genital system				360.4	128.6	122.6-134.9							38.8	17.1	14.8-19.8			
Prostate				344.0	121.2	115.4-127.3							37.4	16.6	14.3-19.2			
Testis				13.6	6.3	4.9-8.0							0.4	0.2	0.0-0.6			
Penis				2.0	0.8	0.4-1.5							0.6	0.2	0.0-0.6			
Other male genital organs				0.8	0.3	0.1-0.8							0.4	0.2	0.0-0.7			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
Richmond (Staten Island)

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	287.2	48.8	46.2-51.4	207.0	79.5	74.5-84.6	80.2	24.6	22.2-27.2	51.6	8.8	7.8-10.0	37.6	15.5	13.3-17.9	14.0	4.2	3.2-5.3
Urinary bladder (including in situ)	152.4	25.8	24.0-27.7	115.2	45.2	41.4-49.1	37.2	11.1	9.5-12.9	28.8	5.0	4.2-5.9	20.8	9.0	7.3-11.0	8.0	2.3	1.7-3.2
Kidney and renal pelvis	127.2	21.7	20.0-23.5	86.6	32.3	29.3-35.6	40.6	12.7	11.0-14.7	21.2	3.6	2.9-4.4	15.8	6.1	4.8-7.7	5.4	1.6	1.1-2.4
Ureter	5.4	0.9	0.6-1.3	3.8	1.5	0.9-2.3	1.6	0.5	0.2-1.0	0.8	0.1	0.0-0.3	0.6	0.2	0.0-0.7	0.2	0.1	0.0-0.4
Other urinary organs	2.2	0.4	0.2-0.7	1.4	0.5	0.2-1.1	0.8	0.3	0.1-0.7	0.8	0.1	0.0-0.4	0.4	0.1	0.0-0.5	0.4	0.1	0.0-0.5
Eye & orbit	4.2	0.7	0.5-1.2	1.4	0.5	0.2-1.2	2.8	0.9	0.5-1.6	0.6	0.1	0.0-0.3	0.0	0.0	0.0-0.3	0.6	0.2	0.0-0.6
Brain / other central nervous system (all behaviors)	121.0	21.8	20.0-23.6	48.4	19.1	16.7-21.8	72.6	23.8	21.3-26.5	22.8	3.9	3.2-4.7	12.0	4.5	3.4-5.8	10.8	3.3	2.5-4.4
Malignant brain / other central nervous system	37.0	6.8	5.8-7.9	18.8	7.4	6.0-9.2	18.2	6.2	4.9-7.6	21.2	3.6	2.9-4.4	11.4	4.2	3.2-5.6	9.8	3.1	2.2-4.1
Malignant brain	35.0	6.4	5.5-7.5	17.8	7.0	5.6-8.7	17.2	5.8	4.6-7.3									
Malignant other central nervous system	2.0	0.4	0.2-0.7	1.0	0.4	0.1-0.9	1.0	0.3	0.1-0.8									
Benign brain / other central nervous system#	84.0	15.0	13.5-16.5	29.6	11.7	9.8-13.8	54.4	17.6	15.5-19.9	1.6	0.3	0.1-0.6	0.6	0.2	0.0-0.7	1.0	0.3	0.1-0.7
Benign brain	6.2	1.3	0.9-1.8	4.0	1.7	1.0-2.6	2.2	0.9	0.5-1.7									
Benign other central nervous system	77.8	13.7	12.3-15.2	25.6	10.0	8.3-12.0	52.2	16.7	14.7-18.9									
Endocrine system	178.6	34.6	32.3-37.0	53.2	21.1	18.6-23.9	125.4	47.2	43.4-51.2	4.6	0.8	0.5-1.2	2.2	0.9	0.4-1.6	2.4	0.8	0.4-1.4
Thyroid	173.8	33.8	31.5-36.2	50.0	19.9	17.4-22.6	123.8	46.7	42.9-50.7	3.8	0.6	0.4-1.0	1.8	0.7	0.3-1.4	2.0	0.6	0.3-1.1
Other endocrine (including thymus)	4.8	0.8	0.5-1.2	3.2	1.2	0.7-2.0	1.6	0.5	0.2-1.1	0.8	0.2	0.0-0.4	0.4	0.2	0.0-0.7	0.4	0.2	0.0-0.6
Lymphomas	159.2	28.6	26.6-30.7	85.0	33.9	30.6-37.3	74.2	24.1	21.6-26.8	26.4	4.7	3.9-5.6	16.0	6.6	5.2-8.3	10.4	3.2	2.3-4.2
Hodgkin lymphoma	17.0	3.5	2.8-4.3	10.8	4.6	3.4-6.0	6.2	2.5	1.6-3.5	2.6	0.4	0.2-0.8	1.8	0.7	0.3-1.3	0.8	0.3	0.1-0.7
Non-Hodgkin lymphomas	142.2	25.1	23.2-27.1	74.2	29.3	26.3-32.5	68.0	21.6	19.3-24.2	23.8	4.3	3.5-5.1	14.2	5.9	4.6-7.6	9.6	2.9	2.1-3.9
Myeloma	52.6	8.9	7.8-10.1	29.0	11.2	9.4-13.3	23.6	7.0	5.8-8.5	15.6	2.6	2.1-3.3	8.8	3.4	2.4-4.6	6.8	2.1	1.4-2.9
Leukemias	103.6	18.5	16.9-20.3	62.8	24.7	22.0-27.7	40.8	13.6	11.8-15.7	35.2	6.3	5.4-7.4	17.2	7.5	5.9-9.3	18.0	5.6	4.5-7.0
Lymphocytic leukemias	52.0	9.3	8.1-10.5	31.6	12.3	10.4-14.5	20.4	6.9	5.5-8.4	7.8	1.4	1.0-1.9	4.0	1.7	1.0-2.6	3.8	1.2	0.7-1.9
Acute lymphocytic leukemia	8.0	1.8	1.3-2.5	3.6	1.7	1.0-2.6	4.4	2.0	1.2-3.0	1.8	0.3	0.2-0.7	0.4	0.2	0.0-0.6	1.4	0.5	0.2-1.1
Chronic lymphocytic leukemia	39.8	6.7	5.8-7.7	24.4	9.4	7.8-11.3	15.4	4.6	3.6-5.8	6.0	1.0	0.7-1.5	3.6	1.5	0.9-2.4	2.4	0.7	0.3-1.2
Other lymphocytic leukemias	4.2	0.7	0.4-1.1	3.6	1.3	0.7-2.0	0.6	0.2	0.0-0.7	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.3	0.0	0.0	0.0-0.3
Myeloid and monocytic leukemias	46.4	8.4	7.3-9.6	28.2	11.3	9.5-13.4	18.2	6.1	4.9-7.5	19.8	3.6	2.9-4.4	10.2	4.4	3.3-5.9	9.6	3.1	2.3-4.2
Acute myeloid leukemia	30.2	5.5	4.7-6.5	16.8	6.9	5.4-8.6	13.4	4.5	3.5-5.8	17.2	3.1	2.5-3.9	8.6	3.8	2.7-5.1	8.6	2.8	2.0-3.9
Acute monocytic leukemia	1.2	0.2	0.1-0.5	1.0	0.4	0.1-0.9	0.2	0.1	0.0-0.5	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.3	0.0	0.0	0.0-0.3
Chronic myeloid leukemia	13.8	2.4	1.9-3.1	9.6	3.7	2.7-4.9	4.2	1.4	0.8-2.1	2.0	0.4	0.2-0.7	1.2	0.5	0.2-1.2	0.8	0.2	0.1-0.7
Other myeloid/monocytic leukemias	1.2	0.2	0.1-0.5	0.8	0.4	0.1-0.9	0.4	0.1	0.0-0.5	0.6	0.1	0.0-0.3	0.4	0.2	0.0-0.6	0.2	0.0	0.0-0.4
Other leukemias	5.2	0.9	0.6-1.3	3.0	1.1	0.6-1.8	2.2	0.7	0.3-1.3	7.6	1.4	1.0-1.9	3.0	1.4	0.7-2.2	4.6	1.3	0.8-2.0
Other acute leukemias	1.2	0.2	0.1-0.5	0.8	0.3	0.1-0.8	0.4	0.1	0.0-0.5	2.6	0.4	0.2-0.8	0.8	0.4	0.1-0.9	1.8	0.5	0.2-0.9

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
Richmond (Staten Island)**

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	4.0	0.7	0.4-1.1	2.2	0.8	0.4-1.5	1.8	0.6	0.3-1.1	5.0	0.9	0.6-1.4	2.2	1.0	0.5-1.8	2.8	0.9	0.5-1.5
Mesothelioma	7.0	1.3	0.9-1.8	5.2	2.3	1.5-3.4	1.8	0.5	0.2-1.1									
Kaposi sarcoma	5.0	0.9	0.6-1.4	3.8	1.6	1.0-2.6	1.2	0.4	0.1-0.9									
Myelodysplastic syndromes	26.4	4.7	4.0-5.6	15.2	6.6	5.1-8.2	11.2	3.4	2.5-4.4									
Chronic myeloproliferative disorders [^]	38.6	7.2	6.2-8.3	18.0	7.3	5.8-9.0	20.6	7.0	5.7-8.6									
Ill defined and unspecified sites	52.0	9.1	8.0-10.3	25.2	9.7	8.0-11.6	26.8	8.5	7.1-10.1	52.2	9.2	8.1-10.4	25.8	10.2	8.5-12.2	26.4	8.2	6.8-9.7

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

[^] Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019**

Erie

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	6561.0	545.2	539.1-551.4	3273.6	598.1	588.6-607.6	3287.4	512.4	504.2-520.8	2074.6	164.0	160.7-167.2	1033.6	193.1	187.7-198.5	1041.0	144.5	140.4-148.6
Oral cavity and pharynx	166.6	13.5	12.5-14.4	115.4	20.2	18.6-22.0	51.2	7.7	6.8-8.8	36.2	2.8	2.4-3.3	27.4	4.9	4.1-5.8	8.8	1.1	0.8-1.6
Lip	6.0	0.5	0.3-0.7	4.2	0.8	0.5-1.3	1.8	0.3	0.1-0.5	0.6	0.1	0.0-0.2	0.6	0.1	0.0-0.4	0.0	0.0	0.0-0.2
Tongue	54.4	4.4	3.8-4.9	37.8	6.5	5.6-7.6	16.6	2.5	2.0-3.2	8.6	0.6	0.5-0.9	6.0	1.0	0.7-1.5	2.6	0.3	0.2-0.6
Salivary gland	18.2	1.6	1.3-2.0	10.0	2.1	1.5-2.7	8.2	1.2	0.9-1.7	3.0	0.3	0.1-0.5	2.2	0.5	0.2-0.8	0.8	0.1	0.0-0.3
Floor of mouth	8.0	0.6	0.4-0.9	4.6	0.8	0.5-1.2	3.4	0.5	0.3-0.8	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.2
Gum & other mouth	19.8	1.6	1.3-2.0	11.2	2.0	1.5-2.6	8.6	1.3	0.9-1.8	4.0	0.3	0.2-0.5	2.8	0.5	0.3-0.9	1.2	0.1	0.1-0.4
Nasopharynx	6.0	0.5	0.3-0.8	4.4	0.8	0.5-1.3	1.6	0.3	0.1-0.5	1.8	0.1	0.1-0.3	1.2	0.2	0.1-0.5	0.6	0.1	0.0-0.3
Tonsil	30.8	2.4	2.0-2.9	25.6	4.2	3.5-5.1	5.2	0.8	0.5-1.2	4.6	0.3	0.2-0.5	4.0	0.6	0.4-1.0	0.6	0.1	0.0-0.3
Oropharynx	7.8	0.6	0.4-0.9	6.4	1.1	0.7-1.6	1.4	0.2	0.1-0.5	6.4	0.5	0.3-0.7	5.2	0.8	0.5-1.3	1.2	0.2	0.1-0.4
Hypopharynx	12.4	1.0	0.7-1.2	9.0	1.6	1.1-2.1	3.4	0.5	0.3-0.8	3.2	0.3	0.1-0.4	2.2	0.4	0.2-0.8	1.0	0.1	0.0-0.4
Other buccal cavity and pharynx	3.2	0.2	0.1-0.4	2.2	0.4	0.2-0.7	1.0	0.2	0.0-0.4	4.0	0.3	0.2-0.5	3.2	0.6	0.3-1.0	0.8	0.1	0.0-0.3
Digestive system	1064.6	87.5	85.1-90.0	578.2	106.9	102.9-111.0	486.4	71.9	68.9-75.0	514.4	40.5	38.9-42.1	292.6	53.4	50.6-56.3	221.8	30.2	28.4-32.2
Esophagus	73.2	5.8	5.2-6.5	55.6	10.0	8.8-11.3	17.6	2.5	2.0-3.1	58.0	4.5	4.0-5.1	46.2	8.2	7.1-9.4	11.8	1.6	1.2-2.1
Stomach	96.8	8.1	7.4-8.9	58.2	11.0	9.7-12.4	38.6	5.8	5.0-6.7	36.0	2.9	2.4-3.3	21.8	4.1	3.4-5.0	14.2	1.8	1.4-2.3
Small intestine	46.0	3.8	3.3-4.3	26.8	5.0	4.1-5.9	19.2	2.8	2.3-3.5	9.6	0.8	0.6-1.0	5.4	1.0	0.7-1.5	4.2	0.5	0.3-0.9
Colorectal	461.2	38.7	37.1-40.4	227.4	43.0	40.5-45.7	233.8	35.3	33.2-37.5	161.0	12.7	11.9-13.7	82.8	15.5	14.0-17.2	78.2	10.6	9.5-11.8
Colon excluding rectum	318.2	26.4	25.1-27.8	147.6	27.9	25.8-30.0	170.6	25.3	23.5-27.1	120.8	9.5	8.7-10.3	60.8	11.4	10.1-12.8	60.0	8.0	7.0-9.0
Cecum	74.2	6.0	5.4-6.7	27.0	5.2	4.3-6.2	47.2	6.6	5.7-7.5									
Appendix	18.8	1.8	1.4-2.2	7.4	1.5	1.0-2.1	11.4	2.1	1.6-2.8									
Ascending colon	53.8	4.3	3.8-4.9	22.6	4.3	3.5-5.1	31.2	4.3	3.6-5.1									
Hepatic flexure	13.6	1.1	0.9-1.5	5.6	1.1	0.7-1.6	8.0	1.1	0.8-1.6									
Transverse colon	30.0	2.4	2.1-2.9	16.0	3.0	2.4-3.8	14.0	2.0	1.5-2.6									
Splenic flexure	10.4	0.8	0.6-1.1	4.8	0.9	0.5-1.3	5.6	0.8	0.5-1.1									
Descending colon	14.0	1.2	0.9-1.5	7.4	1.4	1.0-1.9	6.6	1.0	0.7-1.4									
Sigmoid colon	80.2	6.9	6.2-7.7	46.2	8.7	7.5-9.9	34.0	5.7	4.8-6.7									
Large intestine, NOS	23.2	1.8	1.5-2.2	10.6	1.9	1.4-2.6	12.6	1.7	1.3-2.3									
Rectum & rectosigmoid	143.0	12.3	11.3-13.2	79.8	15.1	13.6-16.7	63.2	10.0	8.8-11.2	40.2	3.3	2.8-3.8	22.0	4.1	3.4-5.0	18.2	2.6	2.1-3.3
Rectosigmoid junction	29.2	2.4	2.0-2.9	15.0	2.8	2.2-3.5	14.2	2.1	1.7-2.7									
Rectum	113.8	9.8	9.0-10.7	64.8	12.3	11.0-13.8	49.0	7.8	6.8-9.0									
Anus, anal canal & anorectum	25.6	2.2	1.8-2.7	9.2	1.9	1.3-2.5	16.4	2.5	2.0-3.2	4.8	0.4	0.3-0.6	2.6	0.5	0.3-0.9	2.2	0.3	0.2-0.6
Liver and intrahepatic bile duct	110.0	8.5	7.8-9.3	82.0	14.1	12.8-15.6	28.0	4.0	3.3-4.7	73.8	5.7	5.1-6.3	52.4	9.2	8.1-10.4	21.4	3.0	2.5-3.7

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019**

Erie

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	86.4	6.6	6.0-7.3	68.2	11.7	10.4-13.0	18.2	2.5	2.0-3.2	50.2	3.8	3.4-4.4	39.8	6.9	6.0-8.0	10.4	1.4	1.1-1.9
Intrahepatic bile duct	23.6	1.9	1.6-2.3	13.8	2.5	1.9-3.1	9.8	1.4	1.0-1.9	23.6	1.9	1.5-2.3	12.6	2.2	1.7-2.9	11.0	1.6	1.2-2.1
Gallbladder	13.8	1.1	0.9-1.5	2.8	0.5	0.3-0.9	11.0	1.7	1.2-2.2	6.2	0.5	0.3-0.7	1.4	0.3	0.1-0.6	4.8	0.7	0.4-1.1
Other biliary	19.4	1.5	1.2-1.9	10.6	1.8	1.4-2.4	8.8	1.2	0.9-1.7	6.4	0.5	0.3-0.7	3.6	0.6	0.4-1.0	2.8	0.4	0.2-0.6
Pancreas	194.4	15.8	14.8-16.8	96.8	17.9	16.3-19.6	97.6	14.0	12.7-15.4	148.6	11.7	10.9-12.6	72.6	13.3	11.9-14.8	76.0	10.4	9.4-11.6
Retroperitoneum	4.4	0.4	0.3-0.6	2.6	0.5	0.3-0.9	1.8	0.3	0.1-0.6	0.8	0.1	0.0-0.2	0.6	0.1	0.0-0.4	0.2	0.0	0.0-0.2
Peritoneum, omentum & mesentery	6.4	0.5	0.3-0.7	0.4	0.1	0.0-0.3	6.0	0.9	0.6-1.3	2.8	0.2	0.1-0.4	0.4	0.1	0.0-0.3	2.4	0.3	0.2-0.6
Other digestive organs	13.4	1.1	0.8-1.3	5.8	1.1	0.7-1.6	7.6	1.0	0.7-1.4	6.4	0.5	0.3-0.7	2.8	0.5	0.3-0.9	3.6	0.5	0.3-0.8
Respiratory system	939.6	74.6	72.4-76.8	448.0	81.7	78.3-85.3	491.6	70.0	67.2-72.9	536.0	42.1	40.5-43.8	261.6	48.2	45.6-51.0	274.4	37.9	35.8-40.0
Nasal cavity, middle ear & sinuses	8.8	0.8	0.6-1.1	4.6	0.9	0.6-1.4	4.2	0.6	0.4-1.0	1.8	0.2	0.1-0.3	1.0	0.2	0.1-0.5	0.8	0.1	0.0-0.4
Larynx	42.4	3.4	3.0-3.9	30.4	5.3	4.5-6.3	12.0	1.9	1.5-2.5	12.8	1.0	0.8-1.3	8.6	1.5	1.1-2.1	4.2	0.6	0.4-1.0
Lung and bronchus	885.8	70.1	68.0-72.3	411.4	75.2	71.9-78.6	474.4	67.2	64.5-70.0	519.8	40.8	39.2-42.5	251.2	46.4	43.8-49.1	268.6	37.0	35.0-39.1
Pleura	1.2	0.1	0.0-0.2	0.8	0.2	0.0-0.4	0.4	0.1	0.0-0.3	0.6	0.0	0.0-0.2	0.4	0.1	0.0-0.3	0.2	0.0	0.0-0.2
Trachea, mediastinum, other respiratory	1.4	0.1	0.1-0.3	0.8	0.2	0.0-0.4	0.6	0.1	0.0-0.4	1.0	0.1	0.0-0.2	0.4	0.1	0.0-0.3	0.6	0.1	0.0-0.3
Bones & joints	10.8	1.1	0.8-1.4	5.0	1.1	0.7-1.6	5.8	1.1	0.7-1.6	3.4	0.4	0.2-0.6	1.6	0.4	0.2-0.7	1.8	0.3	0.1-0.7
Soft tissue (including heart)	43.0	3.9	3.4-4.5	24.4	4.8	4.0-5.8	18.6	3.2	2.6-4.0	17.0	1.4	1.1-1.8	11.0	2.1	1.6-2.7	6.0	0.9	0.6-1.3
Skin*	386.6	32.9	31.4-34.5	221.0	41.0	38.6-43.6	165.6	27.4	25.5-29.5	40.8	3.2	2.8-3.7	25.6	4.9	4.1-5.8	15.2	2.1	1.6-2.6
Melanoma of the skin	356.0	30.3	28.8-31.8	204.0	37.7	35.4-40.2	152.0	25.2	23.3-27.2	27.0	2.2	1.8-2.6	16.6	3.2	2.5-4.0	10.4	1.5	1.1-2.0
Breast	923.2	80.1	77.7-82.5	8.0	1.4	1.0-2.0	915.2	147.4	142.9-151.9	159.2	12.8	11.9-13.8	1.8	0.3	0.2-0.7	157.4	22.5	20.9-24.2
Breast (in situ)#	235.2	21.6	20.3-22.9	1.2	0.2	0.1-0.5	234.0	40.7	38.2-43.2									
Female genital system							376.0	59.5	56.7-62.4							111.6	16.4	15.0-17.8
Cervix uteri							35.2	7.2	6.1-8.4							12.0	2.0	1.5-2.6
Corpus uterus and NOS							219.2	33.4	31.4-35.5							36.6	5.2	4.5-6.1
Ovary							75.0	11.9	10.7-13.3							52.0	7.6	6.7-8.6
Vagina							5.0	0.8	0.5-1.2							1.4	0.2	0.1-0.5
Vulva							27.8	4.2	3.5-5.0							6.0	0.8	0.5-1.1
Other female genital organs							13.8	2.0	1.5-2.6							3.6	0.5	0.3-0.9
Male genital system				883.6	151.9	147.3-156.6							97.8	19.0	17.4-20.8			
Prostate				845.0	143.2	138.8-147.7							95.4	18.6	17.0-20.4			
Testis				32.2	7.4	6.3-8.7							0.6	0.1	0.0-0.4			
Penis				6.0	1.2	0.8-1.7							1.4	0.2	0.1-0.5			
Other male genital organs				0.4	0.1	0.0-0.3							0.4	0.1	0.0-0.3			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019**

Erie

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	591.4	48.0	46.2-49.8	407.0	75.7	72.4-79.2	184.4	26.9	25.1-28.8	105.8	8.2	7.5-9.0	67.0	12.7	11.4-14.2	38.8	5.1	4.4-5.9
Urinary bladder (including in situ)	352.2	28.0	26.7-29.4	249.4	46.3	43.7-49.0	102.8	14.4	13.2-15.8	62.4	4.8	4.3-5.4	41.6	8.0	7.0-9.2	20.8	2.7	2.2-3.3
Kidney and renal pelvis	225.6	19.0	17.8-20.1	148.6	27.7	25.7-29.8	77.0	11.8	10.6-13.2	40.2	3.1	2.7-3.6	23.6	4.3	3.5-5.2	16.6	2.3	1.8-2.9
Ureter	8.4	0.7	0.5-0.9	5.2	1.0	0.7-1.5	3.2	0.4	0.2-0.7	1.2	0.1	0.0-0.2	0.8	0.2	0.0-0.4	0.4	0.0	0.0-0.2
Other urinary organs	5.2	0.4	0.3-0.6	3.8	0.7	0.4-1.1	1.4	0.2	0.1-0.4	2.0	0.2	0.1-0.3	1.0	0.2	0.1-0.5	1.0	0.1	0.0-0.3
Eye & orbit	9.8	0.9	0.6-1.2	4.6	0.9	0.5-1.3	5.2	0.9	0.6-1.3	1.0	0.1	0.0-0.2	0.6	0.1	0.0-0.3	0.4	0.1	0.0-0.3
Brain / other central nervous system (all behaviors)	256.4	23.2	21.9-24.6	102.4	20.0	18.2-21.9	154.0	26.2	24.2-28.2	59.8	5.0	4.4-5.7	32.0	6.0	5.1-7.1	27.8	4.2	3.5-5.0
Malignant brain / other central nervous system	72.6	7.0	6.3-7.8	40.2	8.2	7.1-9.5	32.4	6.1	5.1-7.1	48.6	4.1	3.6-4.7	27.6	5.2	4.4-6.2	21.0	3.2	2.6-3.9
Malignant brain	66.4	6.3	5.6-7.0	37.0	7.4	6.4-8.6	29.4	5.4	4.5-6.4									
Malignant other central nervous system	6.2	0.7	0.5-1.1	3.2	0.8	0.4-1.2	3.0	0.7	0.4-1.2									
Benign brain / other central nervous system#	183.8	16.2	15.1-17.4	62.2	11.8	10.5-13.3	121.6	20.1	18.4-21.9	11.2	0.9	0.7-1.2	4.4	0.8	0.5-1.2	6.8	0.9	0.6-1.4
Benign brain	20.2	2.0	1.6-2.5	8.4	1.7	1.2-2.4	11.8	2.3	1.7-3.0									
Benign other central nervous system	163.6	14.2	13.2-15.3	53.8	10.1	8.9-11.4	109.8	17.9	16.3-19.5									
Endocrine system	176.0	18.4	17.1-19.7	45.2	9.5	8.3-10.9	130.8	26.8	24.7-29.1	8.0	0.6	0.5-0.9	3.6	0.7	0.4-1.1	4.4	0.6	0.4-1.0
Thyroid	167.8	17.6	16.3-18.8	42.8	8.9	7.7-10.3	125.0	25.8	23.7-28.0	4.4	0.3	0.2-0.5	2.0	0.4	0.2-0.7	2.4	0.3	0.2-0.6
Other endocrine (including thymus)	8.2	0.8	0.6-1.1	2.4	0.6	0.3-1.0	5.8	1.0	0.7-1.5	3.6	0.3	0.2-0.5	1.6	0.3	0.1-0.6	2.0	0.3	0.2-0.6
Lymphomas	316.0	27.3	25.9-28.7	167.6	32.3	30.1-34.6	148.4	23.6	21.8-25.4	75.0	5.9	5.3-6.6	47.2	9.1	8.0-10.4	27.8	3.8	3.2-4.5
Hodgkin lymphoma	29.0	3.0	2.6-3.6	15.6	3.4	2.7-4.3	13.4	2.7	2.1-3.5	1.8	0.1	0.1-0.3	1.2	0.2	0.1-0.5	0.6	0.1	0.0-0.3
Non-Hodgkin lymphomas	287.0	24.2	22.9-25.6	152.0	28.9	26.8-31.1	135.0	20.8	19.2-22.6	73.2	5.8	5.2-6.4	46.0	8.9	7.8-10.2	27.2	3.7	3.1-4.4
Myeloma	98.6	8.1	7.3-8.8	50.0	9.4	8.3-10.7	48.6	7.1	6.2-8.1	39.0	3.1	2.7-3.6	22.2	4.3	3.5-5.2	16.8	2.3	1.8-2.8
Leukemias	207.8	17.6	16.5-18.8	127.2	24.4	22.5-26.5	80.6	12.3	11.1-13.6	85.6	6.8	6.2-7.5	50.8	9.9	8.7-11.2	34.8	4.6	3.9-5.4
Lymphocytic leukemias	101.0	8.6	7.8-9.4	67.0	12.6	11.2-14.1	34.0	5.4	4.5-6.3	23.8	1.9	1.5-2.2	13.8	2.7	2.1-3.4	10.0	1.3	0.9-1.7
Acute lymphocytic leukemia	13.0	1.5	1.2-2.0	6.4	1.5	1.0-2.2	6.6	1.5	1.0-2.1	5.4	0.5	0.3-0.8	3.0	0.7	0.4-1.1	2.4	0.4	0.2-0.8
Chronic lymphocytic leukemia	81.2	6.4	5.8-7.1	55.4	10.0	8.8-11.3	25.8	3.6	3.0-4.4	17.2	1.2	1.0-1.5	10.2	1.9	1.4-2.5	7.0	0.8	0.5-1.1
Other lymphocytic leukemias	6.8	0.6	0.4-0.9	5.2	1.0	0.6-1.5	1.6	0.2	0.1-0.5	1.2	0.1	0.0-0.2	0.6	0.1	0.0-0.4	0.6	0.1	0.0-0.3
Myeloid and monocytic leukemias	95.4	8.1	7.3-8.9	55.4	10.8	9.6-12.2	40.0	6.0	5.1-6.9	46.2	3.7	3.2-4.2	29.2	5.6	4.7-6.6	17.0	2.4	1.9-3.0
Acute myeloid leukemia	66.0	5.5	4.9-6.1	37.6	7.2	6.2-8.4	28.4	4.2	3.5-5.0	40.4	3.2	2.8-3.7	26.0	4.9	4.1-5.9	14.4	2.0	1.6-2.6
Acute monocytic leukemia	3.0	0.3	0.1-0.5	1.8	0.4	0.2-0.7	1.2	0.2	0.1-0.5	0.2	0.0	0.0-0.1	0.2	0.0	0.0-0.2	0.0	0.0	0.0-0.2
Chronic myeloid leukemia	25.6	2.3	1.9-2.7	15.4	3.1	2.5-4.0	10.2	1.6	1.1-2.1	3.2	0.3	0.1-0.4	1.4	0.3	0.1-0.6	1.8	0.2	0.1-0.5
Other myeloid/monocytic leukemias	0.8	0.1	0.0-0.2	0.6	0.1	0.0-0.3	0.2	0.0	0.0-0.2	2.4	0.2	0.1-0.4	1.6	0.3	0.1-0.6	0.8	0.1	0.0-0.3
Other leukemias	11.4	1.0	0.7-1.3	4.8	1.0	0.6-1.5	6.6	1.0	0.7-1.4	15.6	1.3	1.0-1.6	7.8	1.7	1.2-2.3	7.8	1.0	0.7-1.4
Other acute leukemias	4.4	0.4	0.2-0.6	2.0	0.5	0.2-0.9	2.4	0.3	0.1-0.5	5.6	0.5	0.3-0.7	2.8	0.6	0.3-1.0	2.8	0.3	0.2-0.6

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019**

Erie

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	7.0	0.6	0.4-0.9	2.8	0.6	0.3-0.9	4.2	0.7	0.4-1.1	10.0	0.8	0.6-1.1	5.0	1.0	0.7-1.6	5.0	0.6	0.4-1.0
Mesothelioma	11.8	1.0	0.7-1.3	8.6	1.7	1.3-2.4	3.2	0.5	0.3-0.8									
Kaposi sarcoma	1.2	0.1	0.0-0.2	1.0	0.2	0.1-0.5	0.2	0.0	0.0-0.2									
Myelodysplastic syndromes	67.8	5.4	4.8-6.0	38.0	7.4	6.4-8.6	29.8	3.9	3.3-4.7									
Chronic myeloproliferative disorders [^]	69.4	5.8	5.2-6.5	31.4	5.9	4.9-6.9	38.0	5.8	5.0-6.8									
All defined and unspecified sites	144.6	11.6	10.7-12.5	69.2	13.3	11.9-14.8	75.4	10.3	9.3-11.5	195.2	15.2	14.2-16.2	95.2	17.8	16.2-19.5	100.0	13.4	12.2-14.7

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

[^] Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019**

Monroe

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	4787.6	510.3	503.6-517.0	2405.2	562.0	551.7-572.4	2382.4	475.9	467.0-484.9	1476.8	152.6	149.1-156.2	742.6	179.6	173.7-185.6	734.2	134.7	130.2-139.3
Oral cavity and pharynx	118.6	12.5	11.5-13.6	80.0	18.5	16.7-20.5	38.6	7.3	6.3-8.5	25.0	2.6	2.1-3.1	16.8	3.9	3.1-4.9	8.2	1.4	1.0-2.0
Lip	3.6	0.4	0.2-0.6	2.0	0.5	0.2-1.0	1.6	0.3	0.1-0.6	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.2
Tongue	37.0	3.9	3.3-4.5	23.4	5.4	4.4-6.5	13.6	2.5	2.0-3.3	6.0	0.6	0.4-0.9	4.0	1.0	0.6-1.5	2.0	0.4	0.2-0.7
Salivary gland	13.0	1.4	1.1-1.8	9.2	2.3	1.7-3.1	3.8	0.8	0.5-1.3	1.4	0.1	0.1-0.3	1.0	0.3	0.1-0.6	0.4	0.1	0.0-0.3
Floor of mouth	5.8	0.6	0.4-0.9	4.2	1.0	0.6-1.6	1.6	0.3	0.1-0.6	0.2	0.0	0.0-0.1	0.2	0.1	0.0-0.3	0.0	0.0	0.0-0.2
Gum & other mouth	17.6	1.9	1.5-2.3	7.4	1.7	1.2-2.4	10.2	2.0	1.5-2.7	4.6	0.5	0.3-0.7	2.4	0.6	0.3-1.1	2.2	0.4	0.2-0.7
Nasopharynx	4.0	0.4	0.3-0.7	3.2	0.7	0.4-1.2	0.8	0.1	0.0-0.4	2.2	0.2	0.1-0.4	1.4	0.3	0.1-0.7	0.8	0.1	0.0-0.4
Tonsil	23.2	2.4	2.0-2.9	19.2	4.3	3.4-5.3	4.0	0.7	0.4-1.2	2.6	0.3	0.1-0.5	2.4	0.5	0.3-0.9	0.2	0.0	0.0-0.3
Oropharynx	6.6	0.7	0.5-1.0	5.4	1.2	0.8-1.8	1.2	0.2	0.1-0.5	2.8	0.3	0.2-0.5	1.2	0.3	0.1-0.6	1.6	0.3	0.1-0.6
Hypopharynx	6.6	0.7	0.5-1.0	5.0	1.2	0.7-1.7	1.6	0.3	0.1-0.6	1.8	0.2	0.1-0.4	1.6	0.4	0.2-0.8	0.2	0.0	0.0-0.3
Other buccal cavity and pharynx	1.2	0.1	0.0-0.3	1.0	0.2	0.1-0.5	0.2	0.0	0.0-0.2	3.4	0.3	0.2-0.6	2.6	0.6	0.3-1.0	0.8	0.1	0.0-0.4
Digestive system	752.8	79.5	76.9-82.2	400.8	94.3	90.1-98.7	352.0	67.7	64.4-71.1	380.0	39.2	37.4-41.1	211.0	49.8	46.7-52.9	169.0	30.9	28.8-33.2
Esophagus	43.6	4.5	3.9-5.1	31.4	7.2	6.0-8.4	12.2	2.2	1.7-2.9	42.4	4.3	3.7-5.0	30.6	7.1	6.0-8.3	11.8	2.1	1.6-2.8
Stomach	61.0	6.5	5.8-7.3	37.2	8.9	7.7-10.4	23.8	4.6	3.8-5.5	24.0	2.5	2.1-3.0	14.4	3.3	2.6-4.2	9.6	1.8	1.3-2.4
Small intestine	27.8	3.0	2.5-3.6	15.6	3.9	3.0-4.9	12.2	2.3	1.8-3.0	4.0	0.4	0.3-0.7	2.4	0.6	0.3-1.1	1.6	0.3	0.1-0.7
Colorectal	343.2	36.9	35.1-38.8	173.8	41.3	38.6-44.3	169.4	33.3	31.0-35.8	115.8	11.9	11.0-13.0	60.4	14.5	12.8-16.3	55.4	9.9	8.8-11.3
Colon excluding rectum	248.8	26.6	25.1-28.2	119.6	28.5	26.2-31.0	129.2	25.2	23.2-27.4	90.6	9.4	8.5-10.3	45.4	11.0	9.6-12.6	45.2	8.1	7.0-9.2
Cecum	47.4	4.8	4.2-5.5	21.2	5.0	4.1-6.1	26.2	4.8	4.0-5.7									
Appendix	20.6	2.5	2.1-3.1	9.4	2.3	1.7-3.1	11.2	2.8	2.1-3.7									
Ascending colon	48.2	5.0	4.4-5.7	23.2	5.3	4.4-6.5	25.0	4.7	3.9-5.7									
Hepatic flexure	13.4	1.4	1.1-1.8	6.2	1.5	1.0-2.2	7.2	1.4	1.0-2.0									
Transverse colon	22.4	2.4	2.0-2.9	10.0	2.4	1.8-3.2	12.4	2.4	1.8-3.2									
Splenic flexure	6.2	0.7	0.5-1.0	2.4	0.6	0.3-1.1	3.8	0.7	0.4-1.2									
Descending colon	12.8	1.4	1.1-1.8	7.0	1.7	1.2-2.4	5.8	1.2	0.8-1.8									
Sigmoid colon	64.6	6.9	6.2-7.8	35.0	8.2	7.0-9.6	29.6	5.7	4.8-6.8									
Large intestine, NOS	13.2	1.4	1.1-1.8	5.2	1.3	0.9-2.0	8.0	1.4	1.0-2.0									
Rectum & rectosigmoid	94.4	10.3	9.3-11.3	54.2	12.8	11.3-14.5	40.2	8.1	7.0-9.3	25.2	2.6	2.1-3.1	15.0	3.5	2.7-4.4	10.2	1.9	1.4-2.5
Rectosigmoid junction	17.6	1.9	1.5-2.4	9.6	2.2	1.6-2.9	8.0	1.7	1.2-2.3									
Rectum	76.8	8.4	7.5-9.3	44.6	10.7	9.3-12.2	32.2	6.4	5.4-7.6									
Anus, anal canal & anorectum	20.4	2.1	1.7-2.5	6.6	1.4	1.0-2.0	13.8	2.7	2.1-3.4	3.8	0.4	0.2-0.6	0.8	0.2	0.0-0.4	3.0	0.6	0.3-1.0
Liver and intrahepatic bile duct	71.0	7.2	6.4-8.0	46.8	10.3	9.0-11.8	24.2	4.6	3.8-5.6	53.4	5.5	4.9-6.3	34.4	8.0	6.8-9.3	19.0	3.7	3.0-4.6

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019**

Monroe

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	50.8	5.0	4.4-5.7	38.2	8.2	7.1-9.5	12.6	2.4	1.8-3.1	32.6	3.3	2.8-3.9	23.6	5.3	4.4-6.4	9.0	1.8	1.3-2.4
Intrahepatic bile duct	20.2	2.2	1.7-2.6	8.6	2.1	1.5-2.8	11.6	2.3	1.7-3.0	20.8	2.2	1.8-2.7	10.8	2.7	2.0-3.5	10.0	1.9	1.4-2.6
Gallbladder	10.2	1.0	0.7-1.3	4.4	1.0	0.6-1.5	5.8	1.0	0.7-1.5	3.8	0.4	0.2-0.6	1.0	0.2	0.1-0.5	2.8	0.5	0.3-0.9
Other biliary	14.2	1.5	1.1-1.8	6.6	1.6	1.1-2.2	7.6	1.4	1.0-1.9	4.8	0.5	0.3-0.7	1.8	0.4	0.2-0.8	3.0	0.5	0.3-0.9
Pancreas	141.8	14.9	13.8-16.1	70.8	17.0	15.2-18.9	71.0	13.2	11.8-14.7	121.6	12.7	11.6-13.7	62.2	14.9	13.3-16.7	59.4	10.8	9.6-12.2
Retroperitoneum	4.8	0.5	0.3-0.8	2.8	0.6	0.3-1.1	2.0	0.4	0.2-0.8	1.2	0.1	0.0-0.3	0.6	0.1	0.0-0.4	0.6	0.1	0.0-0.4
Peritoneum, omentum & mesentery	6.0	0.6	0.4-0.8	0.4	0.1	0.0-0.4	5.6	1.0	0.7-1.5	2.6	0.2	0.1-0.4	0.4	0.1	0.0-0.4	2.2	0.4	0.2-0.7
Other digestive organs	8.8	0.9	0.7-1.3	4.4	1.0	0.6-1.6	4.4	0.8	0.5-1.3	2.6	0.3	0.1-0.5	2.0	0.4	0.2-0.8	0.6	0.1	0.0-0.4
Respiratory system	653.4	66.9	64.6-69.3	322.6	74.9	71.2-78.8	330.8	61.4	58.4-64.5	365.4	37.6	35.9-39.5	193.0	46.2	43.2-49.3	172.4	31.6	29.5-33.8
Nasal cavity, middle ear & sinuses	8.4	0.9	0.6-1.2	4.4	1.0	0.6-1.6	4.0	0.8	0.5-1.3	1.8	0.2	0.1-0.4	0.8	0.2	0.0-0.5	1.0	0.2	0.1-0.5
Larynx	28.6	2.9	2.4-3.4	22.8	5.0	4.1-6.1	5.8	1.1	0.7-1.6	8.4	0.8	0.6-1.1	6.2	1.4	0.9-2.0	2.2	0.4	0.2-0.8
Lung and bronchus	615.8	63.1	60.8-65.4	295.2	68.8	65.3-72.5	320.6	59.4	56.5-62.5	354.6	36.5	34.8-38.3	185.4	44.4	41.6-47.5	169.2	31.0	28.9-33.2
Pleura	0.2	0.0	0.0-0.1	0.0	0.0	0.0-0.2	0.2	0.0	0.0-0.3	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.2
Trachea, mediastinum, other respiratory	0.4	0.0	0.0-0.2	0.2	0.1	0.0-0.3	0.2	0.0	0.0-0.3	0.6	0.1	0.0-0.3	0.6	0.2	0.0-0.6	0.0	0.0	0.0-0.2
Bones & joints	7.2	0.9	0.6-1.3	2.8	0.7	0.4-1.2	4.4	1.1	0.7-1.7	4.8	0.5	0.3-0.8	2.8	0.7	0.4-1.2	2.0	0.4	0.2-0.8
Soft tissue (including heart)	29.8	3.4	2.9-4.0	18.4	4.6	3.7-5.7	11.4	2.3	1.7-3.1	12.0	1.3	1.0-1.7	7.0	1.8	1.2-2.5	5.0	1.0	0.6-1.5
Skin*	270.2	30.2	28.6-31.9	150.6	37.0	34.4-39.9	119.6	25.8	23.7-28.1	26.2	2.7	2.3-3.3	16.4	4.1	3.2-5.1	9.8	1.8	1.3-2.5
Melanoma of the skin	244.8	27.5	26.0-29.2	135.2	33.3	30.8-36.0	109.6	23.8	21.7-26.0	16.8	1.7	1.4-2.2	10.4	2.6	1.9-3.4	6.4	1.2	0.8-1.7
Breast	730.2	80.8	78.1-83.6	7.4	1.8	1.3-2.5	722.8	148.2	143.1-153.3	97.6	10.4	9.5-11.4	1.2	0.3	0.1-0.7	96.4	18.3	16.7-20.1
Breast (in situ)#	164.6	18.6	17.2-19.9	1.4	0.4	0.1-0.8	163.2	34.6	32.1-37.1									
Female genital system							276.8	55.2	52.2-58.4							89.6	16.3	14.8-18.0
Cervix uteri							23.8	5.6	4.6-6.8							10.0	2.1	1.5-2.8
Corpus uterus and NOS							166.4	32.2	30.0-34.6							36.2	6.5	5.5-7.5
Ovary							52.4	10.8	9.5-12.3							34.2	6.2	5.3-7.3
Vagina							2.2	0.4	0.2-0.7							0.6	0.1	0.0-0.3
Vulva							14.6	2.9	2.3-3.7							4.4	0.7	0.4-1.1
Other female genital organs							17.4	3.3	2.6-4.1							4.2	0.7	0.4-1.2
Male genital system				702.2	155.2	149.9-160.5							75.8	19.2	17.3-21.2			
Prostate				672.6	146.8	141.8-152.0							75.2	19.0	17.1-21.1			
Testis				27.2	7.8	6.5-9.3							0.4	0.1	0.0-0.4			
Penis				1.0	0.2	0.1-0.5							0.2	0.1	0.0-0.3			
Other male genital organs				1.4	0.3	0.1-0.7							0.0	0.0	0.0-0.2			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019**

Monroe

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	425.8	44.8	42.9-46.8	304.8	72.6	68.9-76.4	121.0	23.3	21.4-25.4	73.8	7.5	6.7-8.3	48.8	11.9	10.4-13.5	25.0	4.3	3.6-5.2
Urinary bladder (including in situ)	229.8	23.6	22.2-25.1	172.0	41.2	38.4-44.1	57.8	10.6	9.4-11.9	42.4	4.2	3.7-4.9	29.4	7.3	6.1-8.6	13.0	2.2	1.7-2.8
Kidney and renal pelvis	186.6	20.2	18.9-21.6	126.0	29.8	27.4-32.3	60.6	12.3	10.9-13.8	30.2	3.1	2.6-3.6	19.0	4.5	3.6-5.6	11.2	2.0	1.5-2.6
Ureter	6.0	0.6	0.4-0.9	4.0	0.9	0.6-1.5	2.0	0.4	0.2-0.8	0.2	0.0	0.0-0.1	0.0	0.0	0.0-0.2	0.2	0.0	0.0-0.3
Other urinary organs	3.4	0.4	0.2-0.6	2.8	0.7	0.4-1.2	0.6	0.1	0.0-0.4	1.0	0.1	0.0-0.3	0.4	0.1	0.0-0.3	0.6	0.1	0.0-0.4
Eye & orbit	6.0	0.7	0.5-1.0	2.0	0.5	0.2-0.9	4.0	0.9	0.6-1.5	0.8	0.1	0.0-0.2	0.2	0.0	0.0-0.3	0.6	0.1	0.0-0.4
Brain / other central nervous system (all behaviors)	185.2	21.2	19.8-22.6	74.2	18.6	16.7-20.7	111.0	23.5	21.5-25.6	47.2	5.2	4.5-5.9	26.6	6.5	5.4-7.7	20.6	4.2	3.4-5.2
Malignant brain / other central nervous system	54.2	6.3	5.5-7.1	29.2	7.3	6.1-8.7	25.0	5.5	4.5-6.6	38.8	4.3	3.7-5.0	22.4	5.4	4.4-6.6	16.4	3.5	2.7-4.3
Malignant brain	52.2	6.0	5.3-6.8	28.4	7.1	5.9-8.4	23.8	5.1	4.2-6.2									
Malignant other central nervous system	2.0	0.3	0.1-0.5	0.8	0.2	0.1-0.6	1.2	0.3	0.1-0.7									
Benign brain / other central nervous system#	131.0	14.9	13.7-16.1	45.0	11.3	9.8-12.9	86.0	18.0	16.3-19.9	8.4	0.9	0.6-1.2	4.2	1.1	0.7-1.7	4.2	0.8	0.5-1.2
Benign brain	10.8	1.4	1.1-1.9	7.0	1.8	1.3-2.6	3.8	1.0	0.6-1.6									
Benign other central nervous system	120.2	13.5	12.4-14.7	38.0	9.5	8.1-10.9	82.2	17.0	15.3-18.8									
Endocrine system	130.4	16.2	15.0-17.6	42.2	10.9	9.4-12.5	88.2	21.2	19.2-23.4	6.4	0.7	0.5-1.0	2.6	0.7	0.3-1.2	3.8	0.7	0.4-1.1
Thyroid	124.0	15.4	14.2-16.8	38.4	9.8	8.4-11.4	85.6	20.7	18.7-22.9	5.0	0.5	0.3-0.8	2.0	0.5	0.2-1.0	3.0	0.5	0.3-0.9
Other endocrine (including thymus)	6.4	0.8	0.5-1.1	3.8	1.1	0.6-1.7	2.6	0.6	0.3-1.0	1.4	0.2	0.1-0.3	0.6	0.2	0.0-0.5	0.8	0.1	0.0-0.4
Lymphomas	233.2	25.9	24.4-27.5	128.6	31.7	29.2-34.3	104.6	21.4	19.5-23.4	60.2	6.3	5.6-7.1	30.8	7.7	6.5-9.0	29.4	5.3	4.5-6.3
Hodgkin lymphoma	27.0	3.6	3.0-4.2	16.6	4.6	3.7-5.8	10.4	2.6	1.9-3.5	3.0	0.3	0.2-0.5	2.0	0.5	0.2-1.0	1.0	0.2	0.1-0.5
Non-Hodgkin lymphomas	206.2	22.3	21.0-23.8	112.0	27.0	24.8-29.5	94.2	18.8	17.1-20.6	57.2	6.0	5.3-6.7	28.8	7.2	6.0-8.5	28.4	5.1	4.3-6.1
Myeloma	69.4	7.2	6.4-8.0	39.2	9.2	7.9-10.6	30.2	5.7	4.8-6.8	30.8	3.2	2.7-3.7	16.6	4.1	3.2-5.1	14.2	2.5	2.0-3.2
Leukemias	140.8	15.2	14.0-16.4	82.0	19.9	18.0-22.0	58.8	11.4	10.1-12.9	59.8	6.3	5.6-7.0	33.2	8.3	7.0-9.6	26.6	4.8	4.0-5.8
Lymphocytic leukemias	74.8	7.9	7.1-8.8	44.0	10.6	9.2-12.1	30.8	5.8	4.9-6.8	16.6	1.8	1.4-2.2	10.0	2.6	1.9-3.4	6.6	1.2	0.8-1.8
Acute lymphocytic leukemia	7.2	1.0	0.7-1.4	4.8	1.4	0.9-2.0	2.4	0.7	0.4-1.3	3.4	0.4	0.3-0.7	1.8	0.5	0.2-0.9	1.6	0.4	0.2-0.8
Chronic lymphocytic leukemia	62.6	6.4	5.7-7.1	36.0	8.5	7.3-9.9	26.6	4.7	3.9-5.6	12.2	1.2	0.9-1.6	7.8	2.0	1.4-2.7	4.4	0.7	0.4-1.1
Other lymphocytic leukemias	5.0	0.6	0.4-0.8	3.2	0.8	0.4-1.3	1.8	0.4	0.2-0.7	1.0	0.1	0.0-0.3	0.4	0.1	0.0-0.4	0.6	0.1	0.0-0.4
Myeloid and monocytic leukemias	60.2	6.6	5.9-7.4	34.8	8.6	7.3-10.0	25.4	5.1	4.2-6.1	34.2	3.6	3.1-4.2	19.2	4.7	3.8-5.8	15.0	2.8	2.2-3.6
Acute myeloid leukemia	38.4	4.2	3.6-4.8	22.8	5.6	4.6-6.7	15.6	3.2	2.5-4.0	26.0	2.8	2.3-3.3	16.0	3.9	3.1-4.9	10.0	2.0	1.4-2.6
Acute monocytic leukemia	2.2	0.3	0.1-0.5	1.2	0.3	0.1-0.7	1.0	0.2	0.1-0.6	0.4	0.0	0.0-0.2	0.0	0.0	0.0-0.2	0.4	0.1	0.0-0.3
Chronic myeloid leukemia	18.8	2.1	1.7-2.5	10.4	2.6	1.9-3.5	8.4	1.6	1.2-2.2	3.4	0.4	0.2-0.6	0.8	0.2	0.0-0.5	2.6	0.5	0.2-0.9
Other myeloid/monocytic leukemias	0.8	0.1	0.0-0.2	0.4	0.1	0.0-0.4	0.4	0.1	0.0-0.3	4.4	0.4	0.3-0.7	2.4	0.6	0.3-1.1	2.0	0.3	0.1-0.6
Other leukemias	5.8	0.6	0.4-0.9	3.2	0.7	0.4-1.2	2.6	0.5	0.3-0.9	9.0	0.9	0.6-1.2	4.0	0.9	0.6-1.5	5.0	0.8	0.5-1.2
Other acute leukemias	1.6	0.1	0.1-0.3	0.8	0.2	0.0-0.5	0.8	0.1	0.0-0.4	4.4	0.4	0.3-0.6	2.4	0.5	0.3-1.0	2.0	0.3	0.2-0.7

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019**

Monroe

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	4.2	0.4	0.3-0.7	2.4	0.6	0.3-1.0	1.8	0.4	0.2-0.7	4.6	0.5	0.3-0.7	1.6	0.4	0.2-0.8	3.0	0.5	0.3-0.8
Mesothelioma	6.4	0.7	0.5-1.0	4.0	1.1	0.6-1.6	2.4	0.5	0.2-0.9									
Kaposi sarcoma	2.2	0.2	0.1-0.4	2.0	0.5	0.2-0.9	0.2	0.0	0.0-0.2									
Myelodysplastic syndromes	43.6	4.5	3.9-5.2	26.6	6.6	5.5-7.9	17.0	3.1	2.5-3.9									
Chronic myeloproliferative disorders^	45.0	4.9	4.2-5.6	18.8	4.6	3.7-5.6	26.2	5.1	4.2-6.1									
All defined and unspecified sites	89.4	9.2	8.3-10.1	41.0	10.1	8.7-11.6	48.4	8.6	7.6-9.9	129.8	13.3	12.2-14.4	64.0	15.7	14.0-17.6	65.8	11.6	10.4-13.0

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019**

Nassau

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	9060.0	511.3	506.4-516.2	4477.6	550.1	542.7-557.6	4582.4	488.0	481.4-494.7	2380.6	126.3	124.0-128.7	1149.6	143.2	139.5-147.1	1231.0	115.2	112.2-118.3
Oral cavity and pharynx	195.0	11.0	10.3-11.8	127.8	15.7	14.4-17.0	67.2	7.1	6.3-8.0	29.8	1.6	1.3-1.9	15.6	1.9	1.5-2.4	14.2	1.3	1.0-1.6
Lip	7.0	0.4	0.3-0.6	4.4	0.6	0.3-0.8	2.6	0.3	0.1-0.5	0.6	0.0	0.0-0.1	0.2	0.0	0.0-0.2	0.4	0.0	0.0-0.1
Tongue	63.4	3.5	3.1-4.0	43.4	5.2	4.5-6.0	20.0	2.1	1.7-2.6	6.8	0.3	0.2-0.5	4.0	0.5	0.3-0.7	2.8	0.2	0.1-0.4
Salivary gland	27.6	1.6	1.3-1.9	14.6	1.9	1.5-2.4	13.0	1.5	1.1-1.9	4.8	0.3	0.2-0.4	1.8	0.2	0.1-0.5	3.0	0.3	0.2-0.5
Floor of mouth	6.2	0.3	0.2-0.5	4.2	0.5	0.3-0.8	2.0	0.2	0.1-0.4	0.2	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.2	0.0	0.0-0.2
Gum & other mouth	30.0	1.7	1.5-2.1	16.0	2.1	1.6-2.6	14.0	1.5	1.2-1.9	5.2	0.3	0.2-0.4	2.2	0.3	0.1-0.5	3.0	0.2	0.1-0.4
Nasopharynx	11.4	0.7	0.5-0.9	7.8	1.0	0.7-1.4	3.6	0.4	0.2-0.7	2.2	0.1	0.1-0.2	1.6	0.2	0.1-0.4	0.6	0.0	0.0-0.2
Tonsil	30.2	1.7	1.4-2.0	24.2	2.9	2.4-3.4	6.0	0.6	0.4-0.9	2.6	0.1	0.1-0.3	1.6	0.2	0.1-0.4	1.0	0.1	0.0-0.3
Oropharynx	7.8	0.4	0.3-0.6	5.2	0.6	0.4-0.9	2.6	0.3	0.1-0.5	3.2	0.2	0.1-0.3	2.0	0.3	0.1-0.5	1.2	0.1	0.0-0.3
Hypopharynx	8.2	0.4	0.3-0.6	5.8	0.7	0.5-1.1	2.4	0.2	0.1-0.4	0.8	0.0	0.0-0.1	0.6	0.1	0.0-0.2	0.2	0.0	0.0-0.1
Other buccal cavity and pharynx	3.2	0.2	0.1-0.3	2.2	0.2	0.1-0.5	1.0	0.1	0.0-0.2	3.4	0.2	0.1-0.3	1.6	0.2	0.1-0.4	1.8	0.2	0.1-0.3
Digestive system	1502.2	82.8	80.9-84.7	786.6	97.2	94.1-100.3	715.6	71.1	68.7-73.6	656.4	34.8	33.6-36.1	353.0	43.6	41.5-45.7	303.4	27.7	26.3-29.2
Esophagus	76.4	4.2	3.8-4.6	56.0	6.9	6.1-7.8	20.4	1.9	1.6-2.4	52.6	2.9	2.5-3.3	40.6	5.1	4.4-5.8	12.0	1.1	0.8-1.4
Stomach	148.4	8.2	7.6-8.9	84.6	10.4	9.4-11.5	63.8	6.5	5.8-7.3	49.2	2.7	2.3-3.0	27.2	3.4	2.9-4.1	22.0	2.1	1.7-2.5
Small intestine	55.0	3.1	2.8-3.6	33.8	4.2	3.6-4.9	21.2	2.3	1.8-2.8	6.8	0.4	0.3-0.5	3.4	0.4	0.3-0.7	3.4	0.3	0.2-0.6
Colorectal	668.6	37.6	36.3-39.0	323.8	40.9	38.9-43.0	344.8	34.9	33.1-36.6	206.4	10.9	10.2-11.6	101.8	12.8	11.7-14.0	104.6	9.3	8.5-10.2
Colon excluding rectum	483.6	26.9	25.8-28.1	224.6	28.3	26.7-30.1	259.0	25.7	24.3-27.3	171.0	9.0	8.4-9.6	79.0	9.9	8.9-11.0	92.0	8.2	7.4-9.0
Cecum	95.6	5.1	4.7-5.6	40.4	5.1	4.4-5.8	55.2	5.1	4.5-5.8									
Appendix	33.8	2.3	1.9-2.7	13.4	1.9	1.4-2.4	20.4	2.6	2.1-3.2									
Ascending colon	102.2	5.5	5.0-6.0	44.2	5.5	4.8-6.3	58.0	5.5	4.9-6.2									
Hepatic flexure	22.0	1.2	1.0-1.5	11.6	1.5	1.1-2.0	10.4	1.0	0.8-1.4									
Transverse colon	39.2	2.1	1.8-2.5	17.8	2.3	1.8-2.8	21.4	2.0	1.6-2.5									
Splenic flexure	10.8	0.6	0.4-0.8	5.8	0.7	0.5-1.1	5.0	0.5	0.3-0.7									
Descending colon	27.8	1.6	1.4-1.9	15.6	2.0	1.6-2.5	12.2	1.3	1.0-1.7									
Sigmoid colon	123.2	6.9	6.4-7.5	62.8	7.7	6.9-8.7	60.4	6.3	5.6-7.1									
Large intestine, NOS	29.0	1.5	1.3-1.8	13.0	1.6	1.2-2.1	16.0	1.4	1.1-1.8									
Rectum & rectosigmoid	185.0	10.7	10.0-11.4	99.2	12.5	11.4-13.7	85.8	9.1	8.2-10.1	35.4	2.0	1.7-2.3	22.8	2.9	2.4-3.5	12.6	1.2	0.9-1.5
Rectosigmoid junction	51.2	2.9	2.6-3.3	24.0	3.0	2.5-3.6	27.2	2.9	2.4-3.4									
Rectum	133.8	7.8	7.2-8.4	75.2	9.6	8.6-10.6	58.6	6.2	5.5-7.0									
Anus, anal canal & anorectum	32.0	1.7	1.5-2.0	9.0	1.1	0.8-1.4	23.0	2.3	1.9-2.8	2.4	0.1	0.1-0.2	1.2	0.1	0.0-0.3	1.2	0.1	0.0-0.3
Liver and intrahepatic bile duct	127.2	6.8	6.3-7.4	88.6	10.3	9.3-11.3	38.6	3.9	3.3-4.5	86.8	4.6	4.2-5.1	58.0	6.9	6.1-7.8	28.8	2.8	2.3-3.3

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019**

Nassau

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	100.8	5.4	4.9-5.9	74.0	8.5	7.7-9.5	26.8	2.7	2.2-3.2	55.8	2.9	2.6-3.3	41.8	4.9	4.3-5.7	14.0	1.3	1.0-1.7
Intrahepatic bile duct	26.4	1.4	1.2-1.7	14.6	1.7	1.4-2.2	11.8	1.2	0.9-1.5	31.0	1.7	1.4-2.0	16.2	2.0	1.6-2.5	14.8	1.5	1.1-1.9
Gallbladder	27.6	1.5	1.2-1.8	9.0	1.1	0.8-1.5	18.6	1.8	1.4-2.2	12.8	0.7	0.5-0.9	3.6	0.4	0.2-0.7	9.2	0.8	0.6-1.2
Other biliary	38.2	2.0	1.7-2.3	22.2	2.7	2.2-3.3	16.0	1.5	1.1-1.8	10.6	0.6	0.4-0.7	5.0	0.6	0.4-1.0	5.6	0.5	0.3-0.8
Pancreas	294.0	15.7	14.9-16.6	147.2	18.0	16.7-19.3	146.8	13.9	12.9-15.0	219.6	11.6	10.9-12.3	109.8	13.4	12.3-14.6	109.8	10.0	9.2-10.9
Retroperitoneum	8.6	0.5	0.3-0.7	4.2	0.5	0.3-0.8	4.4	0.4	0.3-0.7	0.8	0.0	0.0-0.1	0.6	0.1	0.0-0.2	0.2	0.0	0.0-0.1
Peritoneum, omentum & mesentery	8.6	0.5	0.3-0.6	1.4	0.2	0.1-0.4	7.2	0.7	0.5-1.0	3.8	0.2	0.1-0.3	0.0	0.0	0.0-0.1	3.8	0.4	0.2-0.6
Other digestive organs	17.6	0.9	0.8-1.2	6.8	0.9	0.6-1.2	10.8	1.0	0.8-1.4	4.6	0.2	0.1-0.4	1.8	0.2	0.1-0.4	2.8	0.3	0.1-0.5
Respiratory system	1039.0	56.5	54.9-58.1	479.0	59.5	57.1-62.0	560.0	54.7	52.6-56.8	494.8	26.1	25.1-27.2	241.4	29.9	28.2-31.6	253.4	23.6	22.3-25.0
Nasal cavity, middle ear & sinuses	14.6	0.8	0.7-1.1	8.6	1.1	0.8-1.5	6.0	0.6	0.4-0.9	1.2	0.1	0.0-0.2	0.8	0.1	0.0-0.3	0.4	0.0	0.0-0.1
Larynx	46.6	2.5	2.2-2.9	38.4	4.6	4.0-5.4	8.2	0.8	0.6-1.1	13.0	0.7	0.5-0.9	10.6	1.3	0.9-1.7	2.4	0.2	0.1-0.4
Lung and bronchus	974.2	52.9	51.3-54.4	429.6	53.5	51.2-55.8	544.6	53.1	51.1-55.2	479.0	25.3	24.3-26.4	228.8	28.3	26.7-30.1	250.2	23.3	22.0-24.7
Pleura	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.4	0.0	0.0-0.1	0.4	0.0	0.0-0.2	0.0	0.0	0.0-0.1
Trachea, mediastinum, other respiratory	3.6	0.2	0.1-0.4	2.4	0.3	0.2-0.6	1.2	0.1	0.0-0.3	1.2	0.1	0.0-0.2	0.8	0.1	0.0-0.3	0.4	0.0	0.0-0.2
Bones & joints	20.4	1.3	1.1-1.6	12.4	1.6	1.2-2.1	8.0	1.0	0.7-1.4	7.2	0.5	0.3-0.6	4.0	0.5	0.3-0.8	3.2	0.4	0.2-0.6
Soft tissue (including heart)	69.2	4.3	3.9-4.9	39.2	5.3	4.5-6.1	30.0	3.6	3.0-4.3	24.2	1.4	1.2-1.7	12.0	1.6	1.2-2.1	12.2	1.3	1.0-1.7
Skin*	436.6	24.7	23.7-25.8	259.4	32.5	30.7-34.3	177.2	19.3	18.0-20.7	45.0	2.4	2.1-2.7	29.0	3.6	3.1-4.3	16.0	1.4	1.1-1.8
Melanoma of the skin	398.8	22.7	21.6-23.7	237.2	29.7	28.0-31.5	161.6	17.7	16.5-19.1	33.4	1.8	1.5-2.1	21.6	2.7	2.2-3.3	11.8	1.1	0.8-1.4
Breast	1359.2	80.5	78.5-82.5	14.6	1.9	1.5-2.4	1344.6	149.3	145.6-153.1	187.2	10.1	9.5-10.8	2.2	0.3	0.2-0.6	185.0	18.0	16.8-19.2
Breast (in situ)#	539.6	33.3	32.0-34.7	1.4	0.2	0.1-0.4	538.2	63.3	60.9-65.9									
Female genital system							545.6	57.2	55.0-59.5							149.4	14.5	13.5-15.7
Cervix uteri							50.2	6.4	5.6-7.3							14.4	1.6	1.2-2.0
Corpus uteri and NOS							322.6	32.4	30.8-34.1							63.4	6.1	5.4-6.9
Ovary							110.8	12.2	11.1-13.3							60.8	5.9	5.2-6.6
Vagina							5.8	0.6	0.4-0.9							1.2	0.1	0.0-0.2
Vulva							27.8	2.8	2.4-3.4							4.8	0.4	0.3-0.7
Other female genital organs							28.4	2.8	2.4-3.4							4.8	0.4	0.3-0.7
Male genital system				1283.0	148.7	145.0-152.5							111.6	14.0	12.8-15.2			
Prostate				1238.4	141.7	138.1-145.3							108.4	13.6	12.5-14.8			
Testis				34.8	5.7	4.9-6.7							1.6	0.2	0.1-0.4			
Penis				7.2	1.0	0.7-1.3							1.6	0.2	0.1-0.4			
Other male genital organs				2.6	0.3	0.2-0.6							0.0	0.0	0.0-0.1			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019**

Nassau

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	799.6	43.7	42.3-45.2	566.0	70.0	67.4-72.7	233.6	23.2	21.9-24.7	131.8	6.7	6.2-7.3	88.4	10.9	9.9-12.0	43.4	3.8	3.3-4.3
Urinary bladder (including in situ)	459.6	24.6	23.6-25.6	347.0	43.1	41.1-45.3	112.6	10.7	9.8-11.6	78.8	4.0	3.6-4.4	54.4	6.9	6.1-7.8	24.4	2.1	1.8-2.6
Kidney and renal pelvis	318.8	18.0	17.1-18.9	204.2	25.0	23.4-26.6	114.6	12.0	11.0-13.1	49.6	2.5	2.2-2.9	32.2	3.9	3.3-4.5	17.4	1.5	1.2-1.9
Ureter	14.8	0.8	0.6-1.0	10.4	1.3	1.0-1.7	4.4	0.4	0.2-0.6	2.0	0.1	0.0-0.2	0.8	0.1	0.0-0.3	1.2	0.1	0.0-0.2
Other urinary organs	6.4	0.4	0.2-0.5	4.4	0.6	0.4-0.9	2.0	0.2	0.1-0.4	1.4	0.1	0.0-0.2	1.0	0.1	0.0-0.3	0.4	0.0	0.0-0.2
Eye & orbit	18.2	1.1	0.9-1.3	8.4	1.1	0.8-1.5	9.8	1.1	0.8-1.5	1.6	0.1	0.0-0.2	1.2	0.2	0.1-0.4	0.4	0.0	0.0-0.2
Brain / other central nervous system (all behaviors)	387.4	23.4	22.3-24.5	151.8	20.3	18.8-21.9	235.6	25.8	24.3-27.4	84.0	4.8	4.3-5.3	45.4	5.6	4.9-6.4	38.6	4.1	3.5-4.7
Malignant brain / other central nervous system	113.4	7.2	6.6-7.9	61.0	8.2	7.3-9.2	52.4	6.3	5.5-7.2	70.6	4.1	3.6-4.5	39.8	4.9	4.2-5.7	30.8	3.3	2.8-3.9
Malignant brain	106.4	6.7	6.1-7.3	57.0	7.6	6.7-8.6	49.4	5.9	5.2-6.8									
Malignant other central nervous system	7.0	0.5	0.3-0.7	4.0	0.6	0.4-1.0	3.0	0.4	0.2-0.7									
Benign brain / other central nervous system#	274.0	16.2	15.3-17.1	90.8	12.1	11.0-13.3	183.2	19.5	18.2-20.9	13.4	0.7	0.5-0.9	5.6	0.7	0.5-1.0	7.8	0.7	0.5-1.1
Benign brain	23.8	1.7	1.4-2.0	12.4	1.8	1.4-2.4	11.4	1.5	1.1-1.9									
Benign other central nervous system	250.2	14.5	13.7-15.4	78.4	10.3	9.2-11.4	171.8	18.0	16.8-19.3									
Endocrine system	370.0	25.0	23.9-26.3	117.0	15.7	14.4-17.1	253.0	34.1	32.1-36.1	17.6	1.0	0.8-1.2	7.8	1.1	0.7-1.5	9.8	0.9	0.7-1.3
Thyroid	347.6	23.7	22.5-24.8	104.2	14.0	12.8-15.3	243.4	32.9	31.0-34.9	12.8	0.7	0.5-0.9	5.2	0.7	0.4-1.0	7.6	0.7	0.5-0.9
Other endocrine (including thymus)	22.4	1.4	1.1-1.7	12.8	1.6	1.3-2.1	9.6	1.2	0.8-1.6	4.8	0.3	0.2-0.5	2.6	0.4	0.2-0.6	2.2	0.3	0.1-0.5
Lymphomas	455.8	26.7	25.6-27.8	241.8	31.2	29.4-33.1	214.0	23.1	21.7-24.6	104.0	5.5	5.1-6.1	56.2	7.0	6.2-7.9	47.8	4.5	3.9-5.1
Hodgkin lymphoma	51.6	3.6	3.2-4.1	26.6	3.8	3.2-4.6	25.0	3.5	2.9-4.2	5.0	0.3	0.2-0.4	2.6	0.3	0.2-0.5	2.4	0.2	0.1-0.4
Non-Hodgkin lymphomas	404.2	23.0	22.0-24.1	215.2	27.4	25.7-29.1	189.0	19.6	18.3-21.0	99.0	5.3	4.8-5.8	53.6	6.7	5.9-7.6	45.4	4.2	3.7-4.9
Myeloma	155.8	8.5	7.9-9.1	85.2	10.5	9.5-11.6	70.6	6.9	6.2-7.7	52.2	2.7	2.4-3.1	27.6	3.4	2.8-4.0	24.6	2.2	1.8-2.6
Leukemias	304.4	17.5	16.6-18.4	182.0	23.2	21.7-24.8	122.4	13.1	12.0-14.2	108.8	5.8	5.3-6.3	65.6	8.5	7.6-9.5	43.2	3.9	3.4-4.5
Lymphocytic leukemias	161.6	9.2	8.6-9.9	97.6	12.4	11.3-13.6	64.0	6.7	6.0-7.5	30.8	1.6	1.3-1.9	18.4	2.4	1.9-3.0	12.4	1.0	0.8-1.3
Acute lymphocytic leukemia	26.6	2.0	1.7-2.4	15.6	2.4	1.9-3.0	11.0	1.6	1.2-2.1	6.6	0.4	0.3-0.6	4.6	0.7	0.4-1.0	2.0	0.2	0.1-0.4
Chronic lymphocytic leukemia	127.0	6.7	6.2-7.3	76.2	9.2	8.3-10.2	50.8	4.8	4.2-5.5	22.8	1.1	0.9-1.3	13.0	1.6	1.3-2.1	9.8	0.7	0.5-1.0
Other lymphocytic leukemias	8.0	0.5	0.3-0.7	5.8	0.8	0.5-1.1	2.2	0.3	0.1-0.5	1.4	0.1	0.0-0.2	0.8	0.1	0.0-0.3	0.6	0.1	0.0-0.2
Myeloid and monocytic leukemias	127.8	7.4	6.8-8.0	75.4	9.7	8.7-10.8	52.4	5.7	5.0-6.5	58.6	3.2	2.8-3.6	34.8	4.5	3.9-5.3	23.8	2.3	1.9-2.8
Acute myeloid leukemia	81.2	4.6	4.2-5.1	50.2	6.4	5.6-7.3	31.0	3.3	2.8-3.9	53.2	2.9	2.6-3.3	31.8	4.1	3.5-4.8	21.4	2.1	1.7-2.6
Acute monocytic leukemia	2.6	0.2	0.1-0.3	1.8	0.3	0.1-0.5	0.8	0.1	0.0-0.2	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.1
Chronic myeloid leukemia	41.6	2.5	2.2-2.9	22.4	2.9	2.4-3.5	19.2	2.2	1.8-2.8	3.2	0.2	0.1-0.3	2.0	0.3	0.1-0.5	1.2	0.1	0.0-0.2
Other myeloid/monocytic leukemias	2.4	0.1	0.1-0.2	1.0	0.1	0.0-0.3	1.4	0.1	0.0-0.3	2.2	0.1	0.1-0.2	1.0	0.1	0.0-0.3	1.2	0.1	0.0-0.3
Other leukemias	15.0	0.9	0.7-1.1	9.0	1.1	0.8-1.6	6.0	0.7	0.4-1.0	19.4	1.0	0.8-1.3	12.4	1.6	1.2-2.1	7.0	0.6	0.4-0.9
Other acute leukemias	3.6	0.2	0.1-0.3	2.0	0.2	0.1-0.5	1.6	0.2	0.1-0.3	7.0	0.4	0.2-0.5	4.8	0.6	0.4-1.0	2.2	0.2	0.1-0.3

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019**

Nassau

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	11.4	0.7	0.5-0.9	7.0	0.9	0.6-1.3	4.4	0.5	0.3-0.8	12.4	0.7	0.5-0.9	7.6	1.0	0.7-1.4	4.8	0.4	0.3-0.7
Mesothelioma	16.8	0.9	0.7-1.1	12.4	1.6	1.2-2.1	4.4	0.4	0.3-0.7									
Kaposi sarcoma	7.2	0.5	0.3-0.6	5.4	0.8	0.5-1.1	1.8	0.2	0.1-0.4									
Myelodysplastic syndromes	107.0	5.6	5.2-6.2	61.8	8.0	7.1-8.9	45.2	4.1	3.5-4.7									
Chronic myeloproliferative disorders [^]	108.6	6.4	5.9-7.0	60.4	8.0	7.1-9.0	48.2	4.9	4.2-5.6									
Ill defined and unspecified sites	153.0	8.2	7.6-8.8	74.2	9.5	8.5-10.5	78.8	7.2	6.5-8.0	188.4	9.8	9.2-10.5	94.2	11.7	10.7-12.9	94.2	8.4	7.6-9.2

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

[^] Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019**

Suffolk

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	10051.2	532.4	527.7-537.2	5092.0	584.6	577.3-592.1	4959.2	498.5	492.1-505.0	2692.4	139.0	136.6-141.4	1355.4	161.7	157.8-165.7	1337.0	123.7	120.7-126.8
Oral cavity and pharynx	231.6	11.9	11.2-12.7	160.2	17.8	16.5-19.1	71.4	6.9	6.2-7.7	38.0	2.0	1.7-2.3	26.8	3.2	2.6-3.8	11.2	1.0	0.8-1.4
Lip	8.8	0.4	0.3-0.6	5.8	0.7	0.4-1.0	3.0	0.3	0.2-0.5	0.2	0.0	0.0-0.1	0.2	0.0	0.0-0.2	0.0	0.0	0.0-0.1
Tongue	74.8	3.9	3.5-4.3	52.8	5.8	5.1-6.6	22.0	2.2	1.8-2.6	9.4	0.5	0.4-0.7	6.6	0.8	0.5-1.1	2.8	0.3	0.1-0.5
Salivary gland	30.6	1.6	1.4-1.9	17.8	2.2	1.7-2.7	12.8	1.3	1.0-1.6	3.6	0.2	0.1-0.3	3.0	0.4	0.2-0.6	0.6	0.1	0.0-0.2
Floor of mouth	11.6	0.6	0.4-0.7	7.4	0.8	0.5-1.1	4.2	0.4	0.2-0.6	0.4	0.0	0.0-0.1	0.2	0.0	0.0-0.1	0.2	0.0	0.0-0.1
Gum & other mouth	27.8	1.4	1.2-1.7	16.8	1.9	1.5-2.3	11.0	1.0	0.8-1.4	7.6	0.4	0.3-0.5	4.0	0.5	0.3-0.7	3.6	0.3	0.2-0.5
Nasopharynx	8.0	0.5	0.3-0.6	5.0	0.6	0.4-0.9	3.0	0.3	0.2-0.6	2.6	0.2	0.1-0.3	1.8	0.2	0.1-0.4	0.8	0.1	0.0-0.3
Tonsil	47.2	2.4	2.1-2.7	39.0	4.1	3.6-4.8	8.2	0.8	0.5-1.1	3.0	0.2	0.1-0.3	2.6	0.3	0.2-0.5	0.4	0.0	0.0-0.1
Oropharynx	11.4	0.6	0.4-0.8	8.0	0.9	0.6-1.2	3.4	0.3	0.2-0.5	3.8	0.2	0.1-0.3	2.8	0.3	0.2-0.6	1.0	0.1	0.0-0.2
Hypopharynx	8.0	0.4	0.3-0.6	5.6	0.7	0.4-1.0	2.4	0.2	0.1-0.4	1.2	0.1	0.0-0.1	1.2	0.2	0.1-0.3	0.0	0.0	0.0-0.1
Other buccal cavity and pharynx	3.4	0.2	0.1-0.3	2.0	0.2	0.1-0.5	1.4	0.1	0.1-0.3	6.2	0.3	0.2-0.5	4.4	0.5	0.3-0.8	1.8	0.2	0.1-0.3
Digestive system	1662.4	86.8	84.9-88.8	921.8	105.3	102.2-108.5	740.6	71.7	69.3-74.1	718.8	36.9	35.7-38.2	407.8	47.5	45.4-49.6	311.0	28.6	27.2-30.1
Esophagus	93.4	4.7	4.3-5.2	72.4	7.9	7.1-8.8	21.0	2.0	1.6-2.4	73.2	3.6	3.3-4.0	59.0	6.6	5.8-7.4	14.2	1.3	1.0-1.6
Stomach	145.8	7.6	7.1-8.2	86.6	9.9	9.0-10.9	59.2	5.8	5.2-6.6	54.8	2.9	2.5-3.2	31.2	3.6	3.1-4.2	23.6	2.3	1.9-2.7
Small intestine	55.8	2.9	2.6-3.3	29.8	3.3	2.8-3.9	26.0	2.6	2.2-3.2	8.4	0.4	0.3-0.6	4.2	0.5	0.3-0.7	4.2	0.4	0.2-0.6
Colorectal	766.2	40.6	39.3-42.0	403.0	46.8	44.7-49.0	363.2	35.6	33.9-37.3	225.6	11.7	11.0-12.4	116.8	14.1	12.9-15.3	108.8	9.9	9.1-10.8
Colon excluding rectum	543.2	28.9	27.8-30.1	268.2	31.6	29.9-33.4	275.0	26.8	25.3-28.3	180.8	9.4	8.8-10.0	91.0	11.0	10.0-12.1	89.8	8.2	7.4-9.0
Cecum	106.6	5.6	5.1-6.1	51.0	6.0	5.2-6.8	55.6	5.2	4.6-5.9									
Appendix	39.4	2.4	2.1-2.8	14.4	1.8	1.4-2.3	25.0	2.9	2.4-3.5									
Ascending colon	101.4	5.3	4.9-5.8	43.8	5.3	4.6-6.1	57.6	5.3	4.7-6.0									
Hepatic flexure	24.2	1.3	1.0-1.5	12.2	1.5	1.1-1.9	12.0	1.1	0.8-1.4									
Transverse colon	47.2	2.5	2.1-2.8	25.2	2.9	2.4-3.4	22.0	2.1	1.7-2.5									
Splenic flexure	14.0	0.8	0.6-1.0	7.4	0.9	0.6-1.2	6.6	0.7	0.5-1.0									
Descending colon	37.6	2.0	1.7-2.4	22.4	2.7	2.2-3.3	15.2	1.5	1.2-1.9									
Sigmoid colon	142.8	7.5	7.0-8.1	76.0	8.6	7.7-9.5	66.8	6.7	6.0-7.5									
Large intestine, NOS	30.0	1.6	1.3-1.9	15.8	2.0	1.5-2.5	14.2	1.3	1.0-1.7									
Rectum & rectosigmoid	223.0	11.7	11.0-12.4	134.8	15.2	14.1-16.5	88.2	8.8	8.0-9.7	44.8	2.3	2.0-2.6	25.8	3.1	2.5-3.6	19.0	1.8	1.4-2.2
Rectosigmoid junction	58.8	3.1	2.7-3.4	35.2	4.0	3.4-4.6	23.6	2.3	1.9-2.7									
Rectum	164.2	8.6	8.0-9.3	99.6	11.3	10.3-12.3	64.6	6.5	5.8-7.3									
Anus, anal canal & anorectum	38.4	2.0	1.7-2.3	13.8	1.5	1.2-2.0	24.6	2.4	2.0-2.9	5.0	0.3	0.2-0.4	2.2	0.3	0.1-0.5	2.8	0.3	0.1-0.4
Liver and intrahepatic bile duct	153.6	7.7	7.2-8.3	110.4	12.0	11.0-13.1	43.2	4.0	3.5-4.6	103.6	5.2	4.8-5.7	67.6	7.7	6.9-8.6	36.0	3.3	2.8-3.8

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019**
Suffolk

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	123.6	6.2	5.7-6.7	96.0	10.3	9.4-11.3	27.6	2.6	2.2-3.1	69.2	3.5	3.1-3.8	53.2	6.0	5.3-6.8	16.0	1.4	1.1-1.8
Intrahepatic bile duct	30.0	1.5	1.3-1.8	14.4	1.7	1.3-2.2	15.6	1.4	1.1-1.8	34.4	1.8	1.5-2.1	14.4	1.7	1.3-2.2	20.0	1.8	1.5-2.2
Gallbladder	24.0	1.3	1.1-1.6	9.6	1.2	0.9-1.6	14.4	1.4	1.1-1.8	9.2	0.5	0.4-0.7	3.8	0.5	0.3-0.7	5.4	0.5	0.3-0.8
Other biliary	35.0	1.9	1.6-2.2	17.4	2.0	1.6-2.5	17.6	1.7	1.4-2.1	10.2	0.5	0.4-0.7	6.0	0.7	0.5-1.1	4.2	0.4	0.2-0.6
Pancreas	311.2	16.1	15.3-16.9	161.8	18.6	17.3-19.9	149.4	14.0	13.0-15.1	215.6	11.1	10.4-11.8	111.6	12.9	11.9-14.1	104.0	9.6	8.8-10.5
Retroperitoneum	7.8	0.4	0.3-0.6	4.6	0.5	0.3-0.8	3.2	0.3	0.2-0.6	1.0	0.1	0.0-0.1	0.6	0.1	0.0-0.2	0.4	0.0	0.0-0.2
Peritoneum, omentum & mesentery	7.6	0.4	0.3-0.5	1.0	0.1	0.0-0.3	6.6	0.6	0.4-0.8	4.4	0.2	0.1-0.3	0.6	0.1	0.0-0.2	3.8	0.3	0.2-0.5
Other digestive organs	23.6	1.2	1.0-1.5	11.4	1.3	1.0-1.7	12.2	1.1	0.8-1.5	7.8	0.4	0.3-0.6	4.2	0.5	0.3-0.8	3.6	0.3	0.2-0.5
Respiratory system	1340.8	69.0	67.3-70.7	642.2	74.8	72.2-77.5	698.6	65.0	62.8-67.2	639.2	32.8	31.7-34.0	317.0	37.6	35.8-39.6	322.2	29.5	28.0-31.0
Nasal cavity, middle ear & sinuses	14.0	0.7	0.6-0.9	9.4	1.0	0.7-1.4	4.6	0.5	0.3-0.7	2.0	0.1	0.1-0.2	1.2	0.1	0.0-0.3	0.8	0.1	0.0-0.2
Larynx	59.6	3.0	2.7-3.4	48.0	5.4	4.7-6.1	11.6	1.1	0.8-1.4	15.0	0.7	0.6-0.9	12.4	1.4	1.1-1.8	2.6	0.2	0.1-0.4
Lung and bronchus	1263.6	65.0	63.4-66.7	581.6	68.0	65.5-70.6	682.0	63.4	61.3-65.6	620.6	31.9	30.8-33.1	302.2	35.9	34.1-37.8	318.4	29.1	27.7-30.6
Pleura	0.4	0.0	0.0-0.1	0.4	0.0	0.0-0.2	0.0	0.0	0.0-0.1	1.0	0.1	0.0-0.1	0.8	0.1	0.0-0.3	0.2	0.0	0.0-0.1
Trachea, mediastinum, other respiratory	3.2	0.2	0.1-0.4	2.8	0.4	0.2-0.6	0.4	0.1	0.0-0.2	0.6	0.0	0.0-0.1	0.4	0.0	0.0-0.2	0.2	0.0	0.0-0.1
Bones & joints	22.4	1.5	1.2-1.8	12.0	1.6	1.2-2.1	10.4	1.4	1.0-1.8	6.2	0.4	0.2-0.5	3.8	0.5	0.3-0.8	2.4	0.3	0.1-0.5
Soft tissue (including heart)	70.0	3.9	3.5-4.4	38.0	4.5	3.9-5.2	32.0	3.5	2.9-4.1	26.2	1.4	1.2-1.7	14.2	1.7	1.3-2.2	12.0	1.2	0.9-1.6
Skin*	523.4	27.9	26.9-29.1	320.4	37.6	35.7-39.5	203.0	21.0	19.6-22.4	55.8	2.8	2.5-3.1	39.0	4.6	4.0-5.3	16.8	1.5	1.2-1.9
Melanoma of the skin	482.2	25.7	24.7-26.8	293.2	34.2	32.4-36.0	189.0	19.5	18.2-20.8	38.6	1.9	1.7-2.2	25.8	3.0	2.5-3.6	12.8	1.2	0.9-1.5
Breast	1376.0	74.6	72.8-76.5	12.4	1.4	1.1-1.8	1363.6	139.7	136.3-143.2	189.2	9.8	9.2-10.5	2.4	0.3	0.1-0.5	186.8	17.5	16.4-18.7
Breast (in situ)#	432.2	24.0	23.0-25.1	1.2	0.2	0.1-0.4	431.0	46.0	44.0-48.1									
Female genital system							577.0	57.2	55.1-59.4							160.4	15.1	14.0-16.2
Cervix uteri							52.2	6.5	5.7-7.4							15.2	1.6	1.2-2.0
Corpus uterus and NOS							336.4	32.1	30.5-33.7							59.2	5.6	4.9-6.3
Ovary							124.6	12.6	11.6-13.7							75.0	6.9	6.2-7.7
Vagina							7.6	0.8	0.5-1.1							1.8	0.2	0.1-0.3
Vulva							27.0	2.6	2.1-3.0							6.4	0.5	0.3-0.7
Other female genital organs							29.2	2.7	2.3-3.2							2.8	0.3	0.1-0.5
Male genital system				1328.2	144.0	140.5-147.6							130.2	16.4	15.1-17.7			
Prostate				1271.8	136.0	132.6-139.5							126.8	15.9	14.7-17.3			
Testis				49.2	7.1	6.2-8.1							1.8	0.2	0.1-0.4			
Penis				5.4	0.6	0.4-1.0							1.2	0.2	0.1-0.3			
Other male genital organs				1.8	0.2	0.1-0.5							0.4	0.1	0.0-0.2			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019**

Suffolk

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	926.2	48.6	47.2-50.0	647.4	76.0	73.4-78.8	278.8	26.8	25.3-28.3	153.8	7.9	7.3-8.5	105.4	13.0	11.9-14.2	48.4	4.3	3.8-4.9
Urinary bladder (including in situ)	530.4	27.7	26.6-28.8	393.2	47.1	45.0-49.2	137.2	12.8	11.9-13.9	92.2	4.8	4.3-5.2	65.6	8.3	7.4-9.3	26.6	2.3	2.0-2.8
Kidney and renal pelvis	375.4	19.8	18.9-20.7	239.8	27.2	25.6-28.8	135.6	13.4	12.3-14.5	57.0	2.9	2.6-3.3	37.0	4.3	3.7-5.0	20.0	1.8	1.5-2.2
Ureter	14.2	0.7	0.6-0.9	9.4	1.2	0.8-1.5	4.8	0.4	0.3-0.7	2.4	0.1	0.1-0.2	0.8	0.1	0.0-0.3	1.6	0.1	0.1-0.3
Other urinary organs	6.2	0.3	0.2-0.5	5.0	0.6	0.4-0.9	1.2	0.1	0.0-0.2	2.2	0.1	0.1-0.2	2.0	0.3	0.1-0.5	0.2	0.0	0.0-0.1
Eye & orbit	17.6	1.0	0.8-1.2	10.0	1.1	0.8-1.5	7.6	0.9	0.6-1.2	2.6	0.1	0.1-0.2	1.2	0.1	0.0-0.3	1.4	0.1	0.1-0.3
Brain / other central nervous system (all behaviors)	463.2	25.9	24.9-27.1	185.8	22.8	21.3-24.4	277.4	28.6	27.0-30.2	95.8	5.0	4.5-5.5	51.0	5.8	5.1-6.6	44.8	4.3	3.8-5.0
Malignant brain / other central nervous system	124.8	7.3	6.7-7.9	68.0	8.3	7.4-9.3	56.8	6.4	5.6-7.2	80.8	4.2	3.8-4.7	43.2	4.9	4.2-5.6	37.6	3.7	3.2-4.3
Malignant brain	119.6	7.0	6.4-7.6	65.4	8.0	7.1-8.9	54.2	6.0	5.3-6.9									
Malignant other central nervous system	5.2	0.3	0.2-0.5	2.6	0.3	0.2-0.6	2.6	0.3	0.2-0.6									
Benign brain / other central nervous system#	338.4	18.6	17.7-19.6	117.8	14.5	13.3-15.8	220.6	22.2	20.9-23.6	15.0	0.8	0.6-1.0	7.8	0.9	0.6-1.3	7.2	0.6	0.4-0.9
Benign brain	44.2	2.8	2.4-3.2	22.6	3.0	2.4-3.6	21.6	2.6	2.1-3.2									
Benign other central nervous system	294.2	15.9	15.0-16.7	95.2	11.5	10.5-12.7	199.0	19.6	18.3-20.9									
Endocrine system	384.6	24.1	23.0-25.2	113.4	13.8	12.7-15.1	271.2	34.3	32.4-36.2	14.0	0.7	0.6-0.9	5.8	0.7	0.4-1.0	8.2	0.8	0.5-1.1
Thyroid	365.4	23.0	21.9-24.1	103.0	12.6	11.5-13.7	262.4	33.3	31.5-35.3	10.8	0.6	0.4-0.7	4.6	0.5	0.3-0.8	6.2	0.6	0.4-0.8
Other endocrine (including thymus)	19.2	1.1	0.9-1.4	10.4	1.3	0.9-1.7	8.8	1.0	0.7-1.3	3.2	0.2	0.1-0.3	1.2	0.1	0.0-0.3	2.0	0.2	0.1-0.4
Lymphomas	487.4	26.7	25.6-27.8	265.4	31.6	29.9-33.4	222.0	22.8	21.4-24.3	95.0	5.0	4.6-5.5	53.8	6.6	5.8-7.4	41.2	3.9	3.4-4.5
Hodgkin lymphoma	50.4	3.2	2.8-3.7	26.2	3.3	2.7-3.9	24.2	3.2	2.6-3.8	4.6	0.3	0.2-0.4	2.0	0.2	0.1-0.5	2.6	0.3	0.2-0.5
Non-Hodgkin lymphomas	437.0	23.5	22.5-24.5	239.2	28.3	26.7-30.0	197.8	19.7	18.4-21.0	90.4	4.7	4.3-5.2	51.8	6.3	5.5-7.1	38.6	3.6	3.1-4.2
Myeloma	169.0	8.8	8.2-9.4	96.8	11.2	10.2-12.2	72.2	6.8	6.1-7.6	54.6	2.7	2.4-3.1	30.8	3.6	3.1-4.3	23.8	2.1	1.7-2.5
Leukemias	373.6	20.3	19.4-21.3	220.6	26.4	24.8-28.0	153.0	15.5	14.4-16.7	108.4	5.8	5.3-6.3	64.8	8.1	7.2-9.1	43.6	4.1	3.5-4.7
Lymphocytic leukemias	212.0	11.4	10.7-12.2	130.0	15.2	14.0-16.5	82.0	8.2	7.4-9.1	28.6	1.5	1.3-1.8	17.0	2.1	1.7-2.7	11.6	1.0	0.8-1.4
Acute lymphocytic leukemia	29.0	2.1	1.7-2.4	16.6	2.4	1.9-2.9	12.4	1.8	1.3-2.3	6.8	0.4	0.3-0.6	3.8	0.5	0.3-0.7	3.0	0.4	0.2-0.6
Chronic lymphocytic leukemia	171.2	8.7	8.2-9.4	104.2	11.8	10.8-12.9	67.0	6.2	5.6-7.0	20.0	1.0	0.8-1.2	12.0	1.5	1.2-2.0	8.0	0.6	0.4-0.9
Other lymphocytic leukemias	11.8	0.6	0.5-0.8	9.2	1.0	0.8-1.4	2.6	0.2	0.1-0.4	1.8	0.1	0.0-0.2	1.2	0.1	0.1-0.3	0.6	0.1	0.0-0.2
Myeloid and monocytic leukemias	146.2	8.1	7.5-8.7	82.0	10.2	9.2-11.2	64.2	6.6	5.8-7.4	60.6	3.3	2.9-3.7	36.0	4.5	3.8-5.2	24.6	2.4	1.9-2.8
Acute myeloid leukemia	91.8	5.1	4.6-5.6	50.6	6.3	5.5-7.2	41.2	4.2	3.7-4.9	51.8	2.8	2.5-3.2	29.8	3.7	3.1-4.4	22.0	2.1	1.7-2.5
Acute monocytic leukemia	4.4	0.3	0.2-0.4	2.4	0.3	0.2-0.6	2.0	0.2	0.1-0.4	0.6	0.0	0.0-0.1	0.4	0.0	0.0-0.2	0.2	0.0	0.0-0.1
Chronic myeloid leukemia	47.8	2.6	2.3-3.0	28.0	3.4	2.9-4.1	19.8	2.0	1.6-2.5	5.2	0.3	0.2-0.4	3.4	0.4	0.3-0.7	1.8	0.2	0.1-0.4
Other myeloid/monocytic leukemias	2.2	0.1	0.1-0.2	1.0	0.1	0.0-0.3	1.2	0.1	0.0-0.3	3.0	0.2	0.1-0.3	2.4	0.3	0.2-0.5	0.6	0.1	0.0-0.2
Other leukemias	15.4	0.8	0.6-1.0	8.6	1.0	0.7-1.4	6.8	0.7	0.5-1.0	19.2	1.0	0.8-1.2	11.8	1.5	1.1-1.9	7.4	0.7	0.5-1.0
Other acute leukemias	5.0	0.3	0.2-0.4	2.8	0.3	0.2-0.6	2.2	0.2	0.1-0.4	7.6	0.4	0.3-0.6	4.2	0.6	0.3-0.9	3.4	0.3	0.2-0.5

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019**

Suffolk

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	10.4	0.6	0.4-0.7	5.8	0.7	0.5-1.0	4.6	0.5	0.3-0.7	11.6	0.6	0.5-0.8	7.6	0.9	0.7-1.3	4.0	0.4	0.2-0.6
Mesothelioma	13.8	0.8	0.6-1.0	9.8	1.2	0.9-1.6	4.0	0.4	0.3-0.7									
Kaposi sarcoma	4.6	0.2	0.2-0.4	4.0	0.4	0.3-0.7	0.6	0.0	0.0-0.2									
Myelodysplastic syndromes	131.0	6.9	6.4-7.5	74.8	9.6	8.6-10.6	56.2	5.0	4.4-5.7									
Chronic myeloproliferative disorders [^]	119.2	6.4	5.9-7.0	60.8	7.3	6.5-8.2	58.4	5.7	5.0-6.4									
All defined and unspecified sites	167.6	8.9	8.3-9.5	85.8	10.7	9.7-11.7	81.8	7.6	6.9-8.5	219.2	11.3	10.6-12.0	109.2	13.1	12.0-14.3	110.0	10.0	9.2-10.9

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

[^] Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
Westchester

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
All Invasive Malignant Tumors	5844.0	474.9	469.3-480.5	2853.8	515.3	506.7-524.1	2990.2	451.4	443.9-459.0	1527.2	116.9	114.3-119.6	739.4	135.0	130.6-139.5	787.8	105.1	101.8-108.6
Oral cavity and pharynx	117.6	9.4	8.7-10.3	80.6	14.1	12.7-15.6	37.0	5.6	4.8-6.5	21.0	1.6	1.3-2.0	14.4	2.6	2.0-3.2	6.6	0.9	0.6-1.3
Lip	3.4	0.3	0.1-0.4	1.8	0.3	0.1-0.6	1.6	0.2	0.1-0.5	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.2
Tongue	39.0	3.1	2.7-3.6	29.8	5.1	4.3-6.1	9.2	1.4	1.0-1.9	6.0	0.5	0.3-0.7	4.6	0.8	0.5-1.2	1.4	0.2	0.1-0.4
Salivary gland	13.6	1.1	0.8-1.4	8.6	1.6	1.1-2.1	5.0	0.8	0.5-1.2	3.6	0.3	0.2-0.5	3.0	0.6	0.3-1.0	0.6	0.1	0.0-0.3
Floor of mouth	3.6	0.3	0.2-0.4	2.2	0.3	0.2-0.7	1.4	0.2	0.1-0.4	0.0	0.0	0.0-0.1	0.0	0.0	0.0-0.2	0.0	0.0	0.0-0.2
Gum & other mouth	19.8	1.6	1.3-2.0	9.0	1.6	1.1-2.1	10.8	1.6	1.2-2.1	3.0	0.2	0.1-0.4	1.6	0.3	0.1-0.5	1.4	0.2	0.1-0.4
Nasopharynx	5.8	0.5	0.4-0.8	4.6	0.9	0.6-1.4	1.2	0.2	0.1-0.5	0.8	0.1	0.0-0.2	0.4	0.1	0.0-0.2	0.4	0.1	0.0-0.2
Tonsil	20.6	1.6	1.3-2.0	15.6	2.7	2.1-3.4	5.0	0.7	0.5-1.1	1.0	0.1	0.0-0.2	0.8	0.2	0.0-0.4	0.2	0.0	0.0-0.2
Oropharynx	3.6	0.3	0.2-0.4	3.0	0.5	0.3-0.8	0.6	0.1	0.0-0.3	2.6	0.2	0.1-0.3	1.8	0.3	0.1-0.6	0.8	0.1	0.0-0.3
Hypopharynx	6.8	0.5	0.4-0.8	5.0	0.9	0.6-1.3	1.8	0.3	0.1-0.5	0.8	0.1	0.0-0.2	0.4	0.1	0.0-0.3	0.4	0.1	0.0-0.2
Other buccal cavity and pharynx	1.4	0.1	0.0-0.2	1.0	0.1	0.0-0.4	0.4	0.1	0.0-0.2	3.2	0.2	0.1-0.4	1.8	0.3	0.2-0.7	1.4	0.2	0.1-0.4
Digestive system	974.4	77.7	75.5-80.0	515.2	93.7	90.1-97.5	459.2	65.4	62.7-68.3	425.4	32.6	31.2-34.0	228.6	41.2	38.8-43.7	196.8	25.9	24.2-27.7
Esophagus	47.0	3.7	3.2-4.2	33.4	6.1	5.2-7.1	13.6	1.9	1.4-2.4	33.6	2.6	2.2-3.1	24.6	4.6	3.8-5.5	9.0	1.2	0.9-1.6
Stomach	103.2	8.4	7.6-9.1	58.4	10.9	9.6-12.2	44.8	6.5	5.7-7.5	40.2	3.1	2.7-3.6	23.4	4.3	3.5-5.1	16.8	2.4	1.9-3.0
Small intestine	38.0	3.1	2.6-3.6	21.8	3.9	3.2-4.8	16.2	2.4	1.9-3.0	5.4	0.4	0.3-0.6	4.4	0.8	0.5-1.2	1.0	0.1	0.0-0.3
Colorectal	417.4	33.7	32.2-35.2	207.6	38.1	35.7-40.5	209.8	30.3	28.5-32.3	133.4	10.1	9.3-10.9	63.4	11.5	10.3-12.9	70.0	8.9	7.9-9.9
Colon excluding rectum	296.6	23.9	22.6-25.1	142.4	26.3	24.4-28.4	154.2	22.0	20.4-23.7	106.0	7.9	7.3-8.7	50.2	9.1	8.0-10.3	55.8	7.1	6.2-8.0
Cecum	53.6	4.2	3.7-4.7	22.6	4.1	3.4-5.0	31.0	4.2	3.5-4.9									
Appendix	23.2	2.2	1.8-2.6	8.4	1.6	1.2-2.2	14.8	2.6	2.0-3.3									
Ascending colon	52.8	4.1	3.6-4.6	23.6	4.4	3.6-5.3	29.2	3.8	3.2-4.6									
Hepatic flexure	12.4	1.0	0.8-1.3	7.0	1.3	0.9-1.9	5.4	0.7	0.5-1.1									
Transverse colon	29.0	2.3	1.9-2.7	15.2	2.9	2.2-3.6	13.8	1.8	1.4-2.3									
Splenic flexure	10.6	0.8	0.6-1.1	5.4	1.0	0.6-1.5	5.2	0.7	0.4-1.1									
Descending colon	21.0	1.8	1.4-2.1	12.2	2.2	1.7-2.8	8.8	1.4	1.0-1.9									
Sigmoid colon	73.2	6.1	5.5-6.8	38.6	7.1	6.1-8.2	34.6	5.3	4.5-6.2									
Large intestine, NOS	20.8	1.5	1.2-1.9	9.4	1.7	1.3-2.3	11.4	1.4	1.0-1.8									
Rectum & rectosigmoid	120.8	9.8	9.1-10.7	65.2	11.7	10.5-13.1	55.6	8.4	7.4-9.5	27.4	2.1	1.8-2.5	13.2	2.4	1.9-3.1	14.2	1.8	1.4-2.3
Rectosigmoid junction	27.8	2.2	1.9-2.7	16.0	2.8	2.2-3.6	11.8	1.8	1.3-2.3									
Rectum	93.0	7.6	6.9-8.3	49.2	8.9	7.8-10.1	43.8	6.6	5.7-7.6									
Anus, anal canal & anorectum	26.0	2.1	1.7-2.5	8.0	1.4	1.0-1.9	18.0	2.7	2.2-3.4	3.0	0.2	0.1-0.4	1.0	0.2	0.1-0.4	2.0	0.3	0.1-0.5
Liver and intrahepatic bile duct	97.8	7.6	7.0-8.4	66.0	11.5	10.3-12.8	31.8	4.5	3.8-5.3	60.4	4.6	4.1-5.2	41.4	7.2	6.2-8.2	19.0	2.7	2.2-3.3

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019
Westchester

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Liver	77.2	6.0	5.4-6.6	55.0	9.4	8.3-10.7	22.2	3.2	2.6-3.9	40.2	3.1	2.7-3.5	30.0	5.1	4.3-6.0	10.2	1.5	1.1-1.9
Intrahepatic bile duct	20.6	1.6	1.3-2.0	11.0	2.1	1.5-2.7	9.6	1.4	1.0-1.8	20.2	1.6	1.3-1.9	11.4	2.1	1.6-2.7	8.8	1.2	0.9-1.7
Gallbladder	17.4	1.3	1.0-1.6	6.2	1.1	0.7-1.6	11.2	1.5	1.1-2.0	9.6	0.8	0.6-1.0	2.6	0.5	0.3-0.9	7.0	0.9	0.7-1.3
Other biliary	23.6	1.8	1.5-2.2	12.6	2.2	1.7-2.8	11.0	1.5	1.1-2.0	5.0	0.4	0.2-0.6	2.0	0.4	0.2-0.7	3.0	0.4	0.2-0.7
Pancreas	184.6	14.5	13.5-15.5	93.0	17.1	15.6-18.8	91.6	12.4	11.2-13.6	127.0	9.7	9.0-10.5	62.0	11.2	10.0-12.6	65.0	8.5	7.6-9.5
Retroperitoneum	6.4	0.6	0.4-0.8	4.0	0.7	0.5-1.2	2.4	0.4	0.2-0.7	0.8	0.1	0.0-0.2	0.8	0.1	0.0-0.4	0.0	0.0	0.0-0.2
Peritoneum, omentum & mesentery	5.4	0.4	0.3-0.6	0.2	0.0	0.0-0.2	5.2	0.7	0.5-1.1	3.0	0.3	0.1-0.4	0.8	0.1	0.0-0.4	2.2	0.4	0.2-0.7
Other digestive organs	7.6	0.6	0.4-0.8	4.0	0.7	0.4-1.1	3.6	0.5	0.3-0.8	4.0	0.3	0.2-0.5	2.2	0.4	0.2-0.7	1.8	0.2	0.1-0.4
Respiratory system	641.6	50.1	48.4-51.9	301.0	54.7	51.9-57.6	340.6	47.0	44.8-49.4	318.2	24.3	23.1-25.6	153.4	27.9	26.0-30.0	164.8	21.5	20.0-23.1
Nasal cavity, middle ear & sinuses	9.8	0.8	0.6-1.1	6.4	1.2	0.8-1.7	3.4	0.5	0.3-0.9	1.6	0.1	0.1-0.3	1.0	0.2	0.1-0.5	0.6	0.1	0.0-0.3
Larynx	31.2	2.4	2.0-2.8	25.4	4.4	3.7-5.3	5.8	0.8	0.5-1.2	9.2	0.7	0.5-0.9	8.2	1.5	1.0-2.0	1.0	0.1	0.0-0.4
Lung and bronchus	597.4	46.6	44.9-48.3	267.0	48.6	46.0-51.4	330.4	45.5	43.3-47.9	305.8	23.4	22.2-24.6	143.0	26.1	24.2-28.1	162.8	21.2	19.8-22.8
Pleura	0.4	0.0	0.0-0.1	0.4	0.1	0.0-0.2	0.0	0.0	0.0-0.2	1.2	0.1	0.0-0.2	0.8	0.2	0.0-0.4	0.4	0.1	0.0-0.3
Trachea, mediastinum, other respiratory	2.8	0.3	0.1-0.5	1.8	0.4	0.2-0.7	1.0	0.2	0.1-0.4	0.4	0.0	0.0-0.1	0.4	0.1	0.0-0.2	0.0	0.0	0.0-0.2
Bones & joints	12.4	1.2	0.9-1.5	7.2	1.4	1.0-2.0	5.2	0.9	0.6-1.4	3.6	0.3	0.2-0.5	2.2	0.4	0.2-0.8	1.4	0.2	0.1-0.5
Soft tissue (including heart)	39.4	3.5	3.0-4.1	21.2	4.1	3.4-5.0	18.2	3.0	2.4-3.8	14.6	1.2	1.0-1.6	7.0	1.4	1.0-1.9	7.6	1.1	0.8-1.6
Skin*	256.2	20.7	19.5-21.9	147.6	27.2	25.2-29.3	108.6	16.0	14.6-17.5	29.4	2.1	1.8-2.5	17.0	3.1	2.4-3.8	12.4	1.5	1.1-1.9
Melanoma of the skin	230.2	18.5	17.4-19.6	133.0	24.3	22.5-26.3	97.2	14.3	13.0-15.7	18.8	1.4	1.1-1.7	11.8	2.1	1.6-2.7	7.0	0.8	0.6-1.2
Breast	934.4	78.9	76.6-81.3	10.8	1.9	1.4-2.6	923.6	145.2	140.9-149.6	122.4	9.7	8.9-10.5	1.8	0.3	0.1-0.6	120.6	17.2	15.8-18.7
Breast (in situ)#	326.8	28.6	27.2-30.1	1.0	0.2	0.1-0.5	325.8	53.9	51.2-56.7									
Female genital system							341.0	51.5	49.0-54.1							101.4	14.0	12.8-15.3
Cervix uteri							33.0	6.0	5.0-7.0							7.6	1.2	0.8-1.6
Corpus uterus and NOS							194.2	28.3	26.5-30.2							41.0	5.6	4.9-6.5
Ovary							85.0	13.3	12.0-14.6							47.0	6.5	5.7-7.4
Vagina							3.0	0.5	0.3-0.8							0.8	0.1	0.0-0.3
Vulva							14.6	1.9	1.5-2.4							4.0	0.5	0.3-0.8
Other female genital organs							11.2	1.6	1.2-2.1							1.0	0.1	0.0-0.3
Male genital system				832.2	144.2	139.8-148.7							87.4	16.3	14.8-17.9			
Prostate				802.4	137.5	133.2-141.9							86.2	16.0	14.5-17.6			
Testis				25.2	5.8	4.8-6.9							0.8	0.2	0.0-0.4			
Penis				4.0	0.8	0.5-1.2							0.4	0.1	0.0-0.3			
Other male genital organs				0.6	0.1	0.0-0.4							0.0	0.0	0.0-0.2			

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019**
Westchester

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Urinary system	476.4	37.8	36.2-39.4	333.6	60.5	57.6-63.5	142.8	20.5	18.9-22.1	72.8	5.4	4.9-6.0	50.6	9.3	8.2-10.6	22.2	2.8	2.3-3.4
Urinary bladder (including in situ)	278.2	21.6	20.4-22.8	202.0	36.8	34.5-39.1	76.2	10.4	9.4-11.6	44.4	3.3	2.8-3.7	30.8	5.7	4.8-6.7	13.6	1.7	1.3-2.1
Kidney and renal pelvis	189.6	15.5	14.5-16.6	125.8	22.7	20.9-24.6	63.8	9.7	8.6-10.8	25.4	2.0	1.6-2.4	18.0	3.3	2.7-4.1	7.4	1.0	0.7-1.4
Ureter	4.6	0.4	0.2-0.6	2.8	0.6	0.3-0.9	1.8	0.2	0.1-0.5	1.6	0.1	0.0-0.2	0.6	0.1	0.0-0.3	1.0	0.1	0.0-0.3
Other urinary organs	4.0	0.3	0.2-0.5	3.0	0.5	0.3-0.8	1.0	0.1	0.0-0.3	1.4	0.1	0.0-0.2	1.2	0.2	0.1-0.5	0.2	0.0	0.0-0.2
Eye & orbit	13.4	1.1	0.8-1.4	5.4	1.0	0.6-1.4	8.0	1.2	0.8-1.7	0.8	0.1	0.0-0.2	0.4	0.1	0.0-0.3	0.4	0.1	0.0-0.2
Brain / other central nervous system (all behaviors)	276.6	23.7	22.4-25.1	102.6	19.6	17.9-21.4	174.0	27.4	25.5-29.4	52.0	4.3	3.8-4.8	26.4	5.0	4.2-5.9	25.6	3.7	3.0-4.4
Malignant brain / other central nervous system	69.4	6.3	5.6-7.0	37.6	7.4	6.3-8.6	31.8	5.3	4.5-6.3	42.4	3.5	3.1-4.1	23.4	4.4	3.6-5.3	19.0	2.8	2.2-3.5
Malignant brain	62.0	5.6	5.0-6.3	33.4	6.5	5.6-7.6	28.6	4.8	4.0-5.7									
Malignant other central nervous system	7.4	0.7	0.5-1.0	4.2	0.9	0.5-1.3	3.2	0.6	0.3-0.9									
Benign brain / other central nervous system#	207.2	17.4	16.3-18.6	65.0	12.2	10.9-13.6	142.2	22.1	20.4-23.9	9.6	0.7	0.5-1.0	3.0	0.6	0.3-0.9	6.6	0.9	0.6-1.3
Benign brain	16.8	1.7	1.3-2.1	8.4	1.7	1.2-2.3	8.4	1.6	1.2-2.3									
Benign other central nervous system	190.4	15.8	14.8-16.8	56.6	10.5	9.3-11.8	133.8	20.4	18.8-22.1									
Endocrine system	229.2	21.8	20.5-23.2	68.6	13.4	12.0-15.0	160.6	29.9	27.8-32.1	11.0	0.8	0.6-1.1	6.8	1.2	0.8-1.7	4.2	0.5	0.3-0.9
Thyroid	216.0	20.7	19.4-22.0	61.2	12.0	10.7-13.5	154.8	28.9	26.8-31.1	8.6	0.6	0.5-0.9	5.2	0.9	0.6-1.4	3.4	0.4	0.2-0.7
Other endocrine (including thymus)	13.2	1.2	0.9-1.5	7.4	1.4	1.0-2.0	5.8	1.0	0.6-1.4	2.4	0.2	0.1-0.3	1.6	0.3	0.1-0.6	0.8	0.1	0.0-0.3
Lymphomas	317.8	26.5	25.2-27.9	172.8	32.3	30.1-34.6	145.0	22.0	20.4-23.8	59.0	4.5	4.0-5.0	29.6	5.3	4.5-6.3	29.4	3.8	3.2-4.5
Hodgkin lymphoma	31.4	3.1	2.7-3.7	15.0	3.1	2.4-3.9	16.4	3.3	2.6-4.1	3.0	0.2	0.1-0.4	1.2	0.2	0.1-0.5	1.8	0.2	0.1-0.5
Non-Hodgkin lymphomas	286.4	23.4	22.1-24.6	157.8	29.2	27.2-31.4	128.6	18.8	17.3-20.3	56.0	4.2	3.7-4.8	28.4	5.1	4.3-6.1	27.6	3.6	3.0-4.3
Myeloma	112.2	9.0	8.3-9.8	59.6	10.9	9.7-12.2	52.6	7.6	6.7-8.6	39.2	3.0	2.6-3.4	20.4	3.7	3.0-4.5	18.8	2.4	1.9-3.0
Leukemias	226.4	18.6	17.5-19.7	131.0	24.3	22.5-26.3	95.4	14.1	12.8-15.5	70.0	5.3	4.8-5.9	39.2	7.2	6.2-8.3	30.8	4.0	3.4-4.7
Lymphocytic leukemias	129.0	10.6	9.8-11.5	79.2	14.6	13.1-16.1	49.8	7.4	6.4-8.4	15.2	1.2	0.9-1.5	9.8	1.8	1.3-2.4	5.4	0.6	0.4-1.0
Acute lymphocytic leukemia	18.6	2.0	1.6-2.4	11.2	2.4	1.8-3.1	7.4	1.6	1.1-2.3	4.4	0.4	0.2-0.6	2.6	0.5	0.3-0.9	1.8	0.3	0.1-0.5
Chronic lymphocytic leukemia	105.0	8.2	7.5-8.9	63.4	11.4	10.2-12.8	41.6	5.6	4.9-6.5	9.8	0.7	0.5-0.9	6.4	1.2	0.8-1.7	3.4	0.3	0.2-0.6
Other lymphocytic leukemias	5.4	0.4	0.3-0.7	4.6	0.8	0.5-1.2	0.8	0.1	0.0-0.3	1.0	0.1	0.0-0.2	0.8	0.1	0.0-0.3	0.2	0.0	0.0-0.2
Myeloid and monocytic leukemias	87.8	7.2	6.6-8.0	46.8	8.8	7.7-10.1	41.0	6.1	5.2-7.0	41.8	3.2	2.8-3.7	22.2	4.1	3.3-4.9	19.6	2.6	2.1-3.3
Acute myeloid leukemia	55.4	4.6	4.0-5.2	30.0	5.7	4.8-6.7	25.4	3.7	3.1-4.5	35.6	2.8	2.4-3.2	18.8	3.5	2.8-4.2	16.8	2.3	1.8-2.9
Acute monocytic leukemia	3.0	0.3	0.1-0.4	1.2	0.3	0.1-0.6	1.8	0.3	0.1-0.5	0.4	0.0	0.0-0.1	0.0	0.0	0.0-0.2	0.4	0.0	0.0-0.2
Chronic myeloid leukemia	28.8	2.4	2.0-2.8	15.4	2.8	2.2-3.6	13.4	2.1	1.6-2.6	3.2	0.2	0.1-0.4	1.4	0.2	0.1-0.5	1.8	0.2	0.1-0.5
Other myeloid/monocytic leukemias	0.6	0.0	0.0-0.1	0.2	0.0	0.0-0.2	0.4	0.0	0.0-0.2	2.6	0.2	0.1-0.4	2.0	0.4	0.2-0.7	0.6	0.1	0.0-0.3
Other leukemias	9.6	0.8	0.6-1.0	5.0	1.0	0.6-1.4	4.6	0.6	0.4-0.9	13.0	0.9	0.7-1.2	7.2	1.3	0.9-1.8	5.8	0.7	0.5-1.0
Other acute leukemias	2.6	0.2	0.1-0.4	1.4	0.3	0.1-0.6	1.2	0.2	0.1-0.4	3.6	0.3	0.1-0.4	2.0	0.4	0.2-0.7	1.6	0.2	0.1-0.4

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

^ Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.

**New York State Department of Health, New York State Cancer Registry
Cancer Incidence and Mortality by Site of Cancer and Gender, 2015-2019**

Westchester

Site of cancer	Incidence									Mortality								
	Males and Females			Males			Females			Males and Females			Males			Females		
	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Cases	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI	Avg Ann Deaths	Rate per 100,000	95% CI
Aleukemic, subacute, leukemia NOS	7.0	0.6	0.4-0.8	3.6	0.7	0.4-1.1	3.4	0.4	0.2-0.7	9.4	0.7	0.5-0.9	5.2	1.0	0.6-1.4	4.2	0.5	0.3-0.8
Mesothelioma	10.6	0.8	0.6-1.1	6.8	1.2	0.9-1.7	3.8	0.5	0.3-0.9									
Kaposi sarcoma	4.2	0.4	0.2-0.6	3.8	0.7	0.4-1.1	0.4	0.0	0.0-0.2									
Myelodysplastic syndromes	66.6	5.1	4.6-5.7	37.2	7.2	6.2-8.3	29.4	3.8	3.2-4.5									
Chronic myeloproliferative disorders [^]	70.0	5.8	5.2-6.4	34.4	6.3	5.4-7.4	35.6	5.2	4.5-6.1									
Ill defined and unspecified sites	98.6	7.4	6.8-8.1	47.2	8.6	7.5-9.8	51.4	6.6	5.7-7.5	108.6	8.2	7.5-8.9	57.2	10.5	9.3-11.8	51.4	6.5	5.7-7.4

Rates are per 100,000 persons, age-adjusted to the 2000 US standard population, with 95% confidence intervals. Incidence data provisional, November 2021

Rates based on fewer than 4 cases or deaths per year are unstable and should be used with caution. NOS=Not otherwise specified.

* Incidence of skin cancer excludes basal and squamous cell cancers. # Breast in situ and brain/other central nervous system tumors with benign or uncertain behaviors are not included in the total for all invasive malignant tumors

[^] Tumors with a histology of 9963 or 9964 are included under Aleukemic, Subacute, Leukemia NOS, instead of Chronic Myeloproliferative Disorders.